WO2003043999A1 - Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 - Google Patents

Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 Download PDF

Info

Publication number
WO2003043999A1
WO2003043999A1 PCT/SE2002/002140 SE0202140W WO03043999A1 WO 2003043999 A1 WO2003043999 A1 WO 2003043999A1 SE 0202140 W SE0202140 W SE 0202140W WO 03043999 A1 WO03043999 A1 WO 03043999A1
Authority
WO
WIPO (PCT)
Prior art keywords
thiazol
methyl
amino
chloro
ethyl
Prior art date
Application number
PCT/SE2002/002140
Other languages
French (fr)
Inventor
Tjeerd Barf
Rikard Emond
Guido Kurz
Jerk VALLGÅRDA
Marianne Nilsson
Lian Zhang
Original Assignee
Biovitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU2002353718A priority Critical patent/AU2002353718B2/en
Application filed by Biovitrum Ab filed Critical Biovitrum Ab
Priority to BR0214343-7A priority patent/BR0214343A/en
Priority to YUP-443/04A priority patent/RS44304A/en
Priority to EA200400707A priority patent/EA200400707A1/en
Priority to DE60236541T priority patent/DE60236541D1/en
Priority to MXPA04004779A priority patent/MXPA04004779A/en
Priority to CA002466490A priority patent/CA2466490C/en
Priority to EP02789090A priority patent/EP1461325B1/en
Priority to IL16115402A priority patent/IL161154A0/en
Priority to JP2003545636A priority patent/JP4559078B2/en
Priority to AT02789090T priority patent/ATE469136T1/en
Publication of WO2003043999A1 publication Critical patent/WO2003043999A1/en
Priority to NO20042596A priority patent/NO20042596L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the present invention relates to novel compounds, to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11 - ⁇ - hydroxysteroid dehydrogenase type 1 enzyme (ll ⁇ HSDl).
  • glucocorticoids have a central role in diabetes, e.g. the removal of the pituitary or the adrenal gland from a diabetic animal alleviates the most severe symptoms of diabetes and lowers the concentration of glucose in the blood (Long, CD. and F.D.W. Leukins (1936) J. Exp. Med. 63: 465-490; Houssay, B.A. (1942) Endocrinology 30: 884-892). It is also well established that glucocorticoids enable the effect of glucagon on the liver.
  • Obesity is an important factor in syndrome X as well as in the majority (> 80%) of type 2 diabetic, and omental fat appears to be of central importance.
  • Abdominal obesity is closely associated with glucose intolerance, hyperinsulinemia, hypertriglyceridemia, and other factors of the so-called syndrome X (e.g. raised blood pressure, decreased levels of HDL and increased levels of VLDL) (Montague & O'Rahilly, Diabetes 49: 883-888, 2000).
  • Inhibition of the enzyme in pre-adipocytes (stromal cells) has been shown to decrease the rate of differentiation into adipocytes. This is predicted to result in diminished expansion (possibly reduction) of the omental fat depot, i.e. reduced central obesity (Bujalska, I.J., S. Kumar, and P.M. Stewart (1997) Lancet 349: 1210-1213).
  • Adrenalectomy attenuates the effect of fasting to increase both food intake and hypothalamic neuropeptide Y expression. This supports the role of glucocorticoids in promoting food intake and suggests that inhibition of 1 l ⁇ HSDl in the brain might increase satiety and therefore reduce food intake (Woods, S.C. et al. (1998) Science, 280: 1378-1383).
  • WO 99/02502 discloses 5HT 6 receptor antagonists for the treatment of CNS disorders. Such antagonists of thiazole structure differ from the compounds according to the present invention in that the former have an aryl group in 4-position. Furthermore, nothing is said about the activity on 1 l ⁇ HSDl . 5. Possible use of immuno-modulation using 1 l ⁇ HSDl inhibitors
  • glucocorticoids suppress the immune system. But in fact there is a dynamic interaction between the immune system and the HPA (hypothalamo-pituitary-adrenal) axis (Rook, G.A.W. (1999) Baillier's Clin. Endocrinol. Metab. 13: 576-581).
  • HPA hypothalamo-pituitary-adrenal
  • the balance between the cell-mediated response and humoral responses is modulated by glucocorticoids.
  • a high glucocorticoid activity such as at a state of stress, is associated with a humoral response.
  • inhibition of the enzyme 1 l ⁇ HSDl has been suggested as a means of shifting the response towards a cell-based reaction.
  • 1 l ⁇ HSDl is suggested to have a role in aqueous production, rather than drainage, but it is presently unknown if this is by interfering with activation of the glucocorticoid or the mineralocorticoid receptor, or both.
  • Glucocorticoids have an essential role in skeletal development and function but are detrimental in excess.
  • Glucocorticoid-induced bone loss is derived, at least in part, via inhibition of bone formation, which includes suppression of osteoblast proliferation and collagen synthesis (Kim, C.H., S.L. Cheng, and G.S. Kim (1999) J. Endocrinol. 162: 371- 379).
  • the negative effect on bone nodule formation could be blocked by the non-specific inhibitor carbenoxolone suggesting an important role of 1 l ⁇ HSDl in the glucocorticoid effect (Bellows, C.G., A. Ciaccia, and J.N.M. Heersche, (1998) Bone 23: 119-125).
  • WO 99/65884 discloses carbon substituted aminothiazole inhibitors of cyclin dependent kinases. These compounds may e.g. be used against cancer, inflammation and arthritis.
  • US 5,856,347 discloses an antibacterial preparation or bactericide comprising 2- aminothiazole derivative and/or salt thereof.
  • US 5,403,857 discloses benzenesulfonamide derivatives having 5-lipoxygenase inhibitory activity.
  • tetrahydrothiazolo[5,4-c]pyridines are disclosed in: Analgesic tetrahydrothiazolo[5,4- c]pyridines. Fr. Addn. (1969), 18 pp, Addn. to Fr. 1498465.
  • the compounds according to the present invention solves the above problems and embraces a novel class of compounds which has been developed and which inhibit the human 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme (1 l- ⁇ -HSD , and may therefore be of use in the treating disorders such as diabetes, obesity, glaucoma, osteoporosis, cognitive disorders, immune disorders, and hypertension.
  • One object of the present invention is a compound of formula (I)
  • T is an aryl ring or heteroaryl ring, optionally independently substituted by [R] n , wherein n is an integer 0-5, and R is hydrogen, aryl, heteroaryl, a heterocyclic ring, optionally halogenated C 1-6 -alkyl, optionally halogenated C 1-6 -alkoxy, C 1-6 -alkylsulfonyl, carboxy, cyano, nitro, halogen, aryloxy, arylsulfonyl, arylamino, wherein aryl, heteroaryl and aryloxy residues and heterocyclic rings can further be optionally substituted in one or more positions independently of each other by C 1-6 -acyl, C 1-6 -alkylthio, cyano, nitro, hydrogen, halogen, optionally halogenated C 1-6 -alkyl, optionally halogenated C 1-6 -alkoxy, amide which is optionally mono- or di-substit
  • R 1 is hydrogen or C 1-6 -alkyl
  • X is CH 2 or CO
  • Y is CH 2 , CO or a single bond
  • B is hydrogen, C 1-6 -alkyl or dimethylaminomethyl;
  • R is selected from C 1-6 -alkyl, azido, arylthio, heteroarylthio, halogen, hydroxymethyl, 2-hydroxyethylaminomethyl, methylsulfonyloxymethyl, 3-oxo-4- morpholinolinylmethylene, C 1-6 -alkoxycarbonyl, 5-methyl- 1 ,3,4-oxadiazol-2-yl;
  • R 3 and R 4 are each independently selected from hydrogen, ethyl, isopropyl, n-propyl, optionally halogenated C 1-6 -alkylsulfonyl, C 1-6 -alkoxy, 2- methoxyethyl, 2-hydroxyethyl, 1-methylimidazolylsulfonyl, C 1-6 -acyl, cyclohexylmethyl, cyclopropanecarbonyl, aryl, optionally halogenated arylsulfonyl, furylcarbonyl, tetrahydro-2-furanylmethyl, N-carbethoxypiperidyl, or C ⁇ -all yl substituted with one or more aryl, heterocyclic or heteroaryl, or NR 3 R 4 represent together heterocyclic systems which can be imidazole, piperidine, pyrrolidine, piperazine, morpholine, oxazepine, oxazole,
  • R 3 and R 4 are each independently selected from hydrogen, C 1-6 -alkyl or form together with the N-atom to which they are attached morpholinyl;
  • R 5 is hydrogen, optionally halogenated C 1-6 -alkyl, aryl, heteroaryl, C 1-6 -acyl, C 1-6 -alkylsulfonyl, arylcarbonyl, heteroarylcarbonyl, 2-carbomethoxyphenyl; or a salt, hydrate or solvate thereof; with the proviso that when:
  • X is CH 2
  • Y is CH 2
  • R 2 is not methyl, ethyl, diethylamino, 1 -pyrrolidinyl, and 1 -piperidinyl
  • X is CH 2 , Y is CH , R 2 is morpholinyl, then T is not 4-methylphenyl; X is CH 2 , Y is CO, then R 2 is not hydroxy;
  • X is CH 2 , Y is a single bond, then R is not ethyl, n-propyl;
  • X is CH , Y is a single bond, R 2 is methyl, B is methyl, then T is not 3-chloro-2- methylphenyl;
  • X is CO, Y is a single bond, then R 2 is not methyl; X is CO, Y is a single bond, R 2 is ethoxy, B is methyl, then T is not 3-chloro-2- methylphenyl, l, -biphenyl-4-yl, 4-n-propylphenyl, 2,4-dichloro-6-methylphenyl, and 2,4,6-trichlorophenyl.
  • T is selected from 5-chloro-l,3-dimethyl-lH-pyrazol-4-yl; 4-chloro-2,3,l- benzoxadiazolyl; 5-(dimethylamino)- 1-naphthyl; l-methylimidazol-4-yl; 1-naphthyl; 2- naphthyl; 8-quinolinyl; thienyl substituted with one or more of (benzoylamino)methyl, bromo, chloro, 3- isoxazolyl, 2-(methylsulfanyl)-4-pyrimidinyl, 1 -methyl-5-(trifluoromethyl)pyrazol-3-yl, phenylsulfonyl, pyridyl; phenyl substituted with one or more of 3-acetylaminophenyl, 3-acetylphenyl, benzeneamino, l,3-benzodioxol-5-yl, 2-benzof
  • R 1 is hydrogen or methyl
  • X is CH 2 or CO
  • Y is CH 2 , CO or a single bond
  • B is hydrogen, methyl or dimethylaminomethyl
  • R 2 is selected from n-propyl, azido, bromo, chloro, 2-pyridmylsulfanyl, 3-oxo-4-morpholinolinyl- methylene, ethoxycarbonyl, 5-methyl-l,3,4-oxadiazol-2-yl, hydroxymethyl, 2- hydroxyethylaminomethyl, methylsulfonyloxymethyl;
  • R 3 and R 4 are each independently selected from acetyl, benzhydryl, l,3-benzodioxol-5-ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexyl, cyclohexylmethyl, cyclopropanecarbonyl, ethyl, 2-furylcarbonyl, 2- furylmethyl, hydrogen, 2-hydroxyethyl, 2-(lH-indol-3-yl)ethyl, isopropyl, methoxy, 2- methoxyethyl, 4-(l-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl, (lS)-phenylethyl, n-propyl, tetrahydro-2-furanylmethyl, trifluoromethylsulfonyl, N-carbethoxypiperidyl; or NR
  • R 3 and R 4 are each independently selected from ethyl, hydrogen or form together with the N-atom to which they are attached mo ⁇ holinyl;
  • R 5 is acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, n-propionyl, 3-pyridinyl, 2,2,2-trifluoroethyl; with the proviso that when:
  • X is CH 2 , Y is CH 2 , then R 2 is not diethylamino, 1 -pyrrolidinyl, and 1 -piperidinyl;
  • X is CH 2 , Y is CH 2 , R 2 is mo ⁇ holinyl, then T is not 4-methylphenyl; X is CH 2 , Y is CO, then R 2 is not hydroxy;
  • X is CH 2 , Y is a single bond, then R 2 is not n-propyl;
  • X is CO, Y is a single bond, R 2 is ethoxy, B is methyl, then T is not 3-chloro-2- methylphenyl, l,l '-biphenyl-4-yl, 4-n-propylphenyl, 2,4-dichloro-6-methylphenyl, and 2,4,6-trichlorophenyl.
  • R 2 is selected from n-propyl, azido, bromo, chloro, 2-pyridinylsulfanyl, 3-oxo-4- mo ⁇ holinolinylmethylene, ethoxycarbonyl, 5-methyl- 1 ,3,4-oxadiazol-2-yl, hydroxymethyl, 2-hydroxyethylaminomethyl, methylsulfonyloxymethyl; NR 3 R 4 , wherein:
  • R 3 and R 4 are either each independently selected from acetyl, benzhydryl, 1,3- benzodioxol-5-ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexyl, cyclohexylmethyl, cyclopropanecarbonyl, 2-furylcarbonyl, 2-furylmethyl, hydrogen, 2-hydroxyethyl, 2-(lH-indol-3-yl)ethyl, isopropyl, methoxy, 2- methoxyethyl, methyl, 4-(l-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl,
  • R 3 is ethyl and R 4 is selected from acetyl, benzhydryl, l,3-benzodioxol-5- ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexyl, cyclohexylmethyl, cyclopropanecarbonyl, 2-furylcarbonyl, 2-furylmethyl, hydrogen, 2-hydroxyethyl, 2-(lH-indol-3-yl)ethyl, isopropyl, methoxy, 2- methoxyethyl, methyl, 4-(l-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl,
  • N-carbethoxypiperidyl; NR 3 R 4 represent together 4-acetylpiperazinyl, 4-t-butoxycarbonylpi ⁇ erazinyl, 2-
  • R 3 and R 4 are each independently selected from ethyl, hydrogen or form together mo ⁇ holinyl; R 5 O, wherein R 5 is acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, n-propionyl, 3-pyridinyl, 2,2,2-trifluoroethyl.
  • T is selected from 5-chloro-l,3-dimethyl-lH-pyrazol-4-yl; 4-chloro-2,3,l- benzoxadiazolyl; 5-(dimethylamino)- 1-naphthyl; l-methylimidazol-4-yl; 1-naphthyl; 2- naphthyl; 8-quinolinyl; thienyl substituted with one or more of (benzoylamino)methyl, bromo, chloro, 3- isoxazolyl, 2-(methylsulfanyl)-4-pyrimidinyl, 1 -methyl-5-(trifluoromethyl)pyrazol-3-yl, phenylsulfonyl, pyridyl; phenyl substituted with either: (i) one or more of 3-acetylaminophenyl,
  • R 2 is selected from n-propyl, azido, bromo, chloro, 2-pyridinylsulfanyl, 3-oxo-4-mo ⁇ holinolinylmethylene, ethoxycarbonyl, 5-methyl-l,3,4-oxadiazol-2-yl, hydroxymethyl, 2- hydroxyethylaminomethyl, methylsulfonyloxymethyl;
  • R 3 and R 4 are each independently selected from acetyl, benzhydryl, l,3-benzodioxol-5-ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexyl, cyclohexylmethyl, cyclopropanecarbonyl, ethyl, 2-furylcarbonyl, 2- furylmethyl, hydrogen, 2-hydroxyethyl, 2-(lH-indol-3-yl)ethyl, isopropyl, methoxy, 2- methoxy ethyl, methyl, 4-(l-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl, (1S)- phenylethyl, n-propyl, tetrahydro-2-furanylmethyl, trifluoromethylsulfonyl, N- carbethoxypiperidyl
  • R 3 and R 4 are each independently selected from ethyl, hydrogen or form together with the N-atom to which they are attached mo ⁇ holinyl;
  • R 5 O wherein R 5 is acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, n- propionyl, 3-pyridinyl, 2,2,2-trifluoroethyl.
  • R 2 is selected from azido, bromo, chloro, 2-pyridinylsulfanyl, 3-oxo-4-mo ⁇ holinolinylmethylene, ethoxycarbonyl, 5-methyl-l,3,4-oxadiazol-2-yl, hydroxymethyl, 2- hydroxyethylaminomethyl, methylsulfonyloxymethyl;
  • R 3 and R 4 are each independently selected from acetyl, benzhydryl, l,3-benzodioxol-5-ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexyl, cyclohexylmethyl, cyclopropanecarbonyl, ethyl, 2-furylcarbonyl, 2- furylmethyl, hydrogen, 2-hydroxyethyl, 2-(lH-indol-3-yl)ethyl, isopropyl, methoxy, 2- methoxyethyl, methyl, 4-(l-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl, (1S)- phenylethyl, n-propyl, tetrahydro-2-furanylmethyl, trifluoromethylsulfonyl, N- carbethoxypiperidyl;
  • NR 3 R 4 represent together 4-acetylpiperazinyl, 4-t-butoxycarbonylpiperazinyl, 2- (3,4-dihydro-2(lH)isoquinolinyl), (2R,6S)-2,6-dimethylmo ⁇ holinyl, (2R)-2,4-dimethyl- 1 -piperazinyl, 2-hydroxy-3-oxomo ⁇ holinyl, imidazolyl, 2-methyl-3-oxomo ⁇ holinyl, 4- methyl-2-oxopiperazinyl, 4-methylpiperazinyl, mo ⁇ holinyl, (lS,4S)-2-oxa-5-aza- bicyclo[2.2.1]hept-5-yl, 2-oxoimidazolinyl, 3-oxomo ⁇ holinyl, 3-oxo-l,4-oxazepinyl, 2- oxooxazolinyl, piperazinyl; piperidiny
  • R 3 and R 4 are each independently selected from ethyl, hydrogen or form together with the N-atom to which they are attached mo ⁇ holinyl;
  • R 5 O wherein R 5 is acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, n-propionyl, 3-pyridinyl, 2,2,2-trifluoroethyl.
  • T is selected from 5-chloro-l,3-dimethyl-lH-pyrazol-4-yl; 4-chloro-2,3,l- benzoxadiazolyl; 5-(dimethylamino)- 1-naphthyl; l-methylimidazol-4-yl; 1-naphthyl; 2- naphthyl; 8-quinolinyl; thienyl substituted with one or more of (benzoylamino)methyl, bromo, chloro, 3- isoxazolyl, 2-(methylsulfanyl)-4-pyrimidinyl, l-methyl-5-(trifluoromethyl)pyrazol-3-yl, phenylsulfonyl, pyridyl; phenyl substituted with either: (i) one or more of 3-acetylarhinophenyl, 3-
  • R 2 is selected from n-propyl, azido, bromo, chloro, 2-pyridinylsulfanyl, 3-oxo-4-mo ⁇ holinolinylmethylene, ethoxycarbonyl, 5-methyl-l,3,4-oxadiazol-2-yl, hydroxymethyl, 2- hydroxyethylaminomethyl, methylsulfonyloxymethyl;
  • R 3 and R 4 are each independently selected from acetyl, benzhydryl, l,3-benzodioxol-5-ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexyl, cyclohexylmethyl, cyclopropanecarbonyl, ethyl, 2-furylcarbonyl, 2- furylmethyl, hydrogen, 2-hydroxyethyl, 2-(lH-indol-3-yl)ethyl, isopropyl, methoxy, 2- methoxyethyl, methyl, 4-(l-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl, (1S)- phenylethyl, n-propyl, tetrahydro-2-furanylmethyl, trifluoromethylsulfonyl, N- carbethoxypiperidyl;
  • R 3 and R 4 are each independently selected from ethyl, hydrogen or form together with the N-atom to which they are attached mo ⁇ holinyl;
  • R 5 is acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, n-propionyl, 3-pyridinyl, 2,2,2-trifluoroethyl;
  • T is selected from 5-chloro-l,3-dimethyl-lH-pyrazol-4-yl; 4-chloro-2,3,l -benzoxadiazolyl; 5-(dimethylamino)- 1-naphthyl; l-methylimidazol-4-yl; 1-naphthyl; 2-naphthyl; 8- quinolinyl; thienyl substituted with one or more of (benzoylamino)methyl, bromo, chloro, 3- isoxazolyl, 2-(methylsulfanyl)-4-pyrimidinyl, 1 -methyl-5-(trifluoromethyl)pyrazol-3-yl, phenylsulfonyl, pyridyl; phenyl substituted with either: (i) one or more of 3-acetylaminophenyl, 3-acety
  • Another object of the present invention is a method for the treatment or prevention of diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, depression, virus diseases or inflammatory disorders without causing hypoglycemia and to achieve immuno- modulation, preferably tuberculosis, lepra, and psoriasis, said method comprising administering to a mammal, including a human, in need of such treatment (e.g., identified as in need thereof) an effective amount of a compound of formula (I) or a composition having a compound of formula (I) in it: wherein
  • T is an aryl ring or heteroaryl ring, optionally independently substituted by [R] n> wherein n is an integer 0-5, and R is hydrogen, aryl, heteroaryl, a heterocyclic ring, optionally halogenated C 1-6 -alkyl, optionally halogenated C 1-6 -alkoxy, C 1-6 -alkylsulfonyl, carboxy, cyano, nitro, halogen, amine which is optionally mono- or di-substituted, amide which is optionally mono- or di-substituted, aryloxy, arylsulfonyl, arylamino, wherein aryl, heteroaryl and aryloxy residues and heterocyclic rings can further be optionally substituted in one or more positions independently of each other by Ci- 6 -acyl, C 1-6 - alkylthio, cyano, nitro, hydrogen, halogen, optionally halogenated C ⁇ -6 -
  • R 1 is hydrogen or C 1-6 -alkyl
  • X is CH 2 or CO
  • Y is CH 2 , CO or a single bond
  • B is hydrogen, C 1-6 -alkyl or dimethylaminomethyl
  • R 2 is selected from C 1-6 -alkyl, azido, arylthio, heteroarylthio, halogen, hydroxymethyl, 2-hydroxyethylaminomethyl, methylsulfonyloxymethyl, 3-oxo-4- mo ⁇ holinolinylmethylene, C 1-6 -alkoxycarbonyl, 5-methyl-l,3,4-oxadiazol-2-yl;
  • R 3 and R 4 are each independently selected from hydrogen, C 1-6 - alkyl, optionally halogenated C 1-6 -alkylsulfonyl, C 1-6 -alkoxy, 2-methoxyethyl, 2- hydroxyethyl, 1-methylimidazolylsulfonyl, C 1-6 -acyl, cyclohexylmethyl, cyclopropanecarbonyl, aryl, optionally halogenated arylsulfonyl, furylcarbonyl, tetrahydro-2-furanylmethyl, N-carbethoxypiperidyl or C 1-6 -alkyl substituted with one or more aryl, heterocyclic or heteroaryl, or
  • NR 3 R 4 represent together heterocyclic systems which can be imidazole, piperidine, pyrrolidine, piperazine, mo ⁇ holine, oxazepine, oxazole, thiomo ⁇ holine, 1,1- dioxidothiomo ⁇ holine, 2-(3,4-dihydro-2(lH)isoquinolinyl), (lS,4S)-2-oxa-5- azabicyclo[2.2.1 ]hept-5-yl, which heterocyclic systems can be optionally substituted by Ci- 6 -alkyl, C 1-6 -acyl, hydroxy, oxo, t-butoxycarbonyl;
  • R 3 and R 4 are each independently selected from hydrogen, C 1-6 -alkyl or form together with the N-atom to which they are attached mo ⁇ holinyl;
  • R 5 is hydrogen, optionally halogenated C 1-6 -alkyl, aryl, heteroaryl, C 1-6 -acyl, C- 6 -alkylsulfonyl, arylcarbonyl, heteroarylcarbonyl, 2-carbomethoxyphenyl; or a salt, hydrate or solvate thereof; with the proviso that when:
  • X is CH 2 , Y is CH 2 , then R 2 is not methyl and ethyl;
  • X is CH 2 , Y is a single bond, then R 2 is not ethyl and n-propyl;
  • X is CH 2 , Y is a single bond, R 2 is methyl, B is methyl, then T is not 3-chloro-2- methylphenyl;
  • X is CO, Y is a single bond, then R 2 is not methyl;
  • X is CO, Y is a single bond, R 2 is ethoxy, B is methyl, then T is not 3-chloro-2- methylphenyl, 1,1 '-biphenyl-4-yl, 4-n-propylphenyl, 2,4-dichloro-6-methylphenyl, and 2,4,6-trichlorophenyl.
  • this invention features a method for inhibiting a human 11- ⁇ - hydroxysteroid dehydrogenase type 1 enzyme.
  • the method includes administering to a subject (e.g., mammal, human, or animal) in need thereof (e.g., identified as in need thereof) an effective amount of a compound of any of the formulae delineated herein or a composition comprising any of the formulae herein.
  • the present invention also features a method for treating 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme-mediated disorders.
  • the method includes administering to a subject (e.g., mammal, human, or animal) in need thereof (e.g., identified as in need thereof) an effective amount of a compound of any of the formulae delineated herein or a composition comprising any of the formulae delineated herein.
  • a subject e.g., mammal, human, or animal
  • the 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme-mediated disorder is any disorder or symptom wherein the 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme is involved in the process or presentation of the disorder or the symptom.
  • the 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme-mediated disorders include, but are not limited to, diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, depression, virus diseases, inflammatory disorders, and immuno-modulation.
  • immuno-modulation are tuberculosis, lepra, and psoriasis.
  • the methods delineated herein can also include the step of identifying that the subject is in need of treatment of diseases or disorders described above.
  • the identification can be in the judgment of a subject or a health professional and can be subjective (e.g., opinion) or objective (e.g., measurable by a test or a diagnostic method).
  • These compounds may also be used in the manufacture of a medicament for the prevention, management or treatment of diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, depression, virus diseases or inflammatory disorders without causing hypoglycemia and to achieve immuno-modulation.
  • Preferred examples of immuno-modulation are tuberculosis, lepra, and psoriasis.
  • T is selected from 5-chloro-l,3-dimethyl-lH-pyrazol-4-yl; 4-chloro-2,3,l- benzoxadiazolyl; 5-(dimethylamino)- 1-naphthyl; l-methylimidazol-4-yl; 1-naphthyl; 2- naphfhyl; 8-quinolinyl; thienyl substituted with one or more of (benzoylamino)methyl, bromo, chloro, 3- isoxazolyl, 2-(methylsulfanyl)-4-pyrimidinyl, 1 -methyl-5-(trifluoromethyl) ⁇ yrazol-3-yl, phenylsulfonyl, pyridyl; phenyl substituted with one or more of acetylamino, 3-acetylaminophenyl, 3- acetylphenyl, benzeneamino, l,3-
  • R 1 is hydrogen or methyl
  • X is CH 2 or CO
  • Y is CH 2 , CO or a single bond
  • B is hydrogen, methyl or dimethylaminomethyl
  • R 2 is selected from n-propyl, azido, bromo, chloro, 2-pyridinylsulfanyl, 3-oxo-4-mo ⁇ holinolinyl- methylene, ethoxycarbonyl, 5-methyl-l,3,4-oxadiazol-2-yl, hydroxymethyl, 2- hydroxyethylaminomethyl, methylsulfonyloxymethyl;
  • R 3 and R 4 are each independently selected from acetyl, benzhydryl, l,3-benzodioxol-5-ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexyl, cyclohexylmethyl, cyclopropanecarbonyl, ethyl, 2-furylcarbonyl, 2- furylmethyl, hydrogen, 2-hydroxyethyl, 2-(lH-indol-3-yl)ethyl, isopropyl, methoxy, 2- methoxyethyl, methyl, 4-(l-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl, (1S)- phenylethyl, n-propyl, tetrahydro-2-furanylmethyl, trifluoromethylsulfonyl, N- carbethoxypiperidyl;
  • NR 3 R 4 represent together 4-acetylpiperazinyl, 4-t-butoxycarbonylpiperazinyl, 2- (3,4-dihydro-2(lH)isoquinolinyl), (2R,6S)-2,6-dimethylmo ⁇ holinyl, (2R)-2,4-dimethyl- 1 -piperazinyl, 2-hydroxy-3-oxomo ⁇ holinyl, imidazolyl, 2-methyl-3-oxomo ⁇ holinyl, 4- methyl-2-oxopiperazinyl, 4-methylpiperazinyl, mo ⁇ holinyl, (lS,4S)-2-oxa-5-aza- bicyclo[2.2.1]hept-5-yl, 2-oxoimidazolinyl, 3-oxomo ⁇ holinyl, 3-oxo-l,4-oxazepinyl, 2- oxooxazolinyl, piperazinyl; piperidiny
  • R O wherein R is acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, n-propionyl, 3-pyridinyl, 2,2,2-trifluoroethyl; with the proviso that when:
  • X is CH 2 , Y is a single bond, then R 2 is not n-propyl;
  • X is CO, Y is a single bond, R 2 is ethoxy, B is methyl, then T is not 3-chloro-2- methylphenyl, l,l '-biphenyl-4-yl, 4-n-pro ⁇ ylphenyl, 2,4-dichloro-6-methylphenyl, and 2,4,6-trichlorophenyl.
  • X is CH 2 and Y is CH 2 , then it is preferred that:
  • R 2 is selected from n-propyl, azido, bromo, chloro, 2-pyridinylsulfanyl, 3-oxo-4- mo ⁇ holinolinylmethylene, ethoxy carbonyl, 5-methyl-l ,3,4-oxadiazol-2-yl, hydroxymethyl, 2-hydroxyethylaminomethyl, methylsulfonyloxymethyl;
  • R 3 and R 4 are either each independently selected from acetyl, benzhydryl, l,3-benzodioxol-5-ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexyl, cyclohexylmethyl, cyclopropanecarbonyl, ethyl, 2-furylcarbonyl, 2- furylmethyl, hydrogen, 2-hydroxyethyl, 2-(lH-indol-3-yl)ethyl, isopropyl, methoxy, 2- methoxyethyl, methyl, 4-(l-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl, (1S)- phenylethyl, n-propyl, tetrahydro-2-furanylmethyl, trifluoromethylsulfonyl, N- carbethoxypiperidyl
  • NR 3 R 4 represent together 4-acetylpiperazinyl, 4-t-butoxycarbonylpiperazinyl, 2- (3,4-dihydro-2(lH)isoquinolinyl), (2R,6S)-2,6-dimethylmo ⁇ holinyl, (2R)-2,4-dimethyl- 1 -piperazinyl, 2-hydroxy-3-oxomo ⁇ holinyl, imidazolyl, 2-methyl-3-oxomo ⁇ holinyl, 4- methyl-2-oxopiperazinyl, 4-methylpiperazinyl, mo ⁇ holinyl, (lS,4S)-2-oxa-5-aza- bicyclo[2.2.1]hept-5-yl, 2-oxoimidazolinyl, 3-oxomo ⁇ holinyl, 3-oxo-l,4-oxazepinyl, 2- oxooxazolinyl, piperazinyl; piperidiny
  • R 3 and R 4 are each independently selected from ethyl, hydrogen or form together mo ⁇ holinyl;
  • R 5 is acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, n-propionyl, 3-pyridinyl, 2,2,2-trifluoroethyl.
  • R 2 is selected from azido, bromo, chloro, 2-pyridinylsulfanyl, 3-oxo-4-mo ⁇ holinolinylmethylene, ethoxycarbonyl, 5-methyl-l,3,4-oxadiazol-2-yl, hydroxymethyl, 2- hydroxyethylaminomethyl, methylsulfonyloxymethyl;
  • R 3 and R 4 are each independently selected from acetyl, benzhydryl, l,3-benzodioxol-5-ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexyl, cyclohexylmethyl, cyclopropanecarbonyl, ethyl, 2-furylcarbonyl, 2- furylmethyl, hydrogen, 2-hydroxyethyl, 2-(lH-indol-3-yl)ethyl, isopropyl, methoxy, 2- methoxyethyl, methyl, 4-(l-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl, (1S)- phenylethyl, n-propyl, tetrahydro-2-furanylmethyl, trifluoromethylsulfonyl, N- carbethoxypiperidyl;
  • R 3 and R 4 are each independently selected from ethyl, hydrogen or form together with the N-atom to which they are attached mo ⁇ holinyl;
  • R 5 is acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, n-propionyl, 3-pyridinyl, 2,2,2-trifluoroethyl.
  • T is selected from 5-chloro-l,3-dimethyl-lH-pyrazol-4-yl; 4-chloro-2,3,l- benzoxadiazolyl; 5-(dimethylamino)- 1-naphthyl; l-methylimidazol-4-yl; 1-naphthyl; 2- naphthyl; 8-quinolinyl; thienyl substituted with one or more of (benzoylamino)methyl, bromo, chloro, 3- isoxazolyl, 2-(methylsulfanyl)-4-pyrimidinyl, 1 -methyl-5-(trifluoromethyl)pyrazol-3-yl, phenylsulfonyl, pyridyl; phenyl substituted with either:
  • R 2 is selected from n-propyl, azido, bromo, chloro, 2-pyridinylsulfanyl, 3-oxo-4-mo ⁇ holinolinylmethylene, ethoxycarbonyl, 5-methyl-l,3,4-oxadiazol-2-yl, hydroxymethyl, 2- hydroxyethylaminomethyl, methylsulfonyloxymethyl;
  • R 3 and R 4 are each independently selected from acetyl, benzhydryl, l,3-benzodioxol-5-yhnethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexyl, cyclohexylmethyl, cyclopropanecarbonyl, ethyl, 2-furylcarbonyl, 2- furylmethyl, hydrogen, 2-hydroxyethyl, 2-(lH-indol-3-yl)ethyl, isopropyl, methoxy, 2- methoxyethyl, methyl, 4-(l-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl, (1S)- phenylethyl, n-propyl, tetrahydro-2-furanylmethyl, trifluoromethylsulfonyl, N- carbethoxypiperidy
  • R 3 and R 4 are each independently selected from ethyl, hydrogen or form together with the N-atom to which they are attached mo ⁇ holinyl;
  • R 5 is acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, n-propionyl, 3-pyridinyl, 2,2,2-trifluoroethyl;
  • T is selected from 5-chloro-l,3-dimethyl-lH-pyrazol-4-yl; 4-chloro-2,3,l -benzoxadiazolyl; 5-(dimethylamino)- 1-naphthyl; l-methylimidazol-4-yl; 1-naphthyl; 2-naphthyl; 8- quinolinyl; thienyl substituted with one or more of (benzoylamino)methyl, bromo, chloro, 3- isoxazolyl, 2-(methylsulfanyl)-4-pyrimidinyl, 1 -methyl-5-(trifluoromethyl)pyrazol-3-yl, phenylsulfonyl, pyridyl; phenyl substituted with either: (i) one or more of acetylamino, 3-acetylaminoph
  • Another object of the present invention is a pharmaceutical composition
  • a pharmaceutical composition comprising at least one compound of formula (I) as defined above, and a pharmaceutically acceptable carrier.
  • a method for making a compound of formula (I) includes taking any intermediate compound delineated herein, reacting it with any one or more reagents to form a compound of formula (I) including any processes specifically delineated herein.
  • the compounds according to the present invention may be used in several indications which involve 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme.
  • the compounds according to the present invention may be used against dementia (see WO97/07789), osteoporosis (see Canalis E 1996, Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis, Journal of Clinical
  • aryl in the present description is intended to include aromatic rings (monocyclic or bicyclic) having from 6 to 10 ring carbon atoms, such as phenyl (Ph) and naphthyl, which optionally may be substituted by C ⁇ -6 -alkyl.
  • substituted aryl groups are benzyl, and 2-methylphenyl.
  • heteroaryl means in the present description a monocyclic, bi- or tricyclic aromatic ring system (only one ring need to be aromatic) having from 5 to 14, preferably 5 to 10 ring atoms such as 5, 6, 7, 8, 9 or 10 ring atoms (mono- or bicyclic), in which one or more of the ring atoms are other than carbon, such as nitrogen, sulfur, oxygen and selenium as part of the ring system.
  • heteroaryl rings examples include pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cinnoline, quinazoline, indole, isoindole, indoline, isoindoline, benzothiophene, benzofuran, isobenzofuran, benzoxazole, 2,1,3-benzoxadiazole, benzothiazole, 2, 1,3 -benzothiazole, 2,1,3-benzoselenadiazole, benzimidazole, indazole, benzodioxane, in
  • heterocyclic in the present description is intended to include unsaturated as well as partially and fully saturated mono-, bi- and tricyclic rings having from 4 to 14, preferably 4 to 10 ring atoms having one or more heteroatoms (e.g., oxygen, sulfur, or nitrogen) as part of the ring system and the remainder being carbon, such as, for example, the heteroaryl groups mentioned above as well as the corresponding partially saturated or fully saturated heterocyclic rings.
  • exemplary saturated heterocyclic rings are azetidine, pynolidine, piperidine, piperazine, mo ⁇ holine, thiomo ⁇ holine and 1,4- oxazepane.
  • C 1-6 -alkyl in the compound of formula (I) according to the present application is preferably C 1-4 -alkyl.
  • Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, isohexyl, and cyclohexyl.
  • C 1-6 -alkyl For parts of the range "C 1-6 -alkyl" all subgroups thereof are contemplated such as C ⁇ - 5 -alkyl, C 1-4 -alkyl, C 1-3 -alkyl, C 1-2 -alkyl, C 2-6 -alkyl, C 2-5 -alkyl, C 2-4 -alkyl, C 2-3 -alkyl, C 3-6 -alkyl, C 4-5 -alkyl, etc.
  • C 1-6 -alkoxy in the compound of formula (I) according to the present application may be straight or branched, is preferably C 1-4 -alkoxy.
  • Exemplary alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, hexyloxy, and isohexyloxy.
  • C 1-6 -alkoxy for parts of the range "C 1-6 -alkoxy" all subgroups thereof are contemplated such as Q.s-alkoxy, Ct-4-alkoxy, C 1-3 -alkoxy, C ⁇ -2 - alkoxy, C 2-6 -alkoxy, C 2-5 -alkoxy, C 2-4 -alkoxy, C 2-3 -alkoxy, C 3-6 -alkoxy, C 4-5 -alkoxy, etc.
  • C 1-6 -acyl, in the compound of formula (I) according to the present application may be saturated or unsaturated and is preferably C 1-4 -acyl.
  • acyl groups include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, butenoyl (e.g. 3- butenoyl), hexenoyl (e.g. 5-hexenoyl).
  • C 1-6 -acyl all subgroups thereof are contemplated such as .s-acyl, C 1-4 -acyl, C 1-3 -acyl, C 1-2 -acyl, C 2-6 -acyl, C 2-5 - acyl, C 2-4 -acyl, C 2 . 3 -acyl, C 3-6 -acyl, C 4-5 -acyl, etc.
  • C 2-6 -alkenyl in the compound of formula (I) according to the present application is preferably C 2-4 -alkenyl.
  • Exemplary alkenyl groups include vinyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 1- pentenyl, 2-pentenyl, 1-hexenyl, 2-hexenyl, and 1-cyclohexenyl.
  • C 2-6 -alkenyl all subgroups thereof are contemplated such as C 2-5 -alkenyl, C 2-4 -alkenyl, C 2-3 -alkenyl, C 3-6 -alkenyl, C 4-5 -alkenyl, etc.
  • halogen in the present description is intended to include fluorine, chlorine, bromine and iodine.
  • sulfanyl in the present description means a thio group.
  • stable refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the pu ⁇ oses detailed herein (e.g., therapeutic administration to a subject for the treatment of disease, 1 l ⁇ HSDl inhibition, 11 ⁇ HSDl -mediated disease).
  • prodrug forms in the present description means a pharmacologically acceptable derivative, such as an ester or an amide, which derivative is biotransformed in the body to form the active drug (see Goodman and Gilman's, The Pharmacological basis of Therapeutics, 8 th ed., McGraw-Hill, Int. Ed. 1992, "Biotransformation of Drugs, p. 13- 15).
  • “Pharmaceutically acceptable” means in the present description being useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes being useful for veterinary use as well as human pharmaceutical use.
  • “Pharmaceutically acceptable salts” mean in the present description salts which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity. Such salts include acid addition salts formed with organic and inorganic acids, such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, phosphoric acid, acetic acid, glycolic acid, maleic acid, malonic acid, oxalic acid, methanesulfonic acid, trifluoroacetic acid, fumaric acid, succinic acid, tartaric acid, citric acid, benzoic acid, ascorbic acid and the like.
  • organic and inorganic acids such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, phosphoric acid, acetic acid, glycolic acid, maleic acid, malonic acid, oxalic acid, methanesulfonic acid, trifluoroacetic acid, fumaric acid, succinic acid, tartaric acid, citric acid, benzoic acid
  • Base addition salts may be formed with organic and inorganic bases, such as sodium, ammonia, potassium, calcium, ethanolamine, diethanolamine, N-methylglucamine, choline and the like. Included in the invention are pharmaceutically acceptable salts or compounds of any of the formulae herein.
  • compositions according to the present invention contain a pharmaceutically acceptable carrier together with at least one of the compounds comprising the formula (I) as described herein above, dissolved or dispersed therein as an active, antimicrobial, ingredient.
  • the therapeutic composition is not immunogenic when administered to a human patient for therapeutic pu ⁇ oses, unless that pu ⁇ ose is to induce an immune response.
  • compositions that contains active ingredients dissolved or dispersed therein are well understood in the art.
  • compositions are prepared as sterile injectables either as liquid solutions or suspensions, aqueous or non-aqueous, however, solid forms suitable for solution, or suspensions, in liquid prior to use can also be prepared.
  • the preparation can also be emulsified.
  • the active ingredient may be mixed with excipients, which are pharmaceutically acceptable and compatible with the active ingredient and in amounts suitable for use in the therapeutic methods described herein.
  • Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like and combinations thereof.
  • the composition may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like which enhance the effectiveness of the active ingredient.
  • Adjuvants may also be present in the composition.
  • liquid carriers are sterile aqueous solutions that contain no materials in addition to the active ingredients and water, or contain a buffer such as sodium phosphate at physiological pH value, physiological saline or both, such as phosphate-buffered saline. Still further, aqueous carriers can contain more than one buffer salt, as well as salts such as sodium and potassium chlorides, dextrose, propylene glycol, polyethylene glycol and other solutes. Liquid compositions can also contain liquid phases in addition to and to the exclusion of water.
  • compositions according to one of the prefened embodiments of the present invention comprising compounds comprising the formula (I), may include pharmaceutically acceptable salts of that component therein as set out above.
  • Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide) that are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic acid, tartaric acid, mandelic acid and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.
  • inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic acid, tartaric acid, mandelic acid and the like.
  • Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine
  • the preparations according to the preferred embodiments may be administered orally, topically, intraperitoneally, intraarticularly, intracranially, intradermally, intramuscularly, intraocularly, intrathecally, intravenously, subcutaneously.
  • Other routes are known to those of ordinary skill in the art.
  • compositions according to the present invention may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical or sterile parenteral solutions or suspensions.
  • Tablets and capsules for oral administration may be in unit dose presentation form and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, traganath or polyvinyl-pyrrolidone; fillers e.g. lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricant e.g.
  • Oral liquid preparations may be in the form of e.g. aqueous or oily suspensions, solutions, emulsions, syrups or elixirs or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives such as suspending agents, e.g. sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents e.g.
  • non-aqueous vehicles which may include edible oils, e.g. almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives e.g. methyl or propyl p- hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
  • edible oils e.g. almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol
  • preservatives e.g. methyl or propyl p- hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
  • a pharmaceutical composition according to the present invention may comprise typically an amount of at least 0.1 weight percent of compound comprising the formula (I) per weight of total therapeutic composition.
  • a weight percent is a ratio by weight of total composition.
  • 0.1 weight percent is 0.1 grams of compound comprising the formula (I) per 100 grams of total composition.
  • a suitable daily oral dose for a mammal, preferably a human being may vary widely depending on the condition of the patient. However a dose of compound comprising the formula (I) of about 0.1 to 300 mg/kg body weight may be appropriate.
  • compositions according to the present invention may also be used veterinarily and thus they may comprise a veterinarily acceptable excipient or carrier.
  • the compounds and compositions may be thus administered to animals, e.g., cats, dogs, or horses, in treatment methods.
  • the compounds of the present invention in labelled form may be used as a diagnostic agent.
  • This invention relates to methods of making compounds of any of the formulae herein comprising reacting any one or more of the compounds of the formulae delineated herein, including any processes delineated herein.
  • the compounds of formula (I) above may be prepared by, or in analogy with, conventional methods, and especially according to or in analogy with the following methods. Further, the pharmacology in- vitro was studied using the following reagents and methods.
  • the chemicals used in the synthetic routes delineated herein may include, for example, solvents, reagents, catalysts, and protecting group and deprotecting group reagents.
  • the methods described above may also additionally include steps, either before or after the steps described specifically herein, to add or remove suitable protecting groups in order to ultimately allow synthesis of the compounds.
  • Synthetic chemistry transformations and protecting group methodologies useful in synthesizing applicable compounds are known in the art and include, for example, those described in R. Larock, Comprehensive Organic Transformations, NCH Publishers (1989); T.W. Greene and P.GM. Wuts, Protective Groups in Organic Synthesis, 3 r Ed., John Wiley and Sons (1999); L. Fieser and M. Fieser, Fieser and Fiesers ' Reagents for Organic Synthesis, John Wiley and Sons (1994); and L.
  • [1, 2(n) - 3 H]-cortisone was purchased from Amersham Pharmacia Biotech.
  • Anti- cortisol monoclonal mouse antibody, clone 6D6.7 was obtained from Immunotech and Scintillation proximity assay (SPA) beads coated with monoclonal antimouse antibodies were from Amersham Pharmacia Biotech.
  • NADPH, tetrasodium salt was from Calbiochem and glucose-6-phosphate (G-6-P) was supplied by Sigma.
  • the human 11- ⁇ - hydroxysteroid dehydrogenase rype-1 enzyme (11- ⁇ -HSDi) was expressed in Pichia pastoris.
  • 18- ⁇ -glycyrrhetinic acid (GA) was obtained from Sigma.
  • the 11- ⁇ -HSU ! enzyme assay was carried out in 96 well microtiter plates (Packard, Optiplate) in a total well volume of 220 ⁇ L and contained 30 mM Tris-HCl, pH 7.2 with 1 mM EDTA, a substrate mixture tritiated Cortisone/NADPH (175 nM / 181 ⁇ M), G-6-P (1 mM) and inhibitors in serial dilutions (9 to 0.15 ⁇ M). Reactions were initiated by the addition of human 1 l- ⁇ -HSD l5 either as Pichia pastoris cell homogenate or microsomes prepared from Pichia pastoris (the final amount of enzyme used was varied between 0.057 to 0.11 mg/mL).
  • the plates were covered with plastic film and incubated on a shaker for 30 minutes, at room temperature, before counting.
  • the amount of [ H]-cortisol, bound to the beads was determined in a microplate liquid scintillation counter.
  • Kj IC 50 (l+[S]/K m ) [Cheng, Y.C.; Prushoff, W.H. Biochem. Pharmacol. 1973, 22, 3099-3108].
  • the IC 50 is measured experimentally in an assay wherein the decrease of the turnover of cortisone to cortisol is dependent on the inhibition potential of each substance.
  • Ki values of the compounds of the present invention for the 11- ⁇ -HSDl enzyme lie typically between about 10 nM and about 10 ⁇ M.
  • Reverse phase preparative HPLC was carried out on a 100 x 21.2 mm, 5 ⁇ Hypersil Elite column eluting with a gradient of 5% AC ⁇ in 95% water to 95% AC ⁇ in 5% water (0.2% TFA buffer) over 10 mins at a flow rate of 20 mL / min with the UN detector set at 254 nm.
  • Thin layer chromatography was carried out using pre-coated silica gel F-254 plates (thickness 0.25 mm). Electrospray MS spectra were obtained on a Micromass platform LCMS spectrometer.
  • DMAP 4-dimethylaminopyridine
  • DME ethyleneglycol dimethyl ether
  • EDCI l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
  • HO AT l-hydroxy-7-azabenzotriazole
  • HOBT 1-hydroxybenzotriazole hydrate
  • HPLC high performance liquid chromatography
  • MTBE tert-butyl methyl ether
  • RP LC-MS reversed-phase liquid chromatography-mass spectrometry
  • TEA triethylamine
  • TFA trifluoroacetic acid
  • THF tetrahydrofuran
  • the carboxylic acid ester was dissolved (0.05 M) in a large excess of the amine in 40 or 70% water-solution.
  • the reaction mixture was stirred at ambient temperature over night.
  • the solvent was removed under reduced pressure and the crude product was purified by flash column chromatography on silica gel eluting with methanol (0— >6%) in DCM.
  • the carboxylic acid was suspended in DCM (0.05M) followed by the addition of EDCI (1.1 eq), triethylamine (3 eq), DMAP (0.5 eq) and the amine of choice (1.2 eq). DMF was added when the starting materials did not dissolve properly. The reaction mixture was stirred at ambient temperature over night. The organic phase was washed with aqueous HCl (1 M), dried over sodium sulfate, filtered and evaporated in vacuo. The crude product amide was purified by flash column chromatography on silica gel, eluting with methanol (l-»3— 6%) in DCM or ethyl acetate.
  • the carboxylic acid was suspended in DCM (0.1 M) and cooled to 0°C under nitrogen (g) atmosphere.
  • EDCI (1 eq)
  • HO AT (1 eq)
  • HOBT (1 eq)
  • TEA 2.2 eq
  • the amine of choice 1.2 eq
  • the reaction mixture was allowed to warm to ambient temperature.
  • the DCM phase was washed with aqueous HCl (1 M) and worked up and purified as described in METHOD E.
  • Arylsulfonyl chlorides that were not commercially available were prepared from the aniline derivatives according to literature procedures (see for instance: Hoffman, R. N. (1981) Org. Synth. 60: 121).
  • 2-amino-5-thiazoleacetic acid, ethyl ester is available from Ambinter, 46 quai Louis Bleriot, Paris, F-75016, France. The preparation thereof has been described in:
  • Step a preparation of 2-(2-amino- 3-thiazol-5-yl)ethanol 2,3-dichlorotetrahydrofurane (5 g; 0,035 mol) and thiourea (2,7 g; 0,035 mol) were refluxed for 12 h in water (20 ml). Then 40 ml of 40% NaOH (aq) were added, the reaction mixture was cooled to room temperature and stirred for one hour. The formed precipitate was filtered off, dried at reduced pressure and recrystallized from EtOH/Et 2 O. HCl, 2M in Et 2 O, was added to form the HCl-salt which was isolated by filtration and dried. Yielded 3,8 g, 61%.
  • Step b preparation of 3-chloro-2-methyl-N-r5-(2-mo ⁇ holin-4-ylethyl)- 3-thiazol-2- yl]benzenesulfonamide
  • methyl 4-oxobutanoate was synthesized from the commercially available methyl 4,4-dimethoxybutyrate according to a literature procedure; Will, S. G.; Magriotis, P.; Marinelli, E. R.; Dolan, J.; Johnson, F. J. Org. Chem., 1985, 50, 5433-5434.
  • methyl 3-bromo-4-oxobutanoate was obtained from methyl 4- oxobutanoate following a literature procedure; Aeberli, M.; Erlenmeyer. H. Hel. Chim. Ada., 1950, 70, 503-505.
  • Step b preparation of methyl (2-([(3-chloro-2-methylphenyl)sulfonvnamino>- 3- thiazol-5-yl)acetate
  • Example 2 To methyl (2- ⁇ [(3-chloro-2-methylphenyl)sulfonyl]amino ⁇ -l,3-thiazol-5- yl)acetate (Example 2) (0.2 g, 0.55 mmol) dissolved in EtOH (5.5 mL) was added aqueous KOH (0.6 mL, 5.5 M). The reaction mixture was stirred at room temperature for

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to compounds with the formula (I), and also to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11-b-hydroxysteroid dehydrogenase type 1 enzyme.

Description

INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE
TYPE 1
RELATED APPLICATIONS
This application claims priority to Swedish application number 0103911-4, filed on November 22, 2001, and U.S. provisional application number 60/348,617, filed on January 14, 2002, the contents of which are incorporated herein by reference.
TECHNICAL FIELD
The present invention relates to novel compounds, to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11 -β- hydroxysteroid dehydrogenase type 1 enzyme (llβHSDl).
BACKGROUND
1. Glucorticoids, diabetes and hepatic glucose production
It has been known for more than half a century that glucocorticoids have a central role in diabetes, e.g. the removal of the pituitary or the adrenal gland from a diabetic animal alleviates the most severe symptoms of diabetes and lowers the concentration of glucose in the blood (Long, CD. and F.D.W. Leukins (1936) J. Exp. Med. 63: 465-490; Houssay, B.A. (1942) Endocrinology 30: 884-892). It is also well established that glucocorticoids enable the effect of glucagon on the liver.
The role of 1 lβHSDl as an important regulator of local glucocorticoid effect and thus of hepatic glucose production is well substantiated (see e.g. Jamieson et al. (2000) J. Endocrinol. 165: p. 685-692). The hepatic insulin sensitivity was improved in healthy human volunteers treated with the non-specific 1 lβHSDl inhibitor carbenoxolone (Walker, B.R. et al. (1995) J. Clin. Endocrinol. Metab. 80: 3155-3159). Furthermore, the expected mechanism has been established by different experiments with mice and rats. These studies showed that the mRNA levels and activities of two key enzymes in hepatic glucose production were reduced, namely: the rate-limiting enzyme in gluconeogenesis, phosphoenolpyruvate carboxykinase (PEPCK), and glucose-6-phosphatase (G6Pase) catalyzing the last common step of gluconeogenesis and glycogenolysis. Finally, the blood glucose level and hepatic glucose production is reduced in mice having the 1 lβHSDl gene knocked-out. Data from this model also confirm that inhibition of 1 lβHSDl will not cause hypoglycemia, as predicted since the basal levels of PEPCK and G6Pase are regulated independently of glucocorticoids (Kotelevtsev, Y. et al., (1997) Proc. Natl. Acad. Sci. USA 94: 14924-14929). FR 2,384,498 discloses compounds having a high hypoglycemic effect. Therefore, treatment of hyperglycemia with these compounds may lead to hypoglycemia.
2. Possible reduction of obesity and obesity related cardiovascular risk factors
Obesity is an important factor in syndrome X as well as in the majority (> 80%) of type 2 diabetic, and omental fat appears to be of central importance. Abdominal obesity is closely associated with glucose intolerance, hyperinsulinemia, hypertriglyceridemia, and other factors of the so-called syndrome X (e.g. raised blood pressure, decreased levels of HDL and increased levels of VLDL) (Montague & O'Rahilly, Diabetes 49: 883-888, 2000). Inhibition of the enzyme in pre-adipocytes (stromal cells) has been shown to decrease the rate of differentiation into adipocytes. This is predicted to result in diminished expansion (possibly reduction) of the omental fat depot, i.e. reduced central obesity (Bujalska, I.J., S. Kumar, and P.M. Stewart (1997) Lancet 349: 1210-1213).
Inhibition of 11 βHSDl in mature adipocytes is expected to attenuate secretion of the plasminogen activator inhibitor 1 (PAI-1) - an independent cardiovascular risk factor (Halleux, CM. et al. (1999) J. Clin. Endocrinol. Metab. 84: 4097-4105). Furthermore, there is a clear correlation between glucocorticoid "activity" and cardiovascular risk factore suggesting that a reduction of the glucocorticoid effects would be beneficial (Walker, B.R. et al. (1998) Hypertension 31 : 891-895; Fraser, R. et al. (1999) Hypertension 33: 1364-1368).
Adrenalectomy attenuates the effect of fasting to increase both food intake and hypothalamic neuropeptide Y expression. This supports the role of glucocorticoids in promoting food intake and suggests that inhibition of 1 lβHSDl in the brain might increase satiety and therefore reduce food intake (Woods, S.C. et al. (1998) Science, 280: 1378-1383).
3. Possible beneficial effect on the pancreas
Inhibition of 1 lβHSDl in isolated murine pancreatic β-cells improves the glucose-stimulated insulin secretion (Davani, B. et al. (2000) J. Biol. Chem. 2000 Nov 10; 275(45): 34841-4). Glucocorticoids were previously known to reduce pancreatic insulin release in vivo (Billaudel, B. and B.CJ. Sutter (1979) Horm. Metab. Res. 11: 555- 560). Thus, inhibition of 1 lβHSDl is predicted to yield other beneficial effects for diabetes treatment, besides effects on liver and fat.
4. Possible beneficial effects on cognition and dementia
Stress and glucocorticoids influence cognitive function (de Quervain, DJ.-F., B.
Roozendaal, and J.L. McGaugh (1998) Nature 394: 787-790). The enzyme 1 lβHSDl controls the level of glucocorticoid action in the brain and thus contributes to neurotoxicity (Rajan, V., C.R.W. Edwards, and J.R. Seckl, J. (1996) Neuroscience 16: 65- 70; Seckl, J.R., Front. (2000) Neuroendocrinol. 18: 49-99). Unpublished results indicate significant memory improvement in rats treated with a non-specific 11 βHSD 1 inhibitor (J. Seckl, personal communication). Based the above and on the known effects of glucocorticoids in the brain, it may also be suggested that inhibiting 1 lβHSDl in the brain may result in reduced anxiety (Tronche, F. et al. (1999) Nature Genetics 23: 99- 103). Thus, taken together, the hypothesis is that inhibition of 1 lβHSDl in the human brain would prevent reactivation of cortisone into cortisol and protect against deleterious glucocorticoid-mediated effects on neuronal survival and other aspects of neuronal function, including cognitive impairment, depression, and increased appetite (previous section).
WO 99/02502 discloses 5HT6 receptor antagonists for the treatment of CNS disorders. Such antagonists of thiazole structure differ from the compounds according to the present invention in that the former have an aryl group in 4-position. Furthermore, nothing is said about the activity on 1 lβHSDl . 5. Possible use of immuno-modulation using 1 lβHSDl inhibitors
The general perception is that glucocorticoids suppress the immune system. But in fact there is a dynamic interaction between the immune system and the HPA (hypothalamo-pituitary-adrenal) axis (Rook, G.A.W. (1999) Baillier's Clin. Endocrinol. Metab. 13: 576-581). The balance between the cell-mediated response and humoral responses is modulated by glucocorticoids. A high glucocorticoid activity, such as at a state of stress, is associated with a humoral response. Thus, inhibition of the enzyme 1 lβHSDl has been suggested as a means of shifting the response towards a cell-based reaction.
In certain disease states, including tuberculosis, lepra and psoriasis the immune reaction is normaly biased towards a humoral response when in fact the appropriate response would be cell based. Temporal inhibition of 1 lβHSDl, local or systemic, might be used to push the immune system into the appropriate response (Mason, D. (1991) Immunology Today 12: 57-60; Rook et al., supra).
An analogous use of 11 βHSDl inhibition, in this case temporal, would be to booster the immune response in association with immunization to ensure that a cell based response would be obtained, when desired.
6. Reduction of intraocular pressure
Recent data suggest that the levels of the glucocorticoid target receptors and the 1 lβHSD enzymes determines the susceptibility to glaucoma (Stokes, J. et al. (2000) Invest. Ophthalmol. 41: 1629-1638). Further, inhibition of 11 βHSDl was recently presented as a novel approach to lower the intraocular pressure (Walker E. A. et al, poster P3-698 at the Endocrine society meeting June 12-15, 1999, San Diego). Ingestion of carbenoxolone, a non-specific inhibitor of 1 lβHSDl, was shown to reduce the intraocular pressure by 20% in normal subjects. In the eye, expression of 1 lβHSDl is confined to basal cells of the corneal epithelium and the non-pigmented epithelialium of the cornea (the site of aqueous production), to ciliary muscle and to the sphincter and dilator muscles of the iris. In contrast, the distant isoenzyme 1 lβHSD2 is highly expressed in the non- pigmented ciliary epithelium and corneal endothelium. None of the enzymes is found at the trabecular meshwork, the site of drainage. Thus, 1 lβHSDl is suggested to have a role in aqueous production, rather than drainage, but it is presently unknown if this is by interfering with activation of the glucocorticoid or the mineralocorticoid receptor, or both.
7. Reduced osteoporosis
Glucocorticoids have an essential role in skeletal development and function but are detrimental in excess. Glucocorticoid-induced bone loss is derived, at least in part, via inhibition of bone formation, which includes suppression of osteoblast proliferation and collagen synthesis (Kim, C.H., S.L. Cheng, and G.S. Kim (1999) J. Endocrinol. 162: 371- 379). The negative effect on bone nodule formation could be blocked by the non-specific inhibitor carbenoxolone suggesting an important role of 1 lβHSDl in the glucocorticoid effect (Bellows, C.G., A. Ciaccia, and J.N.M. Heersche, (1998) Bone 23: 119-125). Other data suggest a role of 1 lβHSDl in providing sufficiently high levels of active glucocorticoid in osteoclasts, and thus in augmenting bone resorption (Cooper, M.S. et al. (2000) Bone 27: 375-381). Taken together, these different data suggest that inhibition of 11 βHSDl may have beneficial effects against osteoporosis by more than one mechanism working in parallel.
8. Reduction of hypertension
Bile acids inhibit 1 lβ-hydroxysteroid dehydrogenase type 2. This results in a shift in the overall body balance in favour of cortisol over cortisone, as shown by studying the ratio of the urinary metabolites (Quattropani C, Vogt B, Odermatt A, Dick B, Frey BM, Frey FJ. 2001. J Clin Invest. Nov; 108(9): 1299-305. "Reduced activity of 1 lbeta- hydroxysteroid dehydrogenase in patients with cholestasis".). Reducing the activity of 1 lβHSDl in the liver by a selective inhibitor is predicted to reverse this imbalance, and acutely counter the symptoms such as hypertension, while awaiting surgical treatment removing the biliary obstruction. WO 99/65884 discloses carbon substituted aminothiazole inhibitors of cyclin dependent kinases. These compounds may e.g. be used against cancer, inflammation and arthritis. US 5,856,347 discloses an antibacterial preparation or bactericide comprising 2- aminothiazole derivative and/or salt thereof. Further, US 5,403,857 discloses benzenesulfonamide derivatives having 5-lipoxygenase inhibitory activity. Additionally, tetrahydrothiazolo[5,4-c]pyridines are disclosed in: Analgesic tetrahydrothiazolo[5,4- c]pyridines. Fr. Addn. (1969), 18 pp, Addn. to Fr. 1498465. CODEN: FAXXA3; FR 94123 19690704 CAN 72:100685 AN 1970:100685 CAPLUS and 4,5,6,7- Tetrahydrothiazolo[5,4-c]pyridines. Neth. Appl. (1967), 39 pp. CODEN: NAXXAN NL 6610324 19670124 CAN 68:49593, AN 1968: 49593 CAPLUS. However, none of the above disclosures discloses the compounds according to the present invention, or their use for the treatment of diabetes, obesity, glaucoma, osteoporosis, cognitive disorders, immune disorders, depression, and hypertension. US 5,594,021 and US 6,030,991 disclose compounds inhibiting the binding of an endothelin peptide to an endothelin receptor. Such compounds of thiazole structure differ from the compounds according to the present invention in that the former are unsubstituted in both 4- and 5-position. Furthermore, nothing is said about the activity on 11 βHSDl . WO 01/54691 discloses thiazole compounds as antimicrobial agents. Only the antibacterial effect of such compounds has been shown in the pharmacological examples. These compounds differ from the compounds according to the present invention in that the former either are unsubstituted in 5-position or have a free amino group in 2-position. US 5,783,597 discloses thiophene derivatives as inhibitors of PGE2 and LTB4. Nothing is said about the activity on 11 βHSD 1.
Consequently, there is a need of new compounds that are useful in the treatment of diabetes, obesity, glaucoma, osteoporosis, cognitive disorders, immune disorders, depression, and hypertension.
SUMMARY OF THE INVENTION
The compounds according to the present invention solves the above problems and embraces a novel class of compounds which has been developed and which inhibit the human 11-β-hydroxysteroid dehydrogenase type 1 enzyme (1 l-β-HSD , and may therefore be of use in the treating disorders such as diabetes, obesity, glaucoma, osteoporosis, cognitive disorders, immune disorders, and hypertension. One object of the present invention is a compound of formula (I)
Figure imgf000008_0001
wherein T is an aryl ring or heteroaryl ring, optionally independently substituted by [R]n, wherein n is an integer 0-5, and R is hydrogen, aryl, heteroaryl, a heterocyclic ring, optionally halogenated C1-6-alkyl, optionally halogenated C1-6-alkoxy, C1-6-alkylsulfonyl, carboxy, cyano, nitro, halogen, aryloxy, arylsulfonyl, arylamino, wherein aryl, heteroaryl and aryloxy residues and heterocyclic rings can further be optionally substituted in one or more positions independently of each other by C1-6-acyl, C1-6-alkylthio, cyano, nitro, hydrogen, halogen, optionally halogenated C1-6-alkyl, optionally halogenated C1-6-alkoxy, amide which is optionally mono- or di-substituted, (benzoylamino)methyl, carboxy, 2- thienylmethylamino or ({[4-(2-ethoxy-2-oxoethyl)-l,3-thiazol-2-yl]amino}carbonyl); or T is selected from 5-(dimethylamino)-l-naphthyl and phenyl substituted with one or more of benzeneamino, benzylamino, 3-pyridylmethylamino and 2-thienylmethylamino;
R1 is hydrogen or C1-6-alkyl;
X is CH2 or CO;
Y is CH2, CO or a single bond;
B is hydrogen, C1-6-alkyl or dimethylaminomethyl; R is selected from C1-6-alkyl, azido, arylthio, heteroarylthio, halogen, hydroxymethyl, 2-hydroxyethylaminomethyl, methylsulfonyloxymethyl, 3-oxo-4- morpholinolinylmethylene, C1-6-alkoxycarbonyl, 5-methyl- 1 ,3,4-oxadiazol-2-yl;
NR3R4, wherein R3 and R4 are each independently selected from hydrogen, ethyl, isopropyl, n-propyl, optionally halogenated C1-6-alkylsulfonyl, C1-6-alkoxy, 2- methoxyethyl, 2-hydroxyethyl, 1-methylimidazolylsulfonyl, C1-6-acyl, cyclohexylmethyl, cyclopropanecarbonyl, aryl, optionally halogenated arylsulfonyl, furylcarbonyl, tetrahydro-2-furanylmethyl, N-carbethoxypiperidyl, or C^-all yl substituted with one or more aryl, heterocyclic or heteroaryl, or NR3R4 represent together heterocyclic systems which can be imidazole, piperidine, pyrrolidine, piperazine, morpholine, oxazepine, oxazole, thiomorpholine, 1,1- dioxidothiomorpholine, 2-(3,4-dihydro-2(lH)isoquinolinyl), (1 S,4S)-2-oxa-5- azabicyclo[2.2.1]hept-5-yl, which heterocyclic systems can be optionally substituted by C1-6-alkyl, C1-6-acyl, hydroxy, oxo, t-butoxycarbonyl;
OCONR3R4, wherein R3 and R4 are each independently selected from hydrogen, C1-6-alkyl or form together with the N-atom to which they are attached morpholinyl;
R5O, wherein R5 is hydrogen, optionally halogenated C1-6-alkyl, aryl, heteroaryl, C1-6-acyl, C1-6-alkylsulfonyl, arylcarbonyl, heteroarylcarbonyl, 2-carbomethoxyphenyl; or a salt, hydrate or solvate thereof; with the proviso that when:
X is CH2, Y is CH2, then R2 is not methyl, ethyl, diethylamino, 1 -pyrrolidinyl, and 1 -piperidinyl;
X is CH2, Y is CH , R2 is morpholinyl, then T is not 4-methylphenyl; X is CH2, Y is CO, then R2 is not hydroxy;
X is CH2, Y is a single bond, then R is not ethyl, n-propyl;
X is CH , Y is a single bond, R2 is methyl, B is methyl, then T is not 3-chloro-2- methylphenyl;
X is CO, Y is a single bond, then R2 is not methyl; X is CO, Y is a single bond, R2 is ethoxy, B is methyl, then T is not 3-chloro-2- methylphenyl, l, -biphenyl-4-yl, 4-n-propylphenyl, 2,4-dichloro-6-methylphenyl, and 2,4,6-trichlorophenyl.
It is preferred that:
T is selected from 5-chloro-l,3-dimethyl-lH-pyrazol-4-yl; 4-chloro-2,3,l- benzoxadiazolyl; 5-(dimethylamino)- 1-naphthyl; l-methylimidazol-4-yl; 1-naphthyl; 2- naphthyl; 8-quinolinyl; thienyl substituted with one or more of (benzoylamino)methyl, bromo, chloro, 3- isoxazolyl, 2-(methylsulfanyl)-4-pyrimidinyl, 1 -methyl-5-(trifluoromethyl)pyrazol-3-yl, phenylsulfonyl, pyridyl; phenyl substituted with one or more of 3-acetylaminophenyl, 3-acetylphenyl, benzeneamino, l,3-benzodioxol-5-yl, 2-benzofuryl, benzylamino, 3,5- bis(trifluoromethyl)phenyl, bromo, butoxy, carboxy, chloro, 4-carboxyphenyl, 3-chloro- 2-cyanophenoxy, 4-chlorophenyl, 5-chloro-2-thienyl, cyano, 3,4-dichlorophenyl, ({[4-(2- ethoxy-2-oxoethyl)-l,3-thiazol-2-yl]amino}carbonyl), fluoro, 5-fluoro-2-methoxyphenyl, 2-furyl, hydrogen, iodo, isopropyl, methanesulfonyl, methoxy, methyl, 4-methyl-l- piperazinyl, 4-methyl-l -piperidinyl, 4-methylsulfanylphenyl, 5-methyl-2-thienyl, 4- morpholinyl, nitro, 3-nitrophenyl, phenoxy, phenyl, n-propyl, 4-pyridyl, 3- pyridylmethylamino, 1 -pyrrolidinyl, 2-thienyl, 3-thienyl, 2-thienylmethylamino, trifluoromethoxy, 4-trifluoromethoxyphenyl, trifluoromethyl; or
R1 is hydrogen or methyl;
X is CH2 or CO;
Y is CH2, CO or a single bond;
B is hydrogen, methyl or dimethylaminomethyl; R2 is selected from n-propyl, azido, bromo, chloro, 2-pyridmylsulfanyl, 3-oxo-4-morpholinolinyl- methylene, ethoxycarbonyl, 5-methyl-l,3,4-oxadiazol-2-yl, hydroxymethyl, 2- hydroxyethylaminomethyl, methylsulfonyloxymethyl;
NR3R4, wherein R3 and R4 are each independently selected from acetyl, benzhydryl, l,3-benzodioxol-5-ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexyl, cyclohexylmethyl, cyclopropanecarbonyl, ethyl, 2-furylcarbonyl, 2- furylmethyl, hydrogen, 2-hydroxyethyl, 2-(lH-indol-3-yl)ethyl, isopropyl, methoxy, 2- methoxyethyl, 4-(l-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl, (lS)-phenylethyl, n-propyl, tetrahydro-2-furanylmethyl, trifluoromethylsulfonyl, N-carbethoxypiperidyl; or NR3R4 represent together 4-acetylpiperazinyl, 4-t-butoxycarbonylpiperazinyl, 2-
(3,4-dihydro-2(lH)isoquinolinyl), (2R,6S)-2,6-dimethylmorpholinyl, (2R)-2,4-dimethyl- 1 -piperazinyl, 2-hydroxy-3-oxomorpholinyl, imidazolyl, 2-methyl-3-oxomorpholinyl, 4- methyl-2-oxoρiperazinyl, 4-methylpiperazinyl, morpholinyl, (lS,4S)-2-oxa-5-aza- bicyclo[2.2.1]hept-5-yl, 2-oxoimidazolinyl, 3-oxomorpholinyl, 3-oxo-l,4-oxazepinyl, 2- oxooxazolinyl, piperazinyl; piperidinyl; pyrrolidinyl; pyrrolidonyl, thiomoφholinyl; 1,1- dioxido-thiomoφholinyl;
OCONR3R4, wherein R3 and R4 are each independently selected from ethyl, hydrogen or form together with the N-atom to which they are attached moφholinyl;
R5O, wherein R5 is acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, n-propionyl, 3-pyridinyl, 2,2,2-trifluoroethyl; with the proviso that when:
X is CH2, Y is CH2, then R2 is not diethylamino, 1 -pyrrolidinyl, and 1 -piperidinyl;
X is CH2, Y is CH2, R2 is moφholinyl, then T is not 4-methylphenyl; X is CH2, Y is CO, then R2 is not hydroxy;
X is CH2, Y is a single bond, then R2 is not n-propyl;
X is CO, Y is a single bond, R2 is ethoxy, B is methyl, then T is not 3-chloro-2- methylphenyl, l,l '-biphenyl-4-yl, 4-n-propylphenyl, 2,4-dichloro-6-methylphenyl, and 2,4,6-trichlorophenyl.
When X is CH2 and Y is CH2, then it is preferred that:
R2 is selected from n-propyl, azido, bromo, chloro, 2-pyridinylsulfanyl, 3-oxo-4- moφholinolinylmethylene, ethoxycarbonyl, 5-methyl- 1 ,3,4-oxadiazol-2-yl, hydroxymethyl, 2-hydroxyethylaminomethyl, methylsulfonyloxymethyl; NR3R4, wherein:
(i) R3 and R4 are either each independently selected from acetyl, benzhydryl, 1,3- benzodioxol-5-ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexyl, cyclohexylmethyl, cyclopropanecarbonyl, 2-furylcarbonyl, 2-furylmethyl, hydrogen, 2-hydroxyethyl, 2-(lH-indol-3-yl)ethyl, isopropyl, methoxy, 2- methoxyethyl, methyl, 4-(l-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl,
(lS)-phenylethyl, n-propyl, tetrahydro-2-furanylmethyl, trifluoromethylsulfonyl,
N-carbethoxypiperidyl; or (ii) R3 is ethyl and R4 is selected from acetyl, benzhydryl, l,3-benzodioxol-5- ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexyl, cyclohexylmethyl, cyclopropanecarbonyl, 2-furylcarbonyl, 2-furylmethyl, hydrogen, 2-hydroxyethyl, 2-(lH-indol-3-yl)ethyl, isopropyl, methoxy, 2- methoxyethyl, methyl, 4-(l-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl,
(lS)-phenylethyl, n-propyl, tetrahydro-2-furanylmethyl, trifluoromethylsulfonyl,
N-carbethoxypiperidyl; NR3R4 represent together 4-acetylpiperazinyl, 4-t-butoxycarbonylpiρerazinyl, 2-
(3,4-dihydro-2(lH)isoquinolinyl), (2R,6S)-2,6-dimethylmoφholinyl, (2R)-2,4-dimethyl- 1 -piperazinyl, 2-hydroxy-3-oxomoφholinyl, imidazolyl, 2-methyl-3-oxomoφholinyl, 4- methyl-2-oxopiperazinyl, 4-methylpiperazinyl, ( 1 S,4S)-2-oxa-5-aza-bicyclo[2.2.1 ]hept-5- yl, 2-oxoimidazolinyl, 3-oxomoφholinyl, 3-oxo-l,4-oxazepinyl, 2-oxooxazolinyl, piperazinyl; pyrrolidonyl, thiomoφholinyl; 1,1-dioxido-thiomoφholinyl;
OCONR3R4, wherein R3 and R4 are each independently selected from ethyl, hydrogen or form together moφholinyl; R5O, wherein R5 is acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, n-propionyl, 3-pyridinyl, 2,2,2-trifluoroethyl.
When X is CH2,Y is CH2, and NR3R4 represent together moφholinyl, then it is preferred that T is selected from 5-chloro-l,3-dimethyl-lH-pyrazol-4-yl; 4-chloro-2,3,l- benzoxadiazolyl; 5-(dimethylamino)- 1-naphthyl; l-methylimidazol-4-yl; 1-naphthyl; 2- naphthyl; 8-quinolinyl; thienyl substituted with one or more of (benzoylamino)methyl, bromo, chloro, 3- isoxazolyl, 2-(methylsulfanyl)-4-pyrimidinyl, 1 -methyl-5-(trifluoromethyl)pyrazol-3-yl, phenylsulfonyl, pyridyl; phenyl substituted with either: (i) one or more of 3-acetylaminophenyl, 3-acetylphenyl, benzeneamino, 1,3- benzodioxol-5-yl, 2-benzofuryl, benzylamino, 3,5-bis(trifluoromethyl)phenyl, bromo, butoxy, carboxy, chloro, 4-carboxyphenyl, 3-chloro-2-cyanophenoxy, 4- chlorophenyl, 5-chloro-2-thienyl, cyano, 3,4-dichlorophenyl, ({[4-(2-ethoxy-2- oxoethyl)-l,3-thiazol-2-yl]amino}carbonyl), fluoro, 5-fluoro-2-rnethoxyphenyl, 2- furyl, hydrogen, iodo, isopropyl, methanesulfonyl, methoxy, 4-methyl-l- piperazinyl, 4-methyl-l -piperidinyl, 4-methylsulfanylphenyl, 5-methyl-2-thienyl,
4-moφholinyl, nitro, 3-nitrophenyl, phenoxy, phenyl, n-propyl, 4-pyridyl, 3- pyridylmethylamino, 1 -pyrrolidinyl, 2-thienyl, 3 -thienyl, 2-thienylmethylamino, trifluoromethoxy, 4-trifluoromethoxyphenyl, trifluoromethyl; or (ii) one or more of methyl in any of positions 2, 3, 5 or 6.
When X is CH2 and Y is CO, then it is preferred that R2 is selected from n-propyl, azido, bromo, chloro, 2-pyridinylsulfanyl, 3-oxo-4-moφholinolinylmethylene, ethoxycarbonyl, 5-methyl-l,3,4-oxadiazol-2-yl, hydroxymethyl, 2- hydroxyethylaminomethyl, methylsulfonyloxymethyl;
NR3R4, wherein R3 and R4 are each independently selected from acetyl, benzhydryl, l,3-benzodioxol-5-ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexyl, cyclohexylmethyl, cyclopropanecarbonyl, ethyl, 2-furylcarbonyl, 2- furylmethyl, hydrogen, 2-hydroxyethyl, 2-(lH-indol-3-yl)ethyl, isopropyl, methoxy, 2- methoxy ethyl, methyl, 4-(l-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl, (1S)- phenylethyl, n-propyl, tetrahydro-2-furanylmethyl, trifluoromethylsulfonyl, N- carbethoxypiperidyl; or NR3R4 represent together 4-acetylpiperazinyl, 4-t-butoxycarbonylpiperazinyl, 2- (3,4-dihydro-2(lH)isoquinolinyl), (2R,6S)-2,6-dimethylmoφholinyl, (2R)-2,4-dimethyl- 1 -piperazinyl, 2-hydroxy-3-oxomoφholinyl, imidazolyl, 2-methyl-3-oxomoφholinyl, 4- methyl-2-oxopiperazinyl, 4-methylpiperazinyl, moφholinyl, (lS,4S)-2-oxa-5-aza- bicyclo[2.2.1]hept-5-yl, 2-oxoimidazolinyl, 3-oxomoφholinyl, 3-oxo-l,4-oxazepinyl, 2- oxooxazolinyl, piperazinyl; piperidinyl; pyrrolidinyl; pyrrolidonyl, thiomoφholinyl; 1,1- dioxido-thiomoφholinyl;
OCONR3R4, wherein R3 and R4 are each independently selected from ethyl, hydrogen or form together with the N-atom to which they are attached moφholinyl; R5O, wherein R5 is acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, n- propionyl, 3-pyridinyl, 2,2,2-trifluoroethyl.
When X is CH2 and Y is a single bond, then it is preferred that R2 is selected from azido, bromo, chloro, 2-pyridinylsulfanyl, 3-oxo-4-moφholinolinylmethylene, ethoxycarbonyl, 5-methyl-l,3,4-oxadiazol-2-yl, hydroxymethyl, 2- hydroxyethylaminomethyl, methylsulfonyloxymethyl;
NR3R4, wherein R3 and R4 are each independently selected from acetyl, benzhydryl, l,3-benzodioxol-5-ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexyl, cyclohexylmethyl, cyclopropanecarbonyl, ethyl, 2-furylcarbonyl, 2- furylmethyl, hydrogen, 2-hydroxyethyl, 2-(lH-indol-3-yl)ethyl, isopropyl, methoxy, 2- methoxyethyl, methyl, 4-(l-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl, (1S)- phenylethyl, n-propyl, tetrahydro-2-furanylmethyl, trifluoromethylsulfonyl, N- carbethoxypiperidyl; or
NR3R4 represent together 4-acetylpiperazinyl, 4-t-butoxycarbonylpiperazinyl, 2- (3,4-dihydro-2(lH)isoquinolinyl), (2R,6S)-2,6-dimethylmoφholinyl, (2R)-2,4-dimethyl- 1 -piperazinyl, 2-hydroxy-3-oxomoφholinyl, imidazolyl, 2-methyl-3-oxomoφholinyl, 4- methyl-2-oxopiperazinyl, 4-methylpiperazinyl, moφholinyl, (lS,4S)-2-oxa-5-aza- bicyclo[2.2.1]hept-5-yl, 2-oxoimidazolinyl, 3-oxomoφholinyl, 3-oxo-l,4-oxazepinyl, 2- oxooxazolinyl, piperazinyl; piperidinyl; pyrrolidinyl; pyrrolidonyl, thiomoφholinyl; 1,1- dioxido-thiomoφholinyl;
OCONR3R4, wherein R3 and R4 are each independently selected from ethyl, hydrogen or form together with the N-atom to which they are attached moφholinyl; R5O, wherein R5 is acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, n-propionyl, 3-pyridinyl, 2,2,2-trifluoroethyl.
When X is CH2, Y is a single bond, R2 is methyl and B is methyl, then it is preferred that T is selected from 5-chloro-l,3-dimethyl-lH-pyrazol-4-yl; 4-chloro-2,3,l- benzoxadiazolyl; 5-(dimethylamino)- 1-naphthyl; l-methylimidazol-4-yl; 1-naphthyl; 2- naphthyl; 8-quinolinyl; thienyl substituted with one or more of (benzoylamino)methyl, bromo, chloro, 3- isoxazolyl, 2-(methylsulfanyl)-4-pyrimidinyl, l-methyl-5-(trifluoromethyl)pyrazol-3-yl, phenylsulfonyl, pyridyl; phenyl substituted with either: (i) one or more of 3-acetylarhinophenyl, 3-acetylphenyl, benzeneamino, 1,3- benzodioxol-5-yl, 2-benzofuryl, benzylamino, 3,5-bis(trifluoromethyl)phenyl, bromo, butoxy, carboxy, 4-carboxyphenyl, 3-chloro-2-cyanophenoxy, 4- chlorophenyl, 5-chloro-2-thienyl, cyano, 3,4-dichlorophenyl, ({[4-(2-ethoxy-2- oxoethyl)-l,3-thiazol-2-yl]amino}carbonyl), fluoro, 5-fluoro-2-methoxyphenyl, 2- furyl, hydrogen, iodo, isopropyl, methanesulfonyl, methoxy, methyl, 4-methyl-l - piperazinyl, 4-methyl-l -piperidinyl, 4-methylsulfanylphenyl, 5-methyl-2-thienyl, 4-moφholinyl, nitro, 3-nitrophenyl, phenoxy, phenyl, n-propyl, 4-pyridyl, 3- pyridylmethylamino, 1 -pyrrolidinyl, 2-thienyl, 3-thienyl, 2-thienylmethylamino, trifluoromethoxy, 4-trifluoromethoxyphenyl, trifluoromethyl; or (ii) one or more of 3-acetylaminophenyl, 3-acetylphenyl, benzeneamino, 1,3- benzodioxol-5-yl, 2-benzofuryl, benzylamino, 3,5-bis(trifluoromethyl)phenyl, bromo, butoxy, carboxy, chloro, 4-carboxyphenyl, 3-chloro-2-cyanophenoxy, 4- chlorophenyl, 5-chloro-2-thienyl, cyano, 3,4-dichlorophenyl, ({[4-(2-ethoxy-2- oxoethyl)-l,3-thiazol-2-yl]amino}carbonyl), fluoro, 5-fluoro-2-methoxyphenyl, 2- furyl, hydrogen, iodo, isopropyl, methanesulfonyl, methoxy, 4-methyl-l- piperazinyl, 4-methyl-l -piperidinyl, 4-methylsulfanylphenyl, 5-methyl-2-thienyl, 4-moφholinyl, nitro, 3-nitrophenyl, phenoxy, phenyl, n-propyl, 4-pyridyl, 3- pyridylmethylamino, 1 -pyrrolidinyl, 2-thienyl, 3-thienyl, 2-thienylmethylamino, trifluoromethoxy, 4-trifluoromethoxyphenyl, trifluoromethyl; or (iii) one or more chloro and, in positions 3, 4, 5, one or more methyl.
When X is CO and Y is a single bond, then it is preferred that R2 is selected from n-propyl, azido, bromo, chloro, 2-pyridinylsulfanyl, 3-oxo-4-moφholinolinylmethylene, ethoxycarbonyl, 5-methyl-l,3,4-oxadiazol-2-yl, hydroxymethyl, 2- hydroxyethylaminomethyl, methylsulfonyloxymethyl;
NR3R4, wherein R3 and R4 are each independently selected from acetyl, benzhydryl, l,3-benzodioxol-5-ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexyl, cyclohexylmethyl, cyclopropanecarbonyl, ethyl, 2-furylcarbonyl, 2- furylmethyl, hydrogen, 2-hydroxyethyl, 2-(lH-indol-3-yl)ethyl, isopropyl, methoxy, 2- methoxyethyl, methyl, 4-(l-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl, (1S)- phenylethyl, n-propyl, tetrahydro-2-furanylmethyl, trifluoromethylsulfonyl, N- carbethoxypiperidyl; or NR3R4 represent together 4-acetylpiperazinyl, 4-t-butoxycarbonylpiperazinyl, 2-
(3,4-dihydro-2(lH)isoquinolinyl), (2R,6S)-2,6-dimethylmoφholinyl, (2R)-2,4-dimethyl- 1 -piperazinyl, 2-hydroxy-3-oxomoφholinyl, imidazolyl, 2-methyl-3-oxomoφholinyl, 4- methyl-2-oxopiperazinyl, 4-methylpiperazinyl, moφholinyl, (lS,4S)-2-oxa-5-aza- bicyclo[2.2.1]hept-5-yl, 2-oxoimidazolinyl, 3-oxomoφholinyl, 3-oxo-l,4-oxazepinyl, 2- oxooxazolinyl, piperazinyl; piperidinyl; pyrrolidinyl; pyrrolidonyl, thiomoφholinyl; 1,1- dioxido-thiomoφholinyl;
OCONR3R4, wherein R3 and R4 are each independently selected from ethyl, hydrogen or form together with the N-atom to which they are attached moφholinyl;
R5O, wherein R5 is acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, n-propionyl, 3-pyridinyl, 2,2,2-trifluoroethyl;
When X is CO and Y is a single bond and R2 is ethoxy, then it is preferred that T is selected from 5-chloro-l,3-dimethyl-lH-pyrazol-4-yl; 4-chloro-2,3,l -benzoxadiazolyl; 5-(dimethylamino)- 1-naphthyl; l-methylimidazol-4-yl; 1-naphthyl; 2-naphthyl; 8- quinolinyl; thienyl substituted with one or more of (benzoylamino)methyl, bromo, chloro, 3- isoxazolyl, 2-(methylsulfanyl)-4-pyrimidinyl, 1 -methyl-5-(trifluoromethyl)pyrazol-3-yl, phenylsulfonyl, pyridyl; phenyl substituted with either: (i) one or more of 3-acetylaminophenyl, 3-acetylphenyl, benzeneamino, 1,3- benzodioxol-5-yl, 2-benzofuryl, benzylamino, 3,5-bis(trifluoromethyl)phenyl, bromo, butoxy, carboxy, 4-carboxyphenyl, 3-chloro-2-cyanophenoxy, 4- chlorophenyl, 5-chloro-2-thienyl, cyano, 3,4-dichlorophenyl, ({[4-(2-ethoxy-2- oxoethyl)-l,3-thiazol-2-yl]amino}carbonyl), fluoro, 5-fluoro-2-methoxyphenyl, 2- furyl, hydrogen, iodo, isopropyl, methanesulfonyl, methoxy, 4-methyl-l - piperazinyl, 4-methyl-l -piperidinyl, 4-methylsulfanylphenyl, 5-methyl-2-thienyl, 4-moφholinyl, nitro, 3-nitrophenyl, phenoxy, 4-pyridyl, 3 -pyridylmethylamino, 1- pyrrolidinyl, 2-thienyl, 3-thienyl, 2-thienylmethylamino, trifluoromethoxy, 4- trifluoromethoxyphenyl, trifluoromethyl;
(ii) one or more of methyl; (iii) one or more of chloro, phenyl and n-propyl in either position, and methyl in any of positions 3, 4 or 5; (iv) one or more of n-propyl and phenyl in any of positions 2, 3, 5 or 6. The following compounds are especially preferred: ethyl (2- {[(2,4-dichloro-5-methylphenyl)sulfonyl]amino}-l ,3-thiazol-5-yl)acetate ethyl (2- {[(4-chlorophenyl)sulfonyl]amino}-l ,3-thiazol-5-yl)acetate ethyl (2- {[(2,4-difluorophenyl)sulfonyl] amino} -1 ,3-thiazol-5-yl)acetate ethyl (2-{[(2,5-dichlorothien-3-yl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate • ethyl (2-{[(2-chlorophenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate ethyl {2-[(l-naphthylsulfonyl)amino]-l,3-thiazol-5-yl}acetate ethyl (2- {[(3-chloro-2-methylphenyl)sulfonyl]amino}-l ,3-thiazol-5-yl)acetate 2-(2- { [(3-chloro-2-methylphenyl)sulfonyl] amino} - 1 ,3-thiazol-5-yl)-N- methylacetamide • 2-(2- { [(3 -chloro-2-methylphenyl)sulfonyl] amino } - 1 ,3 -thiazol-5-yl)-N- ethylacetamide ethyl {2-[( 1 , 1 '-biphenyl-4-ylsulfonyl)amino]- 1 ,3 -thiazol-5-yl} acetate ethyl (2- {[(4-nitrophenyl)sulfonyl]amino}-l ,3-thiazol-5-yl)acetate ethyl (2- { [(4-methoxyphenyl)sulfonyl] amino } - 1 ,3 -thiazol-5-yl)acetate • ethyl (2-{[(2,5-dichlorophenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate
3-cWoro-N-[5-(2-hydroxyethyl)-l,3-thiazol-2-yl]-2-methylbenzenesulfonamide 3-c oro-N-[5-(2-emoxyemyl)-l,3-thiazol-2-yl]-2-methylbenzenesulfonamide ethyl (2-{[(3-chlorophenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate ethyl (2- {[(4-fluorophenyl)sulfonyl] amino} - 1 ,3-thiazol-5-yl)acetate • ethyl (2-{[(4-isopropylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate ethyl [2-({[4-({[4-(2-ethoxy-2-oxoethyl)-l,3-thiazol-2- yl] amino } carbonyl)phenyl] sulfonyl } amino)- 1 ,3 -thiazol-5-yl] acetate 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)-N,N- diethylacetamide ethyl [2-( { [2-(trifluoromethyl)phenyl] sulfonyl } amino)- 1 ,3 -thiazol-5-yl] acetate ethyl [2-({[3-(trifluoromethyl)phenyl]sulfonyl}amino)-l,3-thiazol-5-yl]acetate ethyl [2-({[4-(trifluoromethyl)phenyl]sulfonyl}amino)-l,3-thiazol-5-yl]acetate methyl (2- {[(3-chloro-2-methylphenyl)sulfonyl]amino} - 1 ,3-thiazol-5-yl)acetate
(Example 2)
3-chloro-N-[5-(2-isopropoxyethyl)-l,3-thiazol-2-yl]-2-methylbenzenesulfonamide
3-cUoro-N-[5-(2-methoxyemyl)-l,3-thiazol-2-yl]-2-methylbenzenesulfonamide
2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)ethyl methanesulfonate
2-(2- { [(3-chloro-2-methylphenyl)sulfonyl] amino } - 1 ,3 -thiazol-5-yl)acetamide
3-chloro-N-{5-[2-(2-fluoroethoxy)ethyl]-l,3-thiazol-2-yl}-2- methylbenzenesulfonamide
3-chloro-2-methyl-N- {5-[2-(2,2,2-trifluoroethoxy)ethyl]- 1 ,3-thiazol-2- yl}benzenesulfonamide
2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)ethyl acetate
3-chloro-2-methyl-N-[5-(2-moφholin-4-ylethyl)- 1 ,3-thiazol-2- yl]benzenesulfonamide (Example 1)
N-[5-(2-bromoethyl)-l,3-thiazol-2-yl]-3-chloro-2-methylbenzenesulfonamide
2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)ethyl moφholine-4-carboxylate
2-(2- { [(3 -chloro-2-methylphenyl)sulfonyl] amino } - 1 ,3 -thiazol-5-yl)ethyl diethylcarbamate
2-(2- { [(3 -chloro-2-methylphenyl)sulfonyl] amino } - 1 ,3-thiazol-5-yl)ethyl propionate
2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)ethyl 2- methylpropanoate
2-(2- {[(3-chloro-2-methylphenyl)sulfonyl]amino} - 1 ,3-thiazol-5-yl)ethyl 2-furoate
2-(2-{[(3-cUoro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)ethyl benzoate
2-(2-{[(3-cWoro-2-memylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)-N-methoxy-
N-methylacetamide 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)ethyl ethylcarbamate
N-[2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)ethyl]-N- ethylacetamide
3-chloro-2-methyl-N-[5-(2-oxopentyl)-l,3-thiazol-2-yl]benzenesulfonamide
N- {5-[2-(l , 1 -dioxidothiomoφholin-4-yl)-2-oxoethyl]-l ,3-thiazol-2-yl} -4- propylbenzenesulfonamide
2,4-dichloro-6-methyl-N-{5-[2-(4-methylpiperazin-l-yl)-2-oxoethyl]-l,3-thiazol-
2-yl}benzenesulfonamide • 3-chloro-2-methyl-N- {5-[2-(3-oxomoφholin-4-yl)ethyl]-l ,3-thiazol-2- yl}benzenesulfonamide
2,4-dichloro-6-methyl-N-[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2- yl]benzenesulfonamide
N-[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2-yl]-l,l'-biρhenyl-4- sulfonamide
N-[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2-yl]-4- propylbenzenesulfonamide
N-[5-(2-oxo-2-thiomoφholin-4-ylethyl)-l ,3-thiazol-2-yl]- 1 , 1 '-biphenyl-4- sulfonamide • N-[5-(2-oxo-2-thiomoφholin-4-ylethyl)-l,3-thiazol-2-yl]-4- propylbenzenesulfonamide
2,4-dichloro-6-methyl-N-[5-(2-oxo-2-thiomoφholin-4-ylethyl)-l,3-thiazol-2- yl]benzenesulfonamide
N- [5-(2-oxo-2-piperidin- 1 -ylethyl)- 1 ,3 -thiazol-2-yl] -1,1 '-biphenyl-4-sulfonamide • N-[5-(2-oxo-2-piperidin-l-ylethyl)-l,3-thiazol-2-yl]-4-propylbenzenesulfonamide
2,4-dichloro-6-methyl-N-[5-(2-oxo-2-piperidin-l-ylethyl)-l,3-thiazol-2- yl]benzenesulfonamide ethyl oxo(2- { [(4-propylphenyl)sulfonyl] amino } - 1 ,3-thiazol-5-yl)acetate ethyl (2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5- yl)(oxo)acetate ethyl oxo(2- { [(2,4,6-trichlorophenyl)sulfonyl] amino } - 1 ,3-thiazol-5-yl)acetate ethyl {2-[( 1 , 1 '-biphenyl-4-ylsulfonyl)amino] -1,3 -thiazol-5-yl } (oxo)acetate • 3-cMoro-2-methyl-N-[4-methyl-5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2- yl]benzenesulfonamide
• 2,4,6-ιrichloro-N-[4-methyl-5-(2-moφholin-4-yl-2-oxoethyl)- 1 ,3-thiazol-2- yljbenzenesulfonamide
• 2- {2-[(l , 1 '-biphenyl-4-ylsulfonyl)amino]-l ,3-thiazol-5-yl} -N-ethyl-N- methylacetamide
• N-ethyl-N-methyl-2-(2-{[(4-proρylphenyl)sulfonyl]amino}-l,3-thiazol-5- yl)acetamide
• 2-(2- { [(2,4-dichloro-6-methylphenyl)sulfonyl]amino } - 1 ,3 -thiazol-5-yl)-N-ethyl- N-methylacetamide
• N-[4-methyl-5-(2-moφholin-4-yl-2-oxoethyl)- 1 ,3 -thiazol-2-yl]- 1 , 1 "-biphenyl-4- sulfonamide
• 2-{2-[(l,l '-biphenyl-4-ylsulfonyl)amino] -1,3 -thiazol-5-yl } -N-isopropyl-N- methylacetamide
• 2- {2-[(l , 1 '-biphenyl-4-ylsulfonyl)amino]-l ,3-thiazol-5-yl} -N,N-diethylacetamide
• N,N-diethyl-2-(2- { [(4-propylphenyl)sulfonyl] amino } - 1 ,3 -thiazol-5-yl)acetamide
• 2-(2-{[(2,4-dichloro-6-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)-N,N- diethylacetamide
• ethyl (2- {[(4-bromo-5-chlorothien-2-yl)sulfonyl]amino}-l ,3-thiazol-5-yl)acetate
• emyl (2-{[(3-bromo-5-chlorothien-2-yl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate
• ethyl {2-[({5-[l-methyl-5-(trifluoromethyl)-lH-ρyrazol-3-yl]thien-2- yl} sulfonyl)amino]- 1 ,3-thiazol-5-yl} acetate
• ethyl {2-[({5-[2-(memylthio)pyrimidin-4-yl]thien-2-yl}sulfonyl)amino]-l,3- thiazol-5-yl} acetate
• 2-{2-[(l,l'-biphenyl-4-ylsulfonyl)amino]-l,3-thiazol-5-yl}-N,N- diisopropylacetamide
• N,N-diisopropyl-2-(2- {[(4-propylphenyl)sulfonyl]amino}-l ,3-thiazol-5- yl)acetamide
• 2-(2-{[(2,4-dichloro-6-methylρhenyl)sulfonyl]amino}-l,3-thiazol-5-yl)-N,N- diisopropylacetamide
• methyl (4-methyl-2-{[(2,4,6-trichlorophenyl)sulfonyl]amino}-l,3-thiazol-5- yl)acetate 2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)-N,N- dipropylacetamide
3-chloro-2-memyl-N-[5-(2-oxo-2-piperazin-l-ylethyl)-l,3-thiazol-2- yl]benzenesulfonamide
4-bromo-2-methyl-N-[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2- yl]benzenesulfonamide
N-[5-(2-moφholin-4-yl-2-oxoethyl)- 1 ,3-thiazol-2-yl]-2,4- bis(trifluoromethyl)benzenesulfonamide
2-methyl-N-[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2-yl]-4-
(trifluoromethoxy)benzenesulfonamide
N-[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-ιhiazol-2-yl]-4- phenoxybenzenesulfonamide ethyl (2- { [(2,3 ,4-trichlorophenyl)sulfonyl] amino } - 1 ,3 -thiazol-5-yl)acetate ethyl (2-{[(4-bromo-2,5-difluorophenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate ethyl [2-({[4-(trifluoromethoxy)phenyl]sulfonyl}amino)-l,3-thiazol-5-yl]acetate ethyl [2-({[4-( henylsulfonyl)thien-2-yl]sulfonyl}amino)-l,3-thiazol-5-yl]acetate ethyl [2-( { [5-(phenylsulfonyl)thien-2-yl] sulfonyl } amino)- 1 ,3 -thiazol-5-yl] acetate ethyl (2-{[(2,6-dichlorophenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate ethyl (2- { [(2,4-dichlorophenyl)sulfonyl]amino } - 1 ,3 -thiazol-5-yl)acetate tert-butyl 4-[(2- {[(3-chloro-2-methylphenyl)sulfonyl]amino}-l ,3-thiazol-5- yl)acetyl]piperazine- 1 -carboxylate
2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)-N,N- dimethylacetamide
3-chloro-2-methyl-N-{5-[2-(ρyridin-3-yloxy)ethyl]-l,3-thiazol-2- yl}benzenesulfonamide
2-(2- { [(3 -chloro-2-methylphenyl)sulfonyl] amino } - 1 ,3 -thiazol-5-yl)-N-isopropyl-
N-methylacetamide
2-(2-{[(3-cWoro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)-N-ethyl-N- methylacetamide
3-c oro-2-methyl-N-[5-(2-oxo-2-thiomoφholin-4-ylethyl)-l,3-thiazol-2- yl]benzenesulfonamide ethyl (2-{[(4-bromo-2-fluorophenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate 3-chloro-2-methyl-N-[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2- yljbenzenesulfonamide (Example 4) methyl (2- { [(4-chlorophenyl)sulfonyl] amino } -4-methyl- 1 ,3 -thiazol-5-yl)acetate methyl (2- { [(3 -chloro-2-methylphenyl)sulfonyl] amino } -4-methyl- 1 ,3 -thiazol-5- yl)acetate
2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)-N,N- diisopropylacetamide (Example 5)
3-chloro-2-methyl-N-[5-(2-oxo-2-ρyrrolidin-l-ylethyl)-l,3-thiazol-2- yl]benzenesulfonamide ethyl (2- { [(3 -methoxyphenyl)sulfonyl] amino } - 1 ,3 -thiazol-5-yl)acetate ethyl (2-{[(5-fluoro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate ethyl (2- {[(4-propylphenyl)sulfonyl]amino}-l ,3-thiazol-5-yl)acetate
3-chloro-2-methyl-N-[5-(2-oxo-2-piperidin- 1 -ylethyl)- 1 ,3 -thiazol-2- yljbenzenesulfonamide ethyl (2- {[(3,5-dichlorophenyl)sulfonyl]amino} - 1 ,3-thiazol-5-yl)acetate ethyl (2- {[(3,4-dichlorophenyl)sulfonyl]amino}-l ,3-thiazol-5-yl)acetate ethyl (2-{[(2,4-dichloro-6-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate
3-chloro-2-methyl-N-[5-(moφholin-4-ylmethyl)-l,3-thiazol-2- yljbenzenesulfonamide
3-chloro-N- {5-[2-(lH-imidazol-l -yl)ethyl]- 1 ,3-thiazol-2-yl} -2- methylbenzenesulfonamide
N- [2-(2- { [(3 -chloro-2-methylphenyl)sulfonyl] amino } - 1 ,3 -thiazol-5- yl)ethyl] acetamide ethyl [2-({[2-memyl-4-(trifluoromethoxy)phenyl]sulfonyl}amino)-l,3-thiazol-5- yl] acetate ethyl (2- { [(2,3 ,4-trifluoroρhenyl)sulfonyl] amino } - 1 ,3 -thiazol-5-yl)acetate ethyl (2- {[(2,4,6-trifluorophenyl)sulfonyl]amino}-l ,3-thiazol-5-yl)acetate
3-chloro-2-methyl-N-(5- {2-[(methylsulfonyl)amino]ethyl} - 1 ,3 -thiazol-2- yl)benzenesulfonamide ethyl (2- {[(5-chlorothien-2-yl)sulfonyl]amino}-l ,3-thiazol-5-yl)acetate emyl (2-{[(2-cMoro-4-fluorophenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate ethyl (2- {[(5-isoxazol-3-ylthien-2-yl)sulfonyl]amino}-l ,3-thiazol-5-yl)acetate ethyl (2-{[(4-phenoxyphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate ethyl [2-({[2,4-bis(tτifluoromethyl)phenyl]sulfonyl} amino)-l ,3-thiazol-5- yl] acetate
3-chloro-2-methyl-N-{5-[2-(3-oxo-l,4-oxazeρan-4-yl)ethyl]-l,3-thiazol-2- yl } benzenesulfonamide
3-chloro-2-methyl-N- {5-[2-(2-oxoρyrrolidin- 1 -yl)ethyl]- 1 ,3-thiazol-2- yl}benzenesulfonamide
3-cUoro-2-memyl-N-(5-{2-[me yl(memylsulfonyl)amino]ethyl}-l,3-thiazol-2- yl)benzenesulfonamide
N-[2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)ethyl]-N- methylcyclopropanecarboxamide
3-chloro-2-methyl-N- {5-[2-(4-methyl-2-oxopiperazin- 1 -yl)ethyl]-l ,3-thiazol-2- yl}benzenesulfonamide
3 -chloro-2-methyl-N- [5-(2- { [(trifluoromethyl)sulfonyl] amino } ethyl)- 1 ,3 -thiazol-
2-yl]benzenesulfonamide
2,4-dichloro-N- {5-[2-(3-oxomoφholin-4-yl)ethyl]- 1 ,3-thiazol-2- yl}benzenesulfonamide
2,4-dichloro-6-methyl-N- {5-[2-(3-oxomoφholin-4-yl)ethyl]- 1 ,3-thiazol-2- yl}benzenesulfonamide
4-(2-furyl)-N-[5-(2-moφholin-4-yl-2-oxoethyl)- 1 ,3-thiazol-2- yljbenzenesulfonamide
5"-fluoro-2'-methoxy-N-[5-(2-moφholin-4-yl-2-oxoethyl)- 1 ,3-thiazol-2-yl]-l , 1 '- biphenyl-4-sulfonamide
4-(5-methylthien-2-yl)-N-[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2- yljbenzenesulfonamide
3l-acetyl-N-[5-(2-moφholin-4-yl-2-oxoethyl)- 1 ,3-thiazol-2-yl]- 1 , l'-biρhenyl-4- sulfonamide
N-[5-(2-moφholin-4-yl-2-oxoe yl)-l,3-thiazol-2-yl]-4!-(trifluoromethoxy)-l, - biphenyl-4-sulfonamide
3*,4'-dichloro-N-[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2-yl]-l,l'-biphenyl-
4-sulfonamide
4-(l ,3-benzodioxol-5-yl)-N-[5-(2-moφholin-4-yl-2-oxoethyl)- 1 ,3-thiazol-2- yl]benzenesulfonamide N-[5-(2-moφholin-4-yl-2-oxoethyl)- 1 ,3-thiazol-2-yl]-4-ρyridin-4- ylbenzenesulfonamide
N-[4'-( { [5-(2-moφholin-4-yl-2-oxoethyl)- 1 ,3 -thiazol-2-yl] amino} sulfonyl)- 1,1'- biphenyl-3 -yl] acetamide
N-[5-(2-moφholin-4-yl-2-oxoe%l)- 1 ,3-thiazol-2-yl]-4-thien-3- ylbenzenesulfonamide
N-[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2-yl]-4-thien-2- ylbenzenesulfonamide
4'-({[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2-yl]amino}sulfonyl)-l, - biphenyl-4-carboxylic acid
4,-(methylthio)-N-[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2-yl]-l,l,- biphenyl-4-sulfonamide
N-[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2-yl]-3',5*-bis(trifluoromethyl)-
1 , 1 '-biphenyl-4-sulfonamide • 4'-chloro-N-[5-(2-moφholin-4-yl-2-oxoethyl)-l ,3-thiazol-2-yl]- 1 , 1 '-biphenyl-4- sulfonamide
N-.[5-(2-moφholin-4-yl-2-oxoethyl)- 1 ,3-thiazol-2-yl]-3'-nitro- 1 , 1 '-biphenyl-4- sulfonamide isopropyl (2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate Another object of the present invention is a compound as described above for medical use.
Another object of the present invention is a method for the treatment or prevention of diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, depression, virus diseases or inflammatory disorders without causing hypoglycemia and to achieve immuno- modulation, preferably tuberculosis, lepra, and psoriasis, said method comprising administering to a mammal, including a human, in need of such treatment (e.g., identified as in need thereof) an effective amount of a compound of formula (I) or a composition having a compound of formula (I) in it: wherein
T is an aryl ring or heteroaryl ring, optionally independently substituted by [R]n> wherein n is an integer 0-5, and R is hydrogen, aryl, heteroaryl, a heterocyclic ring, optionally halogenated C1-6-alkyl, optionally halogenated C1-6-alkoxy, C1-6-alkylsulfonyl, carboxy, cyano, nitro, halogen, amine which is optionally mono- or di-substituted, amide which is optionally mono- or di-substituted, aryloxy, arylsulfonyl, arylamino, wherein aryl, heteroaryl and aryloxy residues and heterocyclic rings can further be optionally substituted in one or more positions independently of each other by Ci-6-acyl, C1-6- alkylthio, cyano, nitro, hydrogen, halogen, optionally halogenated Cι-6-alkyl, optionally halogenated C1-6-alkoxy, amide which is optionally mono- or di-substituted, (benzoylamino)methyl, carboxy, 2-thienylmethylamino or ({[4-(2-ethoxy-2-oxoethyl)~ 1 , 3 -thiazol-2-yl] amino } carbonyl) ;
R1 is hydrogen or C1-6-alkyl; X is CH2 or CO;
Y is CH2, CO or a single bond;
B is hydrogen, C1-6-alkyl or dimethylaminomethyl;
R2 is selected from C1-6-alkyl, azido, arylthio, heteroarylthio, halogen, hydroxymethyl, 2-hydroxyethylaminomethyl, methylsulfonyloxymethyl, 3-oxo-4- moφholinolinylmethylene, C1-6-alkoxycarbonyl, 5-methyl-l,3,4-oxadiazol-2-yl;
NR3R4, wherein R3 and R4 are each independently selected from hydrogen, C1-6- alkyl, optionally halogenated C1-6-alkylsulfonyl, C1-6-alkoxy, 2-methoxyethyl, 2- hydroxyethyl, 1-methylimidazolylsulfonyl, C1-6-acyl, cyclohexylmethyl, cyclopropanecarbonyl, aryl, optionally halogenated arylsulfonyl, furylcarbonyl, tetrahydro-2-furanylmethyl, N-carbethoxypiperidyl or C1-6-alkyl substituted with one or more aryl, heterocyclic or heteroaryl, or
NR3R4 represent together heterocyclic systems which can be imidazole, piperidine, pyrrolidine, piperazine, moφholine, oxazepine, oxazole, thiomoφholine, 1,1- dioxidothiomoφholine, 2-(3,4-dihydro-2(lH)isoquinolinyl), (lS,4S)-2-oxa-5- azabicyclo[2.2.1 ]hept-5-yl, which heterocyclic systems can be optionally substituted by Ci-6-alkyl, C1-6-acyl, hydroxy, oxo, t-butoxycarbonyl;
OCONR3R4, wherein R3 and R4 are each independently selected from hydrogen, C1-6-alkyl or form together with the N-atom to which they are attached moφholinyl;
R5O, wherein R5 is hydrogen, optionally halogenated C1-6-alkyl, aryl, heteroaryl, C1-6-acyl, C-6-alkylsulfonyl, arylcarbonyl, heteroarylcarbonyl, 2-carbomethoxyphenyl; or a salt, hydrate or solvate thereof; with the proviso that when:
X is CH2, Y is CH2, then R2 is not methyl and ethyl;
X is CH2, Y is a single bond, then R2 is not ethyl and n-propyl; X is CH2, Y is a single bond, R2 is methyl, B is methyl, then T is not 3-chloro-2- methylphenyl;
X is CO, Y is a single bond, then R2 is not methyl;
X is CO, Y is a single bond, R2 is ethoxy, B is methyl, then T is not 3-chloro-2- methylphenyl, 1,1 '-biphenyl-4-yl, 4-n-propylphenyl, 2,4-dichloro-6-methylphenyl, and 2,4,6-trichlorophenyl.
In another aspect, this invention features a method for inhibiting a human 11-β- hydroxysteroid dehydrogenase type 1 enzyme. The method includes administering to a subject (e.g., mammal, human, or animal) in need thereof (e.g., identified as in need thereof) an effective amount of a compound of any of the formulae delineated herein or a composition comprising any of the formulae herein.
The present invention also features a method for treating 11-β-hydroxysteroid dehydrogenase type 1 enzyme-mediated disorders. The method includes administering to a subject (e.g., mammal, human, or animal) in need thereof (e.g., identified as in need thereof) an effective amount of a compound of any of the formulae delineated herein or a composition comprising any of the formulae delineated herein. The 11-β-hydroxysteroid dehydrogenase type 1 enzyme-mediated disorder is any disorder or symptom wherein the 11-β-hydroxysteroid dehydrogenase type 1 enzyme is involved in the process or presentation of the disorder or the symptom. The 11-β-hydroxysteroid dehydrogenase type 1 enzyme-mediated disorders include, but are not limited to, diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, depression, virus diseases, inflammatory disorders, and immuno- modulation. Preferred examples of immuno-modulation are tuberculosis, lepra, and psoriasis. When the disorder is hyperglycemia, the treatment thereof does not cause hypoglycemia.
The methods delineated herein can also include the step of identifying that the subject is in need of treatment of diseases or disorders described above. The identification can be in the judgment of a subject or a health professional and can be subjective (e.g., opinion) or objective (e.g., measurable by a test or a diagnostic method). These compounds may also be used in the manufacture of a medicament for the prevention, management or treatment of diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, depression, virus diseases or inflammatory disorders without causing hypoglycemia and to achieve immuno-modulation. Preferred examples of immuno-modulation are tuberculosis, lepra, and psoriasis.
It is preferred that: T is selected from 5-chloro-l,3-dimethyl-lH-pyrazol-4-yl; 4-chloro-2,3,l- benzoxadiazolyl; 5-(dimethylamino)- 1-naphthyl; l-methylimidazol-4-yl; 1-naphthyl; 2- naphfhyl; 8-quinolinyl; thienyl substituted with one or more of (benzoylamino)methyl, bromo, chloro, 3- isoxazolyl, 2-(methylsulfanyl)-4-pyrimidinyl, 1 -methyl-5-(trifluoromethyl)ρyrazol-3-yl, phenylsulfonyl, pyridyl; phenyl substituted with one or more of acetylamino, 3-acetylaminophenyl, 3- acetylphenyl, benzeneamino, l,3-benzodioxol-5-yl, 2-benzofuryl, benzylamino, 3,5- bis(trifluoromethyl)phenyl, bromo, butoxy, carboxy, chloro, 4-carboxyphenyl, 3-chloro- 2-cyanophenoxy, 4-chlorophenyl, 5-chloro-2-thienyl, cyano, 3,4-dichlorophenyl, ({[4-(2- ethoxy-2-oxoethyl)-l,3-thiazol-2-yl]amino}carbonyl), fluoro, 5-fluoro-2-methoxyphenyl, 2-furyl, hydrogen, iodo, isopropyl, methanesulfonyl, methoxy, methyl, 4-methyl- 1- piperazinyl, 4-methyl-l -piperidinyl, 4-methylsulfanylphenyl, 5-methyl-2-thienyl, 4- moφholinyl, nitro, 3-nitrophenyl, phenoxy, phenyl, n-propyl, 4-pyridyl, 3- pyridylmethylamino, 1 -pyrrolidinyl, 2-thienyl, 3-thienyl, 2-thienylmethylamino, trifluoromethoxy, 4-trifluoromethoxyphenyl, trifluoromethyl; or
R1 is hydrogen or methyl;
X is CH2 or CO;
Y is CH2, CO or a single bond;
B is hydrogen, methyl or dimethylaminomethyl; R2 is selected from n-propyl, azido, bromo, chloro, 2-pyridinylsulfanyl, 3-oxo-4-moφholinolinyl- methylene, ethoxycarbonyl, 5-methyl-l,3,4-oxadiazol-2-yl, hydroxymethyl, 2- hydroxyethylaminomethyl, methylsulfonyloxymethyl;
NR3R4, wherein R3 and R4 are each independently selected from acetyl, benzhydryl, l,3-benzodioxol-5-ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexyl, cyclohexylmethyl, cyclopropanecarbonyl, ethyl, 2-furylcarbonyl, 2- furylmethyl, hydrogen, 2-hydroxyethyl, 2-(lH-indol-3-yl)ethyl, isopropyl, methoxy, 2- methoxyethyl, methyl, 4-(l-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl, (1S)- phenylethyl, n-propyl, tetrahydro-2-furanylmethyl, trifluoromethylsulfonyl, N- carbethoxypiperidyl; or
NR3R4 represent together 4-acetylpiperazinyl, 4-t-butoxycarbonylpiperazinyl, 2- (3,4-dihydro-2(lH)isoquinolinyl), (2R,6S)-2,6-dimethylmoφholinyl, (2R)-2,4-dimethyl- 1 -piperazinyl, 2-hydroxy-3-oxomoφholinyl, imidazolyl, 2-methyl-3-oxomoφholinyl, 4- methyl-2-oxopiperazinyl, 4-methylpiperazinyl, moφholinyl, (lS,4S)-2-oxa-5-aza- bicyclo[2.2.1]hept-5-yl, 2-oxoimidazolinyl, 3-oxomoφholinyl, 3-oxo-l,4-oxazepinyl, 2- oxooxazolinyl, piperazinyl; piperidinyl; pyrrolidinyl; pyrrolidonyl, thiomoφholinyl; 1,1- dioxido-thiomoφholinyl; OCONR3R4, wherein R3 and R4 are each independently selected from ethyl, hydrogen or form together with the N-atom to which they are attached moφholinyl;
R O, wherein R is acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, n-propionyl, 3-pyridinyl, 2,2,2-trifluoroethyl; with the proviso that when:
X is CH2, Y is a single bond, then R2 is not n-propyl;
X is CO, Y is a single bond, R2 is ethoxy, B is methyl, then T is not 3-chloro-2- methylphenyl, l,l '-biphenyl-4-yl, 4-n-proρylphenyl, 2,4-dichloro-6-methylphenyl, and 2,4,6-trichlorophenyl. When X is CH2 and Y is CH2, then it is preferred that:
R2 is selected from n-propyl, azido, bromo, chloro, 2-pyridinylsulfanyl, 3-oxo-4- moφholinolinylmethylene, ethoxy carbonyl, 5-methyl-l ,3,4-oxadiazol-2-yl, hydroxymethyl, 2-hydroxyethylaminomethyl, methylsulfonyloxymethyl;
NR3R4, wherein R3 and R4 are either each independently selected from acetyl, benzhydryl, l,3-benzodioxol-5-ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexyl, cyclohexylmethyl, cyclopropanecarbonyl, ethyl, 2-furylcarbonyl, 2- furylmethyl, hydrogen, 2-hydroxyethyl, 2-(lH-indol-3-yl)ethyl, isopropyl, methoxy, 2- methoxyethyl, methyl, 4-(l-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl, (1S)- phenylethyl, n-propyl, tetrahydro-2-furanylmethyl, trifluoromethylsulfonyl, N- carbethoxypiperidyl; or
NR3R4 represent together 4-acetylpiperazinyl, 4-t-butoxycarbonylpiperazinyl, 2- (3,4-dihydro-2(lH)isoquinolinyl), (2R,6S)-2,6-dimethylmoφholinyl, (2R)-2,4-dimethyl- 1 -piperazinyl, 2-hydroxy-3-oxomoφholinyl, imidazolyl, 2-methyl-3-oxomoφholinyl, 4- methyl-2-oxopiperazinyl, 4-methylpiperazinyl, moφholinyl, (lS,4S)-2-oxa-5-aza- bicyclo[2.2.1]hept-5-yl, 2-oxoimidazolinyl, 3-oxomoφholinyl, 3-oxo-l,4-oxazepinyl, 2- oxooxazolinyl, piperazinyl; piperidinyl; pyrrolidinyl; pyrrolidonyl, thiomoφholinyl; 1,1- dioxido-thiomoφholinyl;
OCONR3R4, wherein R3 and R4 are each independently selected from ethyl, hydrogen or form together moφholinyl;
R5O, wherein R5 is acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, n-propionyl, 3-pyridinyl, 2,2,2-trifluoroethyl.
When X is CH2 and Y is a single bond, then it is preferred that R2 is selected from azido, bromo, chloro, 2-pyridinylsulfanyl, 3-oxo-4-moφholinolinylmethylene, ethoxycarbonyl, 5-methyl-l,3,4-oxadiazol-2-yl, hydroxymethyl, 2- hydroxyethylaminomethyl, methylsulfonyloxymethyl;
NR3R4, wherein R3 and R4 are each independently selected from acetyl, benzhydryl, l,3-benzodioxol-5-ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexyl, cyclohexylmethyl, cyclopropanecarbonyl, ethyl, 2-furylcarbonyl, 2- furylmethyl, hydrogen, 2-hydroxyethyl, 2-(lH-indol-3-yl)ethyl, isopropyl, methoxy, 2- methoxyethyl, methyl, 4-(l-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl, (1S)- phenylethyl, n-propyl, tetrahydro-2-furanylmethyl, trifluoromethylsulfonyl, N- carbethoxypiperidyl; or NR3R4 represent together 4-acetylpiperazinyl, 4-t-butoxycarbonylpiperazinyl, 2-
(3,4-dihydro-2(lH)isoquinolinyl), (2R,6S)-2,6-dimethylmoφholinyl, (2R)-2,4-dimethyl- 1 -piperazinyl, 2-hydroxy-3-oxomoφholinyl, imidazolyl, 2-methyl-3-oxomoφholinyl, 4- methyl-2-oxopiperazinyl, 4-methylpiperazinyl, moφholinyl, (lS,4S)-2-oxa-5-aza- bicyclo[2.2.1]hept-5-yl, 2-oxoimidazolinyl, 3-oxomoφholinyl, 3-oxo-l,4-oxazepinyl, 2- oxooxazolinyl, piperazinyl; piperidinyl; pyrrolidinyl; pyrrolidonyl, thiomoφholinyl; 1,1- dioxido-thiomoφholinyl;
OCONR3R4, wherein R3 and R4 are each independently selected from ethyl, hydrogen or form together with the N-atom to which they are attached moφholinyl;
R5O, wherein R5 is acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, n-propionyl, 3-pyridinyl, 2,2,2-trifluoroethyl.
When X is CH2, Y is a single bond, R2 is methyl and B is methyl, then it is preferred that T is selected from 5-chloro-l,3-dimethyl-lH-pyrazol-4-yl; 4-chloro-2,3,l- benzoxadiazolyl; 5-(dimethylamino)- 1-naphthyl; l-methylimidazol-4-yl; 1-naphthyl; 2- naphthyl; 8-quinolinyl; thienyl substituted with one or more of (benzoylamino)methyl, bromo, chloro, 3- isoxazolyl, 2-(methylsulfanyl)-4-pyrimidinyl, 1 -methyl-5-(trifluoromethyl)pyrazol-3-yl, phenylsulfonyl, pyridyl; phenyl substituted with either:
(i) one or more of 3-acetylaminophenyl, 3-acetylphenyl, benzeneamino, 1,3- benzodioxol-5-yl, 2-benzofuryl, benzylamino, 3,5-bis(trifluoromethyl)phenyl, bromo, butoxy, carboxy, 4-carboxyphenyl, 3-chloro-2-cyanophenoxy, 4- chlorophenyl, 5-chloro-2-thienyl, cyano, 3,4-dichlorophenyl, ({[4-(2-ethoxy-2- oxoethyl)-l,3-thiazol-2-yl]amino}carbonyl), fluoro, 5-fluoro-2-methoxyphenyl, 2- furyl, hydrogen, iodo, isopropyl, methanesulfonyl, methoxy, methyl, 4-methyl- 1- piperazinyl, 4-methyl-l -piperidinyl, 4-methylsulfanylphenyl, 5-methyl-2-thienyl, 4-moφholinyl, nitro, 3-nitrophenyl, phenoxy, phenyl, n-propyl, 4-pyridyl, 3- pyridylmethylamino, 1 -pyrrolidinyl, 2-thienyl, 3-thienyl, 2-thienylmethylamino, trifluoromethoxy, 4-trifluoromethoxyphenyl, trifluoromethyl; or
(ii) one or more of 3-acetylaminophenyl, 3-acetylphenyl, benzeneamino, 1,3- benzodioxol-5-yl, 2-benzofuryl, benzylamino, 3,5-bis(trifluoromethyl)phenyl, bromo, butoxy, carboxy, chloro, 4-carboxyphenyl, 3-chloro-2-cyanophenoxy, 4- chlorophenyl, 5-chloro-2-thienyl, cyano, 3,4-dichlorophenyl, ({[4-(2-ethoxy-2- oxoethyl)-l,3-thiazol-2-yl]amino}carbonyl), fluoro, 5-fluoro-2-methoxyphenyl, 2- furyl, hydrogen, iodo, isopropyl, methanesulfonyl, methoxy, 4-methyl- 1- piperazinyl, 4-methyl-l -piperidinyl, 4-methylsulfanylphenyl, 5-methyl-2-thienyl, 4-moφholinyl, nitro, 3-nitrophenyl, phenoxy, phenyl, n-propyl, 4-pyridyl, 3- pyridylmethylamino, 1 -pyrrolidinyl, 2-thienyl, 3-thienyl, 2-thienylmethylamino, trifluoromethoxy, 4-trifluoromethoxyphenyl, trifluoromethyl; or
(iii) one or more chloro and, in positions 3, 4, 5, one or more methyl.
When X is CO and Y is a single bond, then it is preferred that R2 is selected from n-propyl, azido, bromo, chloro, 2-pyridinylsulfanyl, 3-oxo-4-moφholinolinylmethylene, ethoxycarbonyl, 5-methyl-l,3,4-oxadiazol-2-yl, hydroxymethyl, 2- hydroxyethylaminomethyl, methylsulfonyloxymethyl;
NR3R4, wherein R3 and R4 are each independently selected from acetyl, benzhydryl, l,3-benzodioxol-5-yhnethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexyl, cyclohexylmethyl, cyclopropanecarbonyl, ethyl, 2-furylcarbonyl, 2- furylmethyl, hydrogen, 2-hydroxyethyl, 2-(lH-indol-3-yl)ethyl, isopropyl, methoxy, 2- methoxyethyl, methyl, 4-(l-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl, (1S)- phenylethyl, n-propyl, tetrahydro-2-furanylmethyl, trifluoromethylsulfonyl, N- carbethoxypiperidyl; or NR3R4 represent together 4-acetylpiperazinyl, 4-t-butoxycarbonylpiperazinyl, 2-
(3,4-dihydro-2(lH)isoquinolinyl), (2R,6S)-2,6-dimethylmoφholinyl, (2R)-2,4-dimethyl- 1 -piperazinyl, 2-hydroxy-3-oxomoφholinyl, imidazolyl, 2-methyl-3-oxomoφholinyl, 4- methyl-2-oxopiperazinyl, 4-methylpiperazinyl, moφholinyl, (lS,4S)-2-oxa-5-aza- bicyclo[2.2.1]hept-5-yl, 2-oxoimidazolinyl, 3-oxomoφholinyl, 3-oxo-l,4-oxazepinyl, 2- oxooxazolinyl, piperazinyl; piperidinyl; pyrrolidinyl; pyrrolidonyl, thiomoφholinyl; 1,1- dioxido-thiomoφholinyl;
OCONR3R4, wherein R3 and R4 are each independently selected from ethyl, hydrogen or form together with the N-atom to which they are attached moφholinyl;
R5O, wherein R5 is acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, n-propionyl, 3-pyridinyl, 2,2,2-trifluoroethyl;
When X is CO and Y is a single bond and R2 is ethoxy, then it is preferred that T is selected from 5-chloro-l,3-dimethyl-lH-pyrazol-4-yl; 4-chloro-2,3,l -benzoxadiazolyl; 5-(dimethylamino)- 1-naphthyl; l-methylimidazol-4-yl; 1-naphthyl; 2-naphthyl; 8- quinolinyl; thienyl substituted with one or more of (benzoylamino)methyl, bromo, chloro, 3- isoxazolyl, 2-(methylsulfanyl)-4-pyrimidinyl, 1 -methyl-5-(trifluoromethyl)pyrazol-3-yl, phenylsulfonyl, pyridyl; phenyl substituted with either: (i) one or more of acetylamino, 3-acetylaminophenyl, 3-acetylphenyl, benzeneamino, l,3-benzodioxol-5-yl, 2-benzofuryl, benzylamino, 3,5-bis(trifluoromethyl)phenyl, bromo, butoxy, carboxy, 4-carboxyphenyl, 3-chloro-2-cyanophenoxy, 4- chlorophenyl, 5-chloro-2-thienyl, cyano, 3,4-dichlorophenyl, ({[4-(2-ethoxy-2- oxoethyl)-l,3-thiazol-2-yl]amino}carbonyl), fluoro, 5-fluoro-2-methoxyphenyl, 2- furyl, hydrogen, iodo, isopropyl, methanesulfonyl, methoxy, 4-methyl- 1- piperazinyl, 4-methyl-l -piperidinyl, 4-methylsulfanylphenyl, 5-methyl-2-thienyl, 4-moφholinyl, nitro, 3-nitrophenyl, phenoxy, 4-pyridyl, 3 -pyridylmethylamino, 1- pyrrolidinyl, 2-thienyl, 3-thienyl, 2-thienylmethylamino, trifluoromethoxy, 4- trifluoromethoxyphenyl, trifluoromethyl; (ii) one or more of methyl;
(iii) one or more of chloro, phenyl and n-propyl in either position, and methyl in any of positions 3, 4 or 5; (iv) one or more of n-propyl and phenyl in any of positions 2, 3, 5 or 6. Specific examples of compounds according to the present invention are given above and also the following compound:
(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetic acid (Example 3).
Another object of the present invention is a pharmaceutical composition comprising at least one compound of formula (I) as defined above, and a pharmaceutically acceptable carrier.
Also within the scope of this invention is a method for making a compound of formula (I). The method includes taking any intermediate compound delineated herein, reacting it with any one or more reagents to form a compound of formula (I) including any processes specifically delineated herein.
Other features and advantages of the invention will be apparent from the detailed description and the claims.
DETAILED DESCRIPTION OF THE INVENTION
The compounds according to the present invention may be used in several indications which involve 11-β-hydroxysteroid dehydrogenase type 1 enzyme. Thus, the compounds according to the present invention may be used against dementia (see WO97/07789), osteoporosis (see Canalis E 1996, Mechanisms of glucocorticoid action in bone: implications to glucocorticoid-induced osteoporosis, Journal of Clinical
Endocrinology and Metabolism, 81, 3441-3447) and may also be used disorders in the immune system (see Franchimont et al, "Inhibition of Thl immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat 4 phosphorylation in T lymphocytes", The journal of Immunology 2000, Feb 15, vol 164 (4), pages 1768- 74) and also in the above listed indications.
The various terms used, separately and in combinations, in the above definition of the compounds having the formula (I) will be explained. The term "aryl" in the present description is intended to include aromatic rings (monocyclic or bicyclic) having from 6 to 10 ring carbon atoms, such as phenyl (Ph) and naphthyl, which optionally may be substituted by Cι-6-alkyl. Examples of substituted aryl groups are benzyl, and 2-methylphenyl. The term "heteroaryl" means in the present description a monocyclic, bi- or tricyclic aromatic ring system (only one ring need to be aromatic) having from 5 to 14, preferably 5 to 10 ring atoms such as 5, 6, 7, 8, 9 or 10 ring atoms (mono- or bicyclic), in which one or more of the ring atoms are other than carbon, such as nitrogen, sulfur, oxygen and selenium as part of the ring system. Examples of such heteroaryl rings are pyrrole, imidazole, thiophene, furan, thiazole, isothiazole, thiadiazole, oxazole, isoxazole, oxadiazole, pyridine, pyrazine, pyrimidine, pyridazine, pyrazole, triazole, tetrazole, chroman, isochroman, quinoline, quinoxaline, isoquinoline, phthalazine, cinnoline, quinazoline, indole, isoindole, indoline, isoindoline, benzothiophene, benzofuran, isobenzofuran, benzoxazole, 2,1,3-benzoxadiazole, benzothiazole, 2, 1,3 -benzothiazole, 2,1,3-benzoselenadiazole, benzimidazole, indazole, benzodioxane, indane, 1,2,3,4- tetrahydroquinoline, 3,4-dihydro-2H-l,4-benzoxazine, 1,5-naphthyridine, 1,8- naphthyridine, acridine, fenazine and xanthene.
The term "heterocyclic" in the present description is intended to include unsaturated as well as partially and fully saturated mono-, bi- and tricyclic rings having from 4 to 14, preferably 4 to 10 ring atoms having one or more heteroatoms (e.g., oxygen, sulfur, or nitrogen) as part of the ring system and the remainder being carbon, such as, for example, the heteroaryl groups mentioned above as well as the corresponding partially saturated or fully saturated heterocyclic rings. Exemplary saturated heterocyclic rings are azetidine, pynolidine, piperidine, piperazine, moφholine, thiomoφholine and 1,4- oxazepane.
C1-6-alkyl in the compound of formula (I) according to the present application, which may be straight, branched or cyclic, is preferably C1-4-alkyl. Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl, isopentyl, hexyl, isohexyl, and cyclohexyl. For parts of the range "C1-6-alkyl" all subgroups thereof are contemplated such as Cι-5-alkyl, C1-4-alkyl, C1-3-alkyl, C1-2-alkyl, C2-6-alkyl, C2-5-alkyl, C2-4-alkyl, C2-3-alkyl, C3-6-alkyl, C4-5-alkyl, etc.
C1-6-alkoxy, in the compound of formula (I) according to the present application may be straight or branched, is preferably C1-4-alkoxy. Exemplary alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, butoxy, sec-butoxy, tert-butoxy, pentyloxy, isopentyloxy, hexyloxy, and isohexyloxy. For parts of the range "C1-6-alkoxy" all subgroups thereof are contemplated such as Q.s-alkoxy, Ct-4-alkoxy, C1-3-alkoxy, Cι-2- alkoxy, C2-6-alkoxy, C2-5-alkoxy, C2-4-alkoxy, C2-3-alkoxy, C3-6-alkoxy, C4-5-alkoxy, etc. C1-6-acyl, in the compound of formula (I) according to the present application may be saturated or unsaturated and is preferably C1-4-acyl. Exemplary acyl groups include formyl, acetyl, propionyl, butyryl, isobutyryl, valeryl, isovaleryl, butenoyl (e.g. 3- butenoyl), hexenoyl (e.g. 5-hexenoyl). For parts of the range "C1-6-acyl" all subgroups thereof are contemplated such as .s-acyl, C1-4-acyl, C1-3-acyl, C1-2-acyl, C2-6-acyl, C2-5- acyl, C2-4-acyl, C2.3-acyl, C3-6-acyl, C4-5-acyl, etc. C2-6-alkenyl in the compound of formula (I) according to the present application, which may be straight, branched or cyclic, is preferably C2-4-alkenyl. Exemplary alkenyl groups include vinyl, 1-propenyl, 2-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 1- pentenyl, 2-pentenyl, 1-hexenyl, 2-hexenyl, and 1-cyclohexenyl. For parts of the range "C2-6-alkenyl" all subgroups thereof are contemplated such as C2-5-alkenyl, C2-4-alkenyl, C2-3-alkenyl, C3-6-alkenyl, C4-5-alkenyl, etc.
The term "halogen" in the present description is intended to include fluorine, chlorine, bromine and iodine.
The term "sulfanyl" in the present description means a thio group.
With the expression mono- or di-substituted is meant in the present description that the functionalities in question may be substituted with independently H, C1-6-acyl, C2- 6-alkenyl, C1-6-(cyclo)alkyl, aryl, pyridylmethyl, or heterocyclic rings e.g. azetidine, pyrrolidine, piperidine, piperazine, moφholine and thiomoφholine, which heterocyclic rings optionally may be substituted with C1-6-alkyl.
Combinations of substituents and variables envisioned by this invention are only those that result in the formation of stable compounds. The term "stable", as used herein, refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the puφoses detailed herein (e.g., therapeutic administration to a subject for the treatment of disease, 1 lβHSDl inhibition, 11 βHSDl -mediated disease). The term "prodrug forms" in the present description means a pharmacologically acceptable derivative, such as an ester or an amide, which derivative is biotransformed in the body to form the active drug (see Goodman and Gilman's, The Pharmacological basis of Therapeutics, 8th ed., McGraw-Hill, Int. Ed. 1992, "Biotransformation of Drugs, p. 13- 15).
"Pharmaceutically acceptable" means in the present description being useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes being useful for veterinary use as well as human pharmaceutical use.
"Pharmaceutically acceptable salts" mean in the present description salts which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity. Such salts include acid addition salts formed with organic and inorganic acids, such as hydrogen chloride, hydrogen bromide, hydrogen iodide, sulfuric acid, phosphoric acid, acetic acid, glycolic acid, maleic acid, malonic acid, oxalic acid, methanesulfonic acid, trifluoroacetic acid, fumaric acid, succinic acid, tartaric acid, citric acid, benzoic acid, ascorbic acid and the like. Base addition salts may be formed with organic and inorganic bases, such as sodium, ammonia, potassium, calcium, ethanolamine, diethanolamine, N-methylglucamine, choline and the like. Included in the invention are pharmaceutically acceptable salts or compounds of any of the formulae herein.
Pharmaceutical compositions according to the present invention contain a pharmaceutically acceptable carrier together with at least one of the compounds comprising the formula (I) as described herein above, dissolved or dispersed therein as an active, antimicrobial, ingredient. In a preferred embodiment, the therapeutic composition is not immunogenic when administered to a human patient for therapeutic puφoses, unless that puφose is to induce an immune response.
The preparation of a pharmacological composition that contains active ingredients dissolved or dispersed therein is well understood in the art. Typically such compositions are prepared as sterile injectables either as liquid solutions or suspensions, aqueous or non-aqueous, however, solid forms suitable for solution, or suspensions, in liquid prior to use can also be prepared. The preparation can also be emulsified.
The active ingredient may be mixed with excipients, which are pharmaceutically acceptable and compatible with the active ingredient and in amounts suitable for use in the therapeutic methods described herein. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol or the like and combinations thereof. In addition, if desired, the composition may contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like which enhance the effectiveness of the active ingredient. Adjuvants may also be present in the composition.
Pharmaceutically acceptable carriers are well known in the art. Exemplary of liquid carriers are sterile aqueous solutions that contain no materials in addition to the active ingredients and water, or contain a buffer such as sodium phosphate at physiological pH value, physiological saline or both, such as phosphate-buffered saline. Still further, aqueous carriers can contain more than one buffer salt, as well as salts such as sodium and potassium chlorides, dextrose, propylene glycol, polyethylene glycol and other solutes. Liquid compositions can also contain liquid phases in addition to and to the exclusion of water. Exemplary of such additional liquid phases are glycerine, vegetable oils such as cottonseed oil, organic esters such as ethyl oleate, and water-oil emulsions. The pharmaceutical composition according to one of the prefened embodiments of the present invention comprising compounds comprising the formula (I), may include pharmaceutically acceptable salts of that component therein as set out above.
Pharmaceutically acceptable salts include the acid addition salts (formed with the free amino groups of the polypeptide) that are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic acid, tartaric acid, mandelic acid and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, 2-ethylamino ethanol, histidine, procaine and the like.
The preparations according to the preferred embodiments may be administered orally, topically, intraperitoneally, intraarticularly, intracranially, intradermally, intramuscularly, intraocularly, intrathecally, intravenously, subcutaneously. Other routes are known to those of ordinary skill in the art.
The orally administrable compositions according to the present invention may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical or sterile parenteral solutions or suspensions. Tablets and capsules for oral administration may be in unit dose presentation form and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, traganath or polyvinyl-pyrrolidone; fillers e.g. lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricant e.g. magnesium stearate, talc, polyethylene glycol or silica; disintegrants e.g. potato starch, or acceptable wetting agents such as sodium lauryl sulfate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of e.g. aqueous or oily suspensions, solutions, emulsions, syrups or elixirs or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, e.g. sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents e.g. lecithin, sorbitan monooleate or acacia, non-aqueous vehicles (which may include edible oils), e.g. almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives e.g. methyl or propyl p- hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
"An effective amount" refers to an amount of a compound which confers a therapeutic effect on the treated subject. The therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect). A pharmaceutical composition according to the present invention, may comprise typically an amount of at least 0.1 weight percent of compound comprising the formula (I) per weight of total therapeutic composition. A weight percent is a ratio by weight of total composition. Thus, for example, 0.1 weight percent is 0.1 grams of compound comprising the formula (I) per 100 grams of total composition. A suitable daily oral dose for a mammal, preferably a human being, may vary widely depending on the condition of the patient. However a dose of compound comprising the formula (I) of about 0.1 to 300 mg/kg body weight may be appropriate.
The compositions according to the present invention may also be used veterinarily and thus they may comprise a veterinarily acceptable excipient or carrier. The compounds and compositions may be thus administered to animals, e.g., cats, dogs, or horses, in treatment methods.
The compounds of the present invention in labelled form, e.g. isotopically labelled, may be used as a diagnostic agent.
This invention relates to methods of making compounds of any of the formulae herein comprising reacting any one or more of the compounds of the formulae delineated herein, including any processes delineated herein. The compounds of formula (I) above may be prepared by, or in analogy with, conventional methods, and especially according to or in analogy with the following methods. Further, the pharmacology in- vitro was studied using the following reagents and methods. The chemicals used in the synthetic routes delineated herein may include, for example, solvents, reagents, catalysts, and protecting group and deprotecting group reagents. The methods described above may also additionally include steps, either before or after the steps described specifically herein, to add or remove suitable protecting groups in order to ultimately allow synthesis of the compounds. In addition, various synthetic steps may be performed in an alternate sequence or order to give the desired compounds. Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing applicable compounds are known in the art and include, for example, those described in R. Larock, Comprehensive Organic Transformations, NCH Publishers (1989); T.W. Greene and P.GM. Wuts, Protective Groups in Organic Synthesis, 3r Ed., John Wiley and Sons (1999); L. Fieser and M. Fieser, Fieser and Fiesers ' Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995) and subsequent editions thereof. All publications mentioned herein are hereby incoφorated by reference. By the expression "comprising" means "including but not limited to." Thus, other non- mentioned substances, additives or carriers may be present.
The invention will now be described in reference to the following Examples. These Examples are not to be regarded as limiting the scope of the present invention, but shall only serve in an illustrative manner.
EXAMPLES
EXPERIMENTAL METHODS Scintillation Proximity Assay
[1, 2(n) - 3H]-cortisone was purchased from Amersham Pharmacia Biotech. Anti- cortisol monoclonal mouse antibody, clone 6D6.7 was obtained from Immunotech and Scintillation proximity assay (SPA) beads coated with monoclonal antimouse antibodies were from Amersham Pharmacia Biotech. NADPH, tetrasodium salt was from Calbiochem and glucose-6-phosphate (G-6-P) was supplied by Sigma. The human 11-β- hydroxysteroid dehydrogenase rype-1 enzyme (11-β-HSDi) was expressed in Pichia pastoris. 18-β-glycyrrhetinic acid (GA) was obtained from Sigma. The serial dilutions of the compounds were performed on a Tecan Genesis RSP 150. Compounds to be tested were dissolved in DMSO (1 mM) and diluted in 50 mM Tris-HCl, pH 7.2 containing 1 mM EDTA.
The multiplication of plates was done on a WallacQuadra. The amount of the product [3H] -cortisol, bound to the beads was determined in a Packard, Top Count microplate liquid scintillation counter.
The 11-β-HSU! enzyme assay was carried out in 96 well microtiter plates (Packard, Optiplate) in a total well volume of 220 μL and contained 30 mM Tris-HCl, pH 7.2 with 1 mM EDTA, a substrate mixture tritiated Cortisone/NADPH (175 nM / 181 μM), G-6-P (1 mM) and inhibitors in serial dilutions (9 to 0.15 μM). Reactions were initiated by the addition of human 1 l-β-HSDl5 either as Pichia pastoris cell homogenate or microsomes prepared from Pichia pastoris (the final amount of enzyme used was varied between 0.057 to 0.11 mg/mL). Following mixing, the plates were shaken for 30 to 45 minutes at room temperature. The reactions were terminated with 10 μL 1 mM GA stop solution. Monoclonal mouse antibody was then added (10 μL of 4 μM) followed by 100 μL of SPA beads (suspended according to the manufacturers instructions).
Appropriate controls were set up by omitting the 11-β-HSDi to obtain the non-specific binding (NSB) value.
The plates were covered with plastic film and incubated on a shaker for 30 minutes, at room temperature, before counting. The amount of [ H]-cortisol, bound to the beads was determined in a microplate liquid scintillation counter.
The calculation of the Kj values for the inhibitors was performed by use of Activity Base. The Kj value is calculated from IC50 and the Km value is calculated using the Cheng Prushoff equation (with reversible inhibition that follows the Michaelis- Menten equation): Kj = IC50(l+[S]/Km) [Cheng, Y.C.; Prushoff, W.H. Biochem. Pharmacol. 1973, 22, 3099-3108]. The IC50 is measured experimentally in an assay wherein the decrease of the turnover of cortisone to cortisol is dependent on the inhibition potential of each substance. The Ki values of the compounds of the present invention for the 11-β-HSDl enzyme lie typically between about 10 nM and about 10 μM. COMPOUND PREPARATION General:
For preparative straight phase HPLC purification a Phenomenex column (250 x 21.1 mm, 10 μm) was used on a Gilson system eluting with ethanol in chloroform (gradient from 0 - 10% in 10 min) with a flow of 20 mL/min. Column chromatography was performed on silica using Silica gel 60 (230-400 mesh), Merck. Melting points were determined on a Gallenkamp apparatus. Elemental analyses were recorded using a Nario EL instrument. HPLC analyses were performed using a Hypersil Elite column (150 x 4.6 mm, 3μ) with a flow of 3 mL / min on a Waters 600E system with monitoring at 254 nm. Reverse phase preparative HPLC was carried out on a 100 x 21.2 mm, 5 μ Hypersil Elite column eluting with a gradient of 5% ACΝ in 95% water to 95% ACΝ in 5% water (0.2% TFA buffer) over 10 mins at a flow rate of 20 mL / min with the UN detector set at 254 nm. Thin layer chromatography was carried out using pre-coated silica gel F-254 plates (thickness 0.25 mm). Electrospray MS spectra were obtained on a Micromass platform LCMS spectrometer. Crude, worked up compounds were purified by flash column chromatography using pre packed silica SPE columns (10 g silica) on an Isco Foxy 200 Combiflash system, and a gradient of 16.67% ethyl acetate in hexane increasing incrementally to 100% ethyl acetate.
List of Abbreviations
ACΝ = acetonitrile
DCM = dichloromethane
DIEA = Ν,Ν-diisopropylethylamine
DMAP = 4-dimethylaminopyridine DME = ethyleneglycol dimethyl ether
DMF = dimethylformamide
DMSO = dimethyl sulfoxide
EDCI = l-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
EDTA = ethylenediaminetetraacetic acid HCOOH = formic acid
HO AT = l-hydroxy-7-azabenzotriazole
HOBT = 1-hydroxybenzotriazole hydrate
HPLC = high performance liquid chromatography MTBE = tert-butyl methyl ether
RP LC-MS = reversed-phase liquid chromatography-mass spectrometry TEA = triethylamine TFA = trifluoroacetic acid THF = tetrahydrofuran
SULFONAMIDE COUPLINGS: METHOD A:
1 Eq of the 2-aminothiazole was dissolved in pyridine (0.5 M solution). The sulfonyl chloride (1.2 eq) was added and the reaction mixture was stirred at ambient temperature under nitrogen atmosphere for 15 h. The reaction mixture was poured into aqueous HC1 (1 M). If the product precipitated it was collected on a filter and washed with aqueous HC1 (1 M) and recrystallised from ethanol. In case an oil was obtained, the crude was extracted with DCM and worked up and purified using standard procedures.
METHOD B:
A solution of the 2-aminothiazole derivative (1 eq), triethylamine (2 eq) and DMAP (1 eq) in DMF (1 M) and DCM (0.225 M) was dispensed into a reaction vial. The sulfonyl chloride (1.2 eq) was dissolved in DCM (0.33 M) and added. The reaction mixtures were kept at room temperature over night. The mixture was then added to petroleum ether (10 times reaction volume). After some hours in refrigerator the supernatants were decanted and (a portion of) the residual materials were dissolved in DMSO-methanol-acetic acid (300 μL + 500 μL + 50 μL) and purified by preparative LCMS (acetonitrile-water gradients). The purest fractions were collected and lyophilized. Alternatively, the crude was isolated using extractive work-up and purified using standard procedures.
SAPONIFICATIONS: METHOD C: 1 Eq of the ester was suspended in 95% ethanol (0.1 M) and treated with KOH
(aqueous, 6 eq). Water was added until a clear solution was achieved. The reaction mixture was stirred for 2-3 h at ambient temperature. The solvent was removed under reduced pressure and the crude was redissolved in water. Addition of cone. HCl until pH 2 gave a precipitate which was collected on a filter and washed with cold water and dried.
AMIDE COUPLINGS: METHOD D:
The carboxylic acid ester was dissolved (0.05 M) in a large excess of the amine in 40 or 70% water-solution. The reaction mixture was stirred at ambient temperature over night. The solvent was removed under reduced pressure and the crude product was purified by flash column chromatography on silica gel eluting with methanol (0— >6%) in DCM.
METHOD E:
The carboxylic acid was suspended in DCM (0.05M) followed by the addition of EDCI (1.1 eq), triethylamine (3 eq), DMAP (0.5 eq) and the amine of choice (1.2 eq). DMF was added when the starting materials did not dissolve properly. The reaction mixture was stirred at ambient temperature over night. The organic phase was washed with aqueous HCl (1 M), dried over sodium sulfate, filtered and evaporated in vacuo. The crude product amide was purified by flash column chromatography on silica gel, eluting with methanol (l-»3— 6%) in DCM or ethyl acetate.
METHOD F:
The carboxylic acid was suspended in DCM (0.1 M) and cooled to 0°C under nitrogen (g) atmosphere. EDCI (1 eq), HO AT (1 eq) or HOBT (1 eq) was added, followed by TEA (2.2 eq). After 10 min, the amine of choice (1.2 eq) was added and the reaction mixture was allowed to warm to ambient temperature. After 5 h, the DCM phase was washed with aqueous HCl (1 M) and worked up and purified as described in METHOD E.
METHOD G: Under N2-atmosρhere, aluminium chloride (1 eq) was suspended in DCM (0.1 M) and treated with the amine of choice (4 eq) at ambient temperature. After 10 min, the alkyl ester (1 eq) was added and the reaction mixture was strrred until starting material had been consumed (TLC). Quenching with saturated aqueous sodium hydrogen carbonate or aqueous HCl (1 M) and extractive workup with ethyl acetate gave the crude products which were then purified by flash chromatography on silica gel eluting with DCM / methanol mixtures.
FORMATION OF THIAZOLE RING:
METHOD H:
To a solution or suspension of an optionally substituted thiourea in ethanol (0.5 M), 1 equivalent of α-haloketone was added at room temperature. The reaction mixture was stirred in a sealed tube at 95 °C for 4 h, cooled, concentrated, redissolved in ethyl acetate, washed with saturated aqueous sodium hydrogen carbonate, dried over sodium sulfate and chromatographed on silica gel using petroleum-ether and ethyl acetate as eluents.
METHOD I: To a 0.5 M solution of ketone (1 eq) and thiourea (2 eq) in ethanol at 60°C, 1 eq of iodine was added in one portion. The reaction tube was sealed and the reaction mixture was stirred at 100°C for 16 hours. After evaporation of the solvent the residue was taken up in DCM, washed with saturated aqueous sodium hydrogen carbonate, dried with magnesium sulfate. Products were purified by chromatography on silica gel using a gradient of petroleum-ether / ethyl acetate from 8:1 to 2:1 for elution.
ACYLATIONS: METHOD J:
To a solution of the alcohol in dry pyridine (0.3 M), 1.1 eq of acid chloride was added at 0 °C. The reaction mixture was stirred at room temperature for 6 h, concentrated, co-evaporated with acetonitrile, re-dissolved in DCM, washed with aqueous HCl (0.5 M), dried with sodium sulfate and chromatographed on silica gel using petroleum-ether and ethyl acetate as eluents.
CARBAMATES:
METHOD K:
To a solution of the alcohol in dry pyridine (0.3 M), 1.5 eq of 4-nitrophenyl chloroformate (0.5 M in dry pyridine) was added at 0°C After the reaction mixture was stirred at room temperature for 12 h, 5 eq of primary or secondary amine were added at 0°C The solution was stirred at room temperature for 3 h, concentrated, co-evaporated with acetonitrile, re-dissolved in DCM, washed with aqueous HCl (0.5 M) and saturated aqueous sodium bicarbonate, dried with sodium sulfate and chromatographed on silica gel using DCM and methanol as eluents.
SULFONYL CHLORIDES
Arylsulfonyl chlorides that were not commercially available were prepared from the aniline derivatives according to literature procedures (see for instance: Hoffman, R. N. (1981) Org. Synth. 60: 121).
2-amino-5-thiazoleacetic acid, ethyl ester is available from Ambinter, 46 quai Louis Bleriot, Paris, F-75016, France. The preparation thereof has been described in:
Aryl diazo compounds and diazonium salts as potential irreversible probes of the GABA receptor. Bouchet, Marie Jeanne; Rendon, Alvaro; Wermuth, Camille G.; Goeldner, Maurice; Hirth, Christian. Fac. Pharm., Univ. Louis Pasteur, Strasbourg, Fr. J. Med. Chem. (1987), 30(12), 2222-7. CODEΝ: JMCMAR ISSN: 0022-2623. Journal written in English. CAN 107:198180 AN 1987:598180 CAPLUS; and
Growth regulating activity of some thiazole-, thiazoline-, and thiazolidineacetic acids. Garraway, J. L. Dep. Phys. Sci., Wye Coll., Ashford/Kent, Engl. Pestic. Sci. (1974), 5(2), 185-8. CODEN: PS SCBG Journal written in English. CAN 81:73315 AN 1974:473315 CAPLUS
PREPARATION OF COMPOUNDS IN EXAMPLES 1-5
EXAMPLE 1 - 3-chloro-2-methyl-N-r5-(2-morDholin-4-ylethvn-1.3-thiazol-2- yllbenzenesulfonamide
Step a - preparation of 2-(2-amino- 3-thiazol-5-yl)ethanol 2,3-dichlorotetrahydrofurane (5 g; 0,035 mol) and thiourea (2,7 g; 0,035 mol) were refluxed for 12 h in water (20 ml). Then 40 ml of 40% NaOH (aq) were added, the reaction mixture was cooled to room temperature and stirred for one hour. The formed precipitate was filtered off, dried at reduced pressure and recrystallized from EtOH/Et2O. HCl, 2M in Et2O, was added to form the HCl-salt which was isolated by filtration and dried. Yielded 3,8 g, 61%.
1H NMR (400 MHz, DMSO-d6) δ ppm 2.71 (t, J=4.88 Hz, 2 H) 3.53 (t, J=5.62
Hz, 2 H) 4.17 (s, 1 H) 7.06 (s, 1 H) 9.37 (s, 2 H). MS m/z: M+H 145
Step b - preparation of 3-chloro-2-methyl-N-r5-(2-moφholin-4-ylethyl)- 3-thiazol-2- yl]benzenesulfonamide
2-(2-amino-l,3-thiazol-5-yl)ethanol (0,16 g; 0,89 mmol), 3-chloro-2- methylbenzenesulfonyl chloride (0,62 g; 2,8 mmol) and NaOH (0,093 g; 2,3 mmol) were dissolved in 9 ml THF:H2O (1 :2) and stirred over night. The reaction mixture was extracted twice with dichloromethane and the organic layers was combined, dried over
MgSO4 and concentrated. The crude material was then stirred in moφholine (10 ml) over night. The reaction mixture was concentrated and purified on preparative RP LC-MS, then further purified on a preparative TLC-column (Trikonex, FlashTube™ 2008) eluted with CHCl3/MeOH 40/3 + triethylamine 1 %. The substance was visualized by UV-light, the relevant band cut out and the silica-gel extracted with the eluent. Fitration and concentration yielded a product which was still found to contain a number of impurities.
This was further purified on preparative RP LC-MS. Yield 0,8 mg.
1H NMR (400 MHz, methanol-d δ ppm 2.65 (m, 3 H) 3.10 (m, 4 H) 3.28 (m, 2 H) 3.45 (m, 2 H) 3.70 (m, 2 H) 4.02 (m, 2 H) 7.00 (m, 1 H) 7.24 (t, J=7.81 Hz, 1 H) 7.54
(d, J=8.06 Hz, 1 H) 7.91 (d, J=7.57 Hz, 1 H). MS m/z: M+H 402. HRMS (El) calcd for
C16H20C1N3O3S2: 401.0635, found 401.0627.
EXAMPLE 2 - methyl (2-{r(3-chloro-2-methylphenyl)sulfonvnamino}-1.3-thiazol-5- vDacetate
Step a - preparation of methyl 3-bromo-4-oxobutanoate
Firstly, methyl 4-oxobutanoate was synthesized from the commercially available methyl 4,4-dimethoxybutyrate according to a literature procedure; Will, S. G.; Magriotis, P.; Marinelli, E. R.; Dolan, J.; Johnson, F. J. Org. Chem., 1985, 50, 5433-5434. Secondly, methyl 3-bromo-4-oxobutanoate was obtained from methyl 4- oxobutanoate following a literature procedure; Aeberli, M.; Erlenmeyer. H. Hel. Chim. Ada., 1950, 70, 503-505. Step b - preparation of methyl (2-([(3-chloro-2-methylphenyl)sulfonvnamino>- 3- thiazol-5-yl)acetate
N-(aminocarbonothioyl)-3-chloro-2-methylbenzenesulfonamide (0.4 g, 1.5 mmol) and methyl 3-bromo-4-oxobutanoate (0.3 g, 1.5 mmol), dissolved in pyridine (5 mL), were irradiated in a microwave oven for 2.5 min at 130 °C The solvent was removed under reduced pressure and the product separated from the starting materials using preparative HPLC (yield 0.2g, 30%).
1H ΝMR (400 MHz, CD3OD) δ ppm 2.70 (s, 3 H) 3.69 (d, J=1.22 Hz, 2 H) 3.70 (s, 3 H) 6.98 (t, J=1.10 Hz, 1 H) 7.29 (t, J=8.30 Hz, 1 H) 7.57 (dd, J=8.06, 1.46 Hz, 1 H) 7.96 (m, 1 H). MS m/z: M+H 361.
EXAMPLE 3 - ("2-{r(3-chloro-2-methylphenyl)sulfonyllamino|-l,3-thiazol-5-yl acetic acid
To methyl (2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5- yl)acetate (Example 2) (0.2 g, 0.55 mmol) dissolved in EtOH (5.5 mL) was added aqueous KOH (0.6 mL, 5.5 M). The reaction mixture was stirred at room temperature for
1 h. The solvent was then removed under reduced pressure and the crude product dissolved in water. The aqueous phase was acidified using cone. HCl so that the product precipitated. Filtration and washing with water (5 mL) afforded 0.2 g, 97% product. The product was used without any further purification.
EXAMPLE 4 - 3-chloro-2-methyl-Ν-r5-(2-morpholin-4-yl-2-oxoethyl)-1.3-thiazol-2- yllbenzenesulfonamide
To a solution of (2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5- yl)acetic acid (Example 3) (0.09 g, 0.25 mmol) in CH2C12 (5.0 mL) and DMF (0.5 mL) were added EDCI (0.05 g, 0.27 mmol), DMAP (0.02 g, 0.12 mmol), triethylamine (0.1 mL, 0.75 mmol) and moφholine (0.03 mL, 0.30 mmol). The reaction mixture was stirred at room temperature overnight. The reaction mixture was then washed with 1 M HCl (2x15 mL) and the organic layer was collected. The organic phase was dried (MgSO ) and concentrated under reduced pressure. Purification using preparative HPLC afforded the desired product (0.0 lg) in 10% yield.
1H NMR (400 MHz, acetone-d6) δ ppm 2.67 (s, 3 H) 3.47-3.63 (m, 8 H) 3.82 (d, J=1.22 Hz, 2 H) 7.05 (t, J=1.22 Hz, 1 H) 7.33 (t, J=8.30 Hz, 1 H) 7.57 (m, 1 H) 7.98 (dd, J=8.06, 1.22 Hz, 1 H). MS m/z: M+H 416.
EXAMPLE 5 - 2-(2-(r(3-chloro-2-methylphenyl sulfonvnaminol-l,3-thiazol-5-vn-N,N- diisopropylacetamide
To a solution of (2- { [(3 -chloro-2-methylphenyl)sulfonyl] amino } - 1 ,3 -thiazol-5- yl)acetic acid (Example 3) (0.09 g, 0.25 mmol) in CH2C12 (5.0 mL) and DMF (0.5 mL) were added EDCI (0.05 g, 0.27 mmol), DMAP (0.02 g, 0.12 mmol), triethylamine (0.1 mL, 0.75 mmol) and diisopropylamine (0.04 mL, 0.30 mmol). The reaction mixture was stirred at room temperature overnight. The reaction mixture was then washed with 1 M HCl (2x15 L) and the organic layer was collected. The organic phase was dried
(MgSO4) and concentrated under reduced pressure. Purification using preperative HPLC afforded the desired product (O.Olg) in 9% yield.
1H NMR (400 MHz, CDC13) δ ppm 1.21 (d, J=6.10 Hz, 6 H) 1.34 (d, J=6.59 Hz, 6 H) 2.64 (s, 3 H) 3.61 (m, J=19.53 Hz, 1 H) 3.63 (s, 2 H) 3.89 (m, 1 H) 6.94 (s, 1 H) 7.23 (m, 1 H) 7.52 (d, J=7.81 Hz, 1 H) 8.04 (d, J=7.81 Hz, 1 H). MS m/z: M+H 430.
Various embodiments of the present invention have been described above but a person skilled in the art realizes further minor alterations which would fall into the scope of the present invention. The breadth and scope of the present invention should not be limited by any of the above-described exemplary embodiments, but should be defined only in accordance with the following claims and their equivalents.

Claims

Claims
1. A compound of formula (I)
Figure imgf000047_0001
wherein
T is an aryl ring or heteroaryl ring, optionally independently substituted by [R]n, wherein n is an integer 0-5, and R is hydrogen, aryl, heteroaryl, a heterocyclic ring, optionally halogenated C1-6-alkyl, optionally halogenated C1-6-alkoxy, Q-β-alkylsulfonyl, carboxy, cyano, nitro, halogen, aryloxy, arylsulfonyl, arylamino, wherein aryl, heteroaryl and aryloxy residues and heterocyclic rings are further optionally substituted in one or more positions independently of each other by C1-6-acyl, Cι-6-alkylthio, cyano, nitro, hydrogen, halogen, optionally halogenated C1-6-alkyl, optionally halogenated C1-6-alkoxy, amide which is optionally mono- or di-substituted, (benzoylamino)methyl, carboxy, 2- thienylmethylamino or ({[4-(2-ethoxy-2-oxoethyl)-l,3-thiazol-2-yl]amino}carbonyl); or T is selected from 5 -(dimethylamino)- 1-naphthyl and phenyl substituted with one or more of benzeneamino, benzylamino, 3 -pyridylmethylamino and 2-thienylmethylamino; R1 is hydrogen or C1-6-alkyl; X is CH2 or CO; Y is CH2, CO or a single bond;
B is hydrogen, Cι-6-alkyl or dimethylaminomethyl; R2 is selected from C1-6-alkyl, azido, arylthio, heteroarylthio, halogen, hydroxymethyl, 2-hydroxyethylaminomethyl, methylsulfonyloxymethyl, 3-oxo-4- moφholinolinylmethylene, C1-6-alkoxycarbonyl, 5-methyl-l,3,4-oxadiazol-2-yl; NR3R4, wherein R3 and R4 are each independently selected from hydrogen, ethyl, isopropyl, n-propyl, optionally halogenated C1-6-alkylsulfonyl, C1-6-alkoxy, 2- methoxyethyl, 2-hydroxyethyl, 1-methylimidazolylsulfonyl, C1-6-acyl, cyclohexylmethyl, cyclopropanecarbonyl, aryl, optionally halogenated arylsulfonyl, furylcarbonyl, tefrahydro-2-furanylmethyl, N-carbethoxypiperidyl, or Q-6-alkyl substituted with one or more aryl, heterocyclic or heteroaryl, or
NR3R4 represent together heterocyclic systems which are imidazole, piperidine, pyrrolidine, piperazine, moφholine, oxazepine, oxazole, thiomoφholine, 1,1- dioxidothiomoφholine, 2-(3,4-dihydro-2(lH)isoquinolinyl), or (lS,4S)-2-oxa-5- azabicyclo[2.2.1]hept-5-yl, which heterocyclic systems are optionally substituted by C1-6- alkyl, C1-6-acyl, hydroxy, oxo, t-butoxycarbonyl;
OCONR3R4, wherein R3 and R4 are each independently selected from hydrogen, C1-6-alkyl or form together with the N-atom to which they are attached moφholinyl; R5O, wherein R5 is hydrogen, optionally halogenated C1-6-alkyl, aryl, heteroaryl,
C1-6-acyl, C1-6-alkylsulfonyl, arylcarbonyl, heteroarylcarbonyl, 2-carbomethoxyphenyl; or a salt, hydrate or solvate thereof; with the proviso that when:
X is CH2, Y is CH2, then R2 is not methyl, ethyl, diethylamino, 1 -pyrrolidinyl, and 1 -piperidinyl;
X is CH2, Y is CH2, R2 is moφholinyl, then T is not 4-methylphenyl;
X is CH2, Y is CO, then R2 is not hydroxy;
X is CH2, Y is a single bond, then R2 is not ethyl, n-propyl;
X is CH2, Y is a single bond, R2 is methyl, B is methyl, then T is not 3-chloro-2- methylphenyl;
X is CO, Y is a single bond, then R is not methyl;
X is CO, Y is a single bond, R2 is ethoxy, B is methyl, then T is not 3-chloro-2- methylphenyl, l,l '-biphenyl-4-yl, 4-n-propylphenyl, 2,4-dichloro-6-methylphenyl, and 2,4,6-trichlorophenyl.
2. The compound according to claim 1, wherein
T is selected from 5-chloro-l,3-dimethyl-lH-pyrazol-4-yl; 4-chloro-2,3,l- benzoxadiazolyl; 5-(dimethylamino)- 1-naphthyl; l-methylimidazol-4-yl; 1-naphthyl; 2- naphthyl; 8-quinolinyl; thienyl substituted with one or more of (benzoylamino)methyl, bromo, chloro, 3- isoxazolyl, 2-(methylsulfanyl)-4-pyrimidinyl, 1 -methyl-5-(trifluoromethyl)pyrazol-3-yl, phenylsulfonyl, pyridyl; phenyl substituted with one or more of 3-acetylaminophenyl, 3-acetylphenyl, benzeneamino, l,3-benzodioxol-5-yl, 2-benzofuryl, benzylamino, 3,5- bis(trifluoromethyl)phenyl, bromo, butoxy, carboxy, chloro, 4-carboxyphenyl, 3-chloro- 2-cyanophenoxy, 4-chlorophenyl, 5-chloro-2-thienyl, cyano, 3,4-dichlorophenyl, ({[4-(2- ethoxy-2-oxoethyl)-l,3-thiazol-2-yl]amino}carbonyl), fluoro, 5-fluoro-2-methoxyphenyl, 2-furyl, hydrogen, iodo, isopropyl, methanesulfonyl, methoxy, methyl, 4-methyl- 1- piperazinyl, 4-methyl-l -piperidinyl, 4-methylsulfanylphenyl, 5-methyl-2-thienyl, 4- moφholinyl, nitro, 3-nitrophenyl, phenoxy, phenyl, n-propyl, 4-pyridyl, 3- pyridylmethylamino, 1-pynolidinyl, 2-thienyl, 3-thienyl, 2-thienylmethylamino, trifluoromethoxy, 4-trifluoromethoxyphenyl, trifluoromethyl; or
R1 is hydrogen or methyl; X is CH2 or CO;
Y is CH2, CO or a single bond;
B is hydrogen, methyl or dimethylaminomethyl;
R is selected from n-propyl, azido, bromo, chloro, 2-pyridinylsulfanyl, 3-oxo-4-moφholinolinyl- methylene, ethoxycarbonyl, 5-methyl-l,3,4-oxadiazol-2-yl, hydroxymethyl, 2- hydroxyethylaminomethyl, methylsulfonyloxymethyl;
NR3R4, wherein R3 and R4 are each independently selected from acetyl, benzhydryl, l,3-benzodioxol-5-ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexyl, cyclohexylmethyl, cyclopropanecarbonyl, ethyl, 2-furylcarbonyl, 2- furylmethyl, hydrogen, 2-hydroxyethyl, 2-(lH-indol-3-yl)ethyl, isopropyl, methoxy, 2- methoxyethyl, 4-(l-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl, (lS)-phenylethyl, n-propyl, tetrahydro-2-furanylmethyl, trifluoromethylsulfonyl, N-carbethoxypiperidyl; or
NR3R4 represent together 4-acetylpiperazinyl, 4-t-butoxycarbonylpiperazinyl, 2- (3,4-dihydro-2(lH)isoquinolinyl), (2R,6S)-2,6-dimethylmoφholinyl, (2R)-2,4-dimethyl- 1 -piperazinyl, 2-hydroxy-3-oxomoιpholinyl, imidazolyl, 2-methyl-3-oxomoφholinyl, 4- methyl-2-oxopiperazinyl, 4-methylpiperazinyl, moφholinyl, (lS,4S)-2-oxa-5-aza- bicyclo[2.2.1]hept-5-yl, 2-oxoimidazolinyl, 3-oxomoφholinyl, 3-oxo-l,4-oxazepinyl, 2- oxooxazolinyl, piperazinyl; piperidinyl; pyrrolidinyl; pyrrolidonyl, thiomoφholinyl; 1,1- dioxido-thiomoφholinyl; OCONR3R4, wherein R3 and R4 are each independently selected from ethyl, hydrogen or form together with the N-atom to which they are attached moφholinyl;
R5O, wherein R5 is acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, n-propionyl, 3-pyridinyl, 2,2,2-trifluoroethyl; with the proviso that when:
X is CH2, Y is CH2, then R2 is not diethylamino, 1 -pyrrolidinyl, and 1 -piperidinyl;
X is CH2, Y is CH2, R2 is moφholinyl, then T is not 4-methylphenyl;
X is CH2, Y is CO, then R2 is not hydroxy;
X is CH2, Y is a single bond, then R2 is not n-propyl;
X is CO, Y is a single bond, R2 is ethoxy, B is methyl, then T is not 3-chloro-2- methylphenyl, l,r-biphenyl-4-yl, 4-n-propylphenyl, 2,4-dichloro-6-methylphenyl, and 2,4,6-trichlorophenyl.
3. The compound of claim 1-2 selected from the group consisting of: ethyl (2-{[(2,4-dichloro-5-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate ethyl (2- { [(4-chlorophenyl)sulfonyl] amino } - 1 ,3 -thiazol-5-yl)acetate ethyl (2-{[(2,4-difluorophenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate ethyl (2- { [(2,5-dichlorothien-3-yl)sulfonyl]amino} - 1 ,3-thiazol-5-yl)acetate ethyl (2-{[(2-chlorophenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate ethyl {2-[(l -naphthylsulfonyl)amino]-l ,3-thiazol-5-yl} acetate ethyl (2- { [(3-chloro-2-methylphenyl)sulfonyl]amino } - 1 ,3 -thiazol-5-yl)acetate
2-(2- { [(3 -chloro-2-methylphenyl)sulfonyl] amino } - 1 ,3 -thiazol-5-yl)-N- methylacetamide
2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)-N- ethylacetamide ethyl {2-[(l , 1 '-biphenyl-4-ylsulfonyl)amino]- 1 ,3-thiazol-5-yl} acetate ethyl (2-{[(4-nitrophenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate ethyl (2- { [(4-methoxyphenyl)sulfonyl] amino } - 1 ,3 -thiazol-5-yl)acetate ethyl (2-{[(2,5-dichlorophenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate
3-cUoro-N-[5-(2-hydroxyethyl)-l,3-thiazol-2-yl]-2-methylbenzenesulfonamide
3-cUoro-N-[5-(2-emoxyemyl)-l,3-thiazol-2-yl]-2-methylbenzenesulfonamide ethyl (2-{[(3-chlorophenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate ethyl (2-{[(4-fluorophenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate ethyl (2- { [(4-isopropylphenyl)sulfonyl]amino } - 1 ,3-thiazol-5-yl)acetate ethyl [2-({[4-({[4-(2-ethoxy-2-oxoethyl)-l ,3-thiazol-2- yl] amino } carbonyl)phenyl] sulfonyl} amino)- 1 ,3-thiazol-5-yl] acetate • 2-(2-{[(3-chloro-2-methylρhenyl)sulfonyl]amino}-l,3-thiazol-5-yl)-N,N- diethylacetamide ethyl [2-( { [2-(trifluoromethyl)phenyl] sulfonyl } amino)- 1 ,3-thiazol-5-yl] acetate ethyl [2-( { [3-(trifluoromethyl)phenyl] sulfonyl } amino)- 1 ,3 -thiazol-5-yl] acetate ethyl [2-({[4-(trifluoromethyl)phenyl]sulfonyl}amino)-l,3-thiazol-5-yl]acetate methyl (2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate 3-chloro-N-[5-(2-isopropoxyethyl)-l,3-thiazol-2-yl]-2-methylbenzenesulfonamide 3-cMoro-N-[5-(2-methoxyethyl)-l,3-thiazol-2-yl]-2-methylbenzenesulfonamide 2-(2- { [(3 -chloro-2-methylphenyl)sulfonyl] amino } - 1 ,3 -thiazol-5-yl)ethyl methanesulfonate
2-(2- { [(3 -chloro-2-methylphenyl)sulfonyl] amino } - 1 ,3 -thiazol-5-yl)acetamide
3-chloro-N- {5-[2-(2-fluoroethoxy)ethyl]- 1 ,3-thiazol-2-yl} -2- methylbenzenesulfonamide
3-chloro-2-methyl-N- {5-[2-(2,2,2-trifluoroethoxy)ethyl]-l ,3-thiazol-2- yl}benzenesulfonamide
2-(2- {[(3-chloro-2-methylphenyl)sulfonyl]amino} - 1 ,3-thiazol-5-yl)ethyl acetate
3-chloro-2-methyl-N-[5-(2-moφholin-4-ylethyl)- 1 ,3-thiazol-2- yl]benzenesulfonamide
N-[5-(2-bromoethyl)-l,3-thiazol-2-yl]-3-chloro-2-methylbenzenesulfonamide • 2-(2-{[(3-cWoro-2-me lphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)ethyl moφholine-4-carboxylate
2-(2-{[(3-cUoro-2-memylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)ethyl diethylcarbamate
2-(2-{[(3-cWoro-2-me ylphenyl)sulfonyl]ammo}-l,3-thiazol-5-yl)ethyl propionate
2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)ethyl 2- methylpropanoate
2-(2- {[(3-chloro-2-methylphenyl)sulfonyl]amino}-l ,3-thiazol-5-yl)ethyl 2-furoate
2-(2-{[(3-cWoro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)ethyl benzoate • 2-(2- {[(3-chloro-2-methylphenyl)sulfonyl]amino}-l ,3-thiazol-5-yl)-N-methoxy-
N-methylacetamide
• 2-(2-{[(3-cWoro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)ethyl ethylcarbamate • N-[2-(2-{[(3-cMoro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)ethyl]-N- ethylacetamide
3-chloro-2-methyl-N-[5-(2-oxopentyl)-l,3-thiazol-2-yl]benzenesulfonamide
N- {5-[2-(l , 1 -dioxidothiomoφholin-4-yl)-2-oxoethyl]-l ,3-thiazol-2-yl} -4- propylbenzenesulfonamide
2,4-dichloro-6-methyl-N- { 5-[2-(4-methylpiperazin- 1 -yl)-2-oxoethyl]- 1 ,3-thiazol-
2-yl}benzenesulfonamide
3-cmoro-2-methyl-N-{5-[2-(3-oxomoφholin-4-yl)ethyl]-l,3-thiazol-2- yl}benzenesulfonamide • 2,4-dichloro-6-methyl-N-[5-(2-moφholin-4-yl-2-oxoethyl)- 1 ,3-thiazol-2- yljbenzenesulfonamide
N-[5-(2-moφholin-4-yl-2-oxoethyl)- 1 ,3-thiazol-2-yl ]- 1 , 1 '-biphenyl-4- sulfonamide
N-[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2-yl]-4- propylbenzenesulfonamide
N-[5-(2-oxo-2-thiomoφholin-4-ylethyl)-l,3-thiazol-2-yl]-l,r-biphenyl-4- sulfonamide
N-[5-(2-oxo-2-thiomoφholin-4-ylethyl)-l,3-thiazol-2-yl]-4- propylbenzenesulfonamide • 2,4-dic oro-6-memyl-N-[5-(2-oxo-2-thiomoφholin-4-ylethyl)- 1 ,3-thiazol-2- yl]benzenesulfonamide
N-[5-(2-oxo-2-piperidin- 1 -ylethyl)- 1 ,3-thiazol-2-yl]- 1 , 1 '-biphenyl-4-sulfonamide
N-[5-(2-oxo-2-piperidin-l-ylethyl)-l,3-thiazol-2-yl]-4-propylbenzenesulfonamide
2,4-dichloro-6-methyl-N-[5-(2-oxo-2-piperidin-l-ylethyl)-l,3-thiazol-2- yl]benzenesulfonamide ethyl oxo(2-{[(4-propylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate ethyl (2- { [(3 -chloro-2-methylphenyl)sulfonyl] amino } - 1 ,3 -thiazol-5- yl)(oxo)acetate ethyl oxo(2-{[(2,4,6-tricMorophenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate • ethyl {2-[(l, -biphenyl-4-ylsulfonyl)amino]-l,3-thiazol-5-yl}(oxo)acetate
3-cωoro-2-memyl-N-[4-memyl-5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2- yl]benzenesulfonamide • 2,4,6-tricMoro-N-[4-methyl-5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2- yljbenzenesulfonamide
• 2- {2-[(l , 1 '-biphenyl-4-ylsulfonyl)amino]-l ,3-thiazol-5-yl} -N-ethyl-N- methylacetamide
• N-ethyl-N-methyl-2-(2- { [(4-propylphenyl)sulfonyl]amino } - 1 ,3 -thiazol-5- yl)acetamide
• 2-(2-{[(2,4-dichloro-6-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)-N-ethyl- N-methylacetamide
• N-[4-methyl-5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2-yl]-l,r-biphenyl-4- sulfonamide
• 2- {2- [( 1 , 1 '-biphenyl-4-ylsulfonyl)amino]- 1 ,3 -fhiazol-5-yl } -N-isopropyl-N- methylacetamide
• 2- {2-[(l , 1 '-biphenyl-4-ylsulfonyl)amino]-l ,3-thiazol-5-yl} -N,N-diethylacetamide
• N,N-diethyl-2-(2-{[(4-propylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetamide
• 2-(2-{[(2,4-dichloro-6-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)-N,N- diethylacetamide
• emyl (2-{[(4-bromo-5-cMorothien-2-yl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate
• ethyl (2-{[(3-bromo-5-chlorothien-2-yl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate
• ethyl {2-[({5-[l-methyl-5-(trifluoromethyl)-lH-pyrazol-3-yl]thien-2- yl}sulfonyl)amino]-l,3-thiazol-5-yl}acetate
• ethyl {2-[({5-[2-(methylthio)pyrimidin-4-yl]thien-2-yl}sulfonyl)amino]-l,3- thiazol-5-yl} acetate
• 2- {2-[(l , 1 '-biphenyl-4-ylsulfonyl)amino]-l ,3-thiazol-5-yl} -N,N- diisopropylacetamide
• N,N-diisopropyl-2-(2-{[(4-propylphenyl)sulfonyl]amino}-l,3-thiazol-5- yl)acetamide
• 2-(2-{[(2,4-dicluoro-6-methylρhenyl)sulfonyl]amino}-l,3-thiazol-5-yl)-N,N- diisopropylacetamide
• memyl (4-memyl-2-{[(2,4,6-trichlorophenyl)sulfonyl]amino}-l,3-thiazol-5- yl)acetate
• 2-(2-{[(3-cUoro-2-me lphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)-N,N- dipropylacetamide 3-chloro-2-methyl-N-[5-(2-oxo-2-piperazin-l-ylethyl)-l,3-thiazol-2- yl]benzenesulfonamide
4-bromo-2-methyl-N-[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2- yl]benzenesulfonamide
N-[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2-yl]-2,4- bis(trifluoromethyl)benzenesulfonamide
2-methyl-N-[5-(2-moφholin-4-yl-2-oxoethyl)- 1 ,3-thiazol-2-yl]-4-
(trifluoromethoxy)benzenesulfonamide
N-[5-(2-moφholin-4-yl-2-oxoethyl)- 1 ,3-thiazol-2-yl]-4- phenoxybenzenesulfonamide ethyl (2-{[(2,3,4-trichlorophenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate ethyl (2-{[(4-bromo-2,5-difluorophenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate ethyl [2-({[4-(trifluoromethoxy)phenyl]sulfonyl}amino)-l,3-thiazol-5-yl]acetate ethyl [2-( { [4-(phenylsulfonyl)thien-2-yl] sulfonyl } amino)- 1 ,3 -thiazol-5-yl] acetate • ethyl [2-({[5-φhenylsulfonyl)thien-2-yl]sulfonyl}amino)-l,3-thiazol-5-yl]acetate ethyl (2-{[(2,6-dichlorophenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate ethyl (2-{[(2,4-dichlorophenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate tert-butyl 4- [(2- { [(3 -chloro-2-methylphenyl)sulfonyl] amino } - 1 ,3 -thiazol-5- yl)acetyl]piperazine- 1 -carboxylate • 2-(2-{[(3-cmoro-2-me lρhenyl)sulfonyl]ammo}-l,3-thiazol-5-yl)-N,N- dimethylacetamide
3-chloro-2-methyl-N- {5-[2-(pyridin-3-yloxy)ethyl]-l ,3-thiazol-2- yl}benzenesulfonamide
2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)-N-isopropyl- N-methylacetamide
2-(2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)-N-ethyl-N- methylacetamide
3-chloro-2-methyl-N-[5-(2-oxo-2-thiomoφholin-4-ylethyl)-l,3-thiazol-2- yl]benzenesulfonamide • ethyl (2-{[(4-bromo-2-fluorophenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate
3-chloro-2-methyl-N-[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2- yl]benzenesulfonamide memyl (2-{[(4-clιlorophenyl)sulfonyl]amino}-4-methyl-l,3-thiazol-5-yl)acetate methyl (2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}-4-methyl-l,3-thiazol-5- yl)acetate
2-(2-{[(3-chloro-2-methylρhenyl)sulfonyl]amino}-l,3-thiazol-5-yl)-N,N- diisopfopylacetamide
3-cmoro-2-methyl-N-[5-(2-oxo-2-pyrrolidin-l-ylefhyl)-l,3-thiazol-2- yl]benzenesulfonamide . ethyl (2- { [(3 -methoxyphenyl)sulfonyl] amino } - 1 ,3 -thiazol-5-yl)acetate ethyl (2-{[(5-fluoro-2-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate ethyl (2- {[(4-propylphenyl)sulfonyl] amino} - 1 ,3-thiazol-5-yl)acetate • 3-chloro-2-methyl-N-[5-(2-oxo-2-piperidin-l-ylethyl)-l,3-thiazol-2- yl]benzenesulfonamide ethyl (2-{[(3,5-dichlorophenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate ethyl (2-{[(3,4-dichlorophenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate ethyl (2-{[(2,4-dichloro-6-methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate • 3 -chloro-2-methyl-N- [5 -(moφholin-4-ylmethyl)- 1 ,3 -thiazol-2- yl]benzenesulfonamide
3-chloro-N-{5-[2-(lH-imidazol-l-yl)ethyl]-l,3-thiazol-2-yl}-2- methylbenzenesulfonamide
N-[2-(2- { [(3 -chloro-2-methylphenyl)sulfonyl] amino } - 1 ,3 -thiazol-5- yl)ethyl]acetamide ethyl [2-({[2-methyl-4-(trifluoromethoxy)phenyl]sulfonyl}amino)-l,3-thiazol-5- yl]acetate ethyl (2-{[(2,3,4-trifluorophenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate emyl (2-{[(2,4,6-trifluorophenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate • 3-chloro-2-methyl-N-(5- {2-[(methylsulfonyl)amino]ethyl}- 1 ,3-thiazol-2- yl)benzenesulfonamide ethyl (2- { [(5-chlorothien-2-yl)sulfonyl] amino } - 1 ,3 -thiazol-5-yl) acetate ethyl (2-{[(2-chloro-4-fluorophenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate ethyl (2- { [(5-isoxazol-3 -ylthien-2-yl)sulfonyl] amino } - 1 ,3 -thiazol-5-yl)acetate • ethyl (2-{[(4-phenoxyphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetate ethyl [2-( { [2,4-bis(trifluoromethyl)phenyl] sulfonyl } amino)- 1 ,3 -thiazol-5- yl] acetate 3-chloro-2-methyl-N-{5-[2-(3-oxo-l,4-oxazepan-4-yl)ethyl]-l,3-thiazol-2- yl}benzenesulfonamide
3-chloro-2-mefhyl-N-{5-[2-(2-oxoρyrrolidin-l-yl)ethyl]-l,3-thiazol-2- yl}benzenesulfonamide
3-chloro-2-methyl-N-(5- {2-[methyl(methylsulfonyl)amino]ethyl} - 1 ,3-thiazol-2- yl)benzenesulfonamide
N-[2-(2-{[(3-chloro-2-methylphenyl)sulfonyl3amino}-l,3-thiazol-5-yl)ethyl]-N- methylcyclopropanecarboxamide
3-clιloro-2-memyl-N-{5-[2-(4-methyl-2-oxopiperazin-l-yl)ethyl]-l,3-thiazol-2- yl}benzenesulfonamide
3-chloro-2-methyl-N-[5-(2- { [(trifluoromethyl)sulfonyl] amino} ethyl)- 1 ,3-thiazol-
2-yl]benzenesulfonamide
.2,4-dichloro-N- {5-[2-(3-oxomoφholin-4-yl)ethyl]- 1 ,3-thiazol-2- yl}benzenesulfonamide • 2,4-dichloro-6-methyl-N-{5-[2-(3-oxomoφholin-4-yl)ethyl]-l,3-thiazol-2- yl}benzenesulfonamide
4-(2-furyl)-N-[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2- yl]benzenesulfonamide
5'-fluoro-2'-methoxy-N-[5-(2-moφholin-4-yl-2-oxoethyl)- 1 ,3-thiazol-2-yl]- 1,1'- biphenyl-4-sulfonamide
4-(5-methyltMen-2-yl)-N-[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-fniazol-2- yl]benzenesulfonamide
3'-acetyl-N-[5-(2-moφholin-4-yl-2-oxoethyl)- 1 ,3-thiazol-2-yl]- 1 , 1 '-biphenyl-4- sulfonamide • N-[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2-yl]-4'-(trifluoromethoxy)-l, - biphenyl-4-sulfonamide
3',4'-dichloro-N-[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2-yl]-l,l'-biphenyl-
4-sulfonamide
4-(l,3-benzodioxol-5-yl)-N-[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2- yl]benzenesulfonamide
N-[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2-yl]-4-pyridin-4- ylbenzenesulfonamide N-[4'-( { [5-(2-moφholin-4-yl-2-oxoethyl)-l ,3-thiazol-2-yl]amino} sulfonyl)-l , 1 '- biphenyl-3-yl]acetamide
N-[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2-yl]-4-thien-3- ylbenzenesulfonamide
N-[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2-yl]-4-thien-2- ylbenzenesulfonamide
4'-( {[5-(2-moφholin-4-yl-2-oxoethyl)- 1 ,3-thiazol-2-yl]amino } sulfonyl)- 1,1'- biphenyl-4-carboxylic acid
4'-(methylthio)-N-[5-(2-moφholin-4-yl-2-oxoethyl)- 1 ,3-thiazol-2-yl]-l , 1 '- biphenyl-4-sulfonamide
N-[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2-yl]-3',5'-bis(trifluoromethyl)-
1 , 1 '-biphenyl-4-sulfonamide
4'-chloro-N-[5-(2-moφholin-4-yl-2-oxoethyl)- 1 ,3-thiazol-2-yl]- 1 , 1 '-biphenyl-4- sulfonamide
N-[5-(2-moφholin-4-yl-2-oxoethyl)-l,3-thiazol-2-yl]-3'-nihO-l,r-biphenyl-4- sulfonamide isopropyl (2- {[(3-chloro-2-methylphenyl)sulfonyl]amino} - 1 ,3-thiazol-5- yl)acetate.
4. A compound according to anyone of claims 1-3, for medical use.
5. A method for the treatment or prevention of diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, depression, virus diseases or inflammatory disorders without causing hypoglycemia and to achieve immuno-modulation, said method comprising administering to a mammal in need of such treatment an effective amount of a compound of formula (I)
Figure imgf000058_0001
wherein
T is an aryl ring or heteroaryl ring, optionally independently substituted by [R]n, wherein n is an integer 0-5, and R is hydrogen, aryl, heteroaryl, a heterocyclic ring, optionally halogenated C1-6-alkyl, optionally halogenated C1-6-alkoxy, Ci-6-alkylsulfonyl, carboxy, cyano, nitro, halogen, amine which is optionally mono- or di-substituted, amide which is optionally mono- or di-substituted, aryloxy, arylsulfonyl, arylamino, wherein aryl, heteroaryl and aryloxy residues and heterocyclic rings are further optionally substituted in one or more positions independently of each other by C1-6-acyl, C1-6- alkylthio, cyano, nitro, hydrogen, halogen, optionally halogenated C1-6-alkyl, optionally halogenated C1-6-alkoxy, amide which is optionally mono- or di-substituted, (benzoylamino)methyl, carboxy, 2-thienylmethylamino or ({[4-(2-ethoxy-2-oxoethyl)- 1 ,3-thiazol-2-yl]amino} carbonyl); R1 is hydrogen or C1-6-alkyl;
X is CH2 or CO; Y is CH2, CO or a single bond; B is hydrogen, C1-6-alkyl or dimethylaminomethyl; R2 is selected from C1-6-alkyl, azido, arylthio, heteroarylthio, halogen, hydroxymethyl, 2-hydroxyethylaminomethyl, methylsulfonyloxymethyl, 3-oxo-4- moφholinolinylmethylene, C1-6-alkoxycarbonyl, 5-methyl-l,3,4-oxadiazol-2-yl;
NR3R4, wherein R3 and R4 are each independently selected from hydrogen, C1-6- alkyl, optionally halogenated C1-6-alkylsulfonyl, C1-6-alkoxy, 2-methoxyethyl, 2- hydroxyethyl, 1-methylimidazolylsulfonyl, C1-6-acyl, cyclohexylmethyl, cyclopropanecarbonyl, aryl, optionally halogenated arylsulfonyl, furylcarbonyl, tetrahydro-2-furanylmethyl, N-carbethoxypiperidyl or C1-6-alkyl substituted with one or more aryl, heterocyclic or heteroaryl, or NR3R4 represent together heterocyclic systems which are imidazole, piperidine, pyrrolidine, piperazine, moφholine, oxazepine, oxazole, thiomoφholine, 1,1- dioxidothiomoφholine, 2-(3,4-dihydro-2(lH)isoquinolinyl), or (lS,4S)-2-oxa-5- azabicyclo[2.2.1]hept-5-yl, which heterocyclic systems are optionally substituted by C1-6- alkyl, C1-6-acyl, hydroxy, oxo, t-butoxycarbonyl;
OCONR3R4, wherein R3 and R4 are each independently selected from hydrogen, C1-6-alkyl or form together with the N-atom to which they are attached moφholinyl;
R5O, wherein R5 is hydrogen, optionally halogenated C1-6-alkyl, aryl, heteroaryl, C1-6-acyl, C1-6-alkylsulfonyl, arylcarbonyl, heteroarylcarbonyl, 2-carbomethoxyphenyl; or a salt, hydrate or solvate thereof; with the proviso that when:
X is CH2, Y is CH2, then R2 is not methyl and ethyl;
X is CH2, Y is a single bond, then R2 is not ethyl and n-propyl;
X is CH2, Y is a single bond, R2 is methyl, B is methyl, then T is not 3-chloro-2- methylphenyl;
X is CO, Y is a single bond, then R2 is not methyl;
X is CO, Y is a single bond, R2 is ethoxy, B is methyl, then T is not 3-chloro-2- methylphenyl, l,l '-biphenyl-4-yl, 4-n-propylphenyl, 2,4-dichloro-6-methylphenyl, and 2,4,6-trichlorophenyl.
6. The method according to claim 5, wherein the immuno-modulation is selected from tuberculosis, lepra, and psoriasis.
7. The method according to claim 5-6, wherein T is selected from 5-chloro-l,3-dimethyl-lH-pyrazol-4-yl; 4-chloro-2,3,l- benzoxadiazolyl; 5-(dimethylamino)- 1-naphthyl; l-methylimidazol-4-yl; 1-naphthyl; 2- naphthyl; 8-quinolinyl; thienyl substituted with one or more of (benzoylamino)methyl, bromo, chloro, 3- isoxazolyl, 2-(methylsulfanyl)-4-pyrimidinyl, 1 -methyl-5-(trifluoromethyl)pyrazol-3-yl, phenylsulfonyl, pyridyl; phenyl substituted with one or more of acetylamino, 3-acetylaminophenyl, 3- acetylphenyl, benzeneamino, l,3-benzodioxol-5-yl, 2-benzofuryl, benzylamino, 3,5- bis(trifluoromethyl)phenyl, bromo, butoxy, carboxy, chloro, 4-carboxyphenyl, 3-chloro- 2-cyanophenoxy, 4-chlorophenyl, 5-chloro-2-thienyl, cyano, 3,4-dichlorophenyl, ({[4-(2- ethoxy-2-oxoethyl)- 1 ,3-thiazol-2-yl]amino} carbonyl), fluoro, 5-fluoro-2-methoxyphenyl, 2-furyl, hydrogen, iodo, isopropyl, methanesulfonyl, methoxy, methyl, 4-methyl- 1- piperazinyl, 4-methyl-l -piperidinyl, 4-methylsulfanylphenyl, 5-methyl-2-thienyl, 4- moφholinyl, nitro, 3-nitrophenyl, phenoxy, phenyl, n-propyl, 4-pyridyl, 3- pyridylmethylamino, 1 -pyrrolidinyl, 2-thienyl, 3-thienyl, 2-thienylmethylamino, trifluoromethoxy, 4-trifluoromethoxyphenyl, trifluoromethyl; or
R1 is hydrogen or methyl;
X is CH2 or CO;
Y is CH2, CO or a single bond; B is hydrogen, methyl or dimethylaminomethyl;
R2 is selected from n-propyl, azido, bromo, chloro, 2-pyridinylsulfanyl, 3-oxo-4-moφholinolinyl- methylene, ethoxycarbonyl, 5-methyl-l,3,4-oxadiazol-2-yl, hydroxymethyl, 2- hydroxyethylaminomethyl, methylsulfonyloxymethyl; NR3R4, wherein R3 and R4 are each independently selected from acetyl, benzhydryl, l,3-benzodioxol-5-ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexyl, cyclohexylmethyl, cyclopropanecarbonyl, ethyl, 2-furylcarbonyl, 2- furylmethyl, hydrogen, 2-hydroxyethyl, 2-(lH-indol-3-yl)ethyl, isopropyl, methoxy, 2- methoxyethyl, methyl, 4-(l-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl, (1S)- phenylethyl, n-propyl, tetrahydro-2-furanylmethyl, trifluoromethylsulfonyl, N- carbethoxypiperidyl; or
NR3R4 represent together 4-acetylpiperazinyl, 4-t-butoxycarbonylpiperazinyl, 2- (3,4-dihydro-2(lH)isoquinolinyl), (2R,6S)-2,6-dimethylmoφholinyl, (2R)-2,4-dimethyl- 1 -piperazinyl, 2-hydroxy-3-oxomoφholinyl, imidazolyl, 2-methyl-3-oxomoφholinyl, 4- methyl-2-oxopiperazinyl, 4-methylpiperazinyl, moφholinyl, (lS,4S)-2-oxa-5-aza- bicyclo[2.2.1]hept-5-yl, 2-oxoimidazolinyl, 3-oxomoφholinyl, 3-oxo-l,4-oxazepinyl, 2- oxooxazolinyl, piperazinyl; piperidinyl; pyrrolidinyl; pyrrolidonyl, thiomoφholinyl; 1,1- dioxido-thiomoφholinyl;
OCONR3R4, wherein R3 and R4 are each independently selected from ethyl, hydrogen or form together with the N-atom to which they are attached moφholinyl;
R5O, wherein R5 is acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, n-propionyl, 3-pyridinyl, 2,2,2-trifluoroethyl; with the proviso that when: X is CH2, Y is a single bond, then R2 is not n-propyl;
X is CO, Y is a single bond, R2 is ethoxy, B is methyl, then T is not 3-chloro-2- methylphenyl, l,l'-biphenyl-4-yl, 4-n-propylphenyl, 2,4-dichloro-6-methylphenyl, and 2,4,6-trichlorophenyl.
8. The method according to claim 5-7, wherein the compound is selected from the compounds as defined in claim 3, and (2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}- l,3-thiazol-5-yl)acetic acid.
9. A method for inhibiting a human 11-β-hydroxysteroid dehydrogenase type 1 enzyme, comprising administering to a subject in need thereof an effective amount of a compound of formula (I):
Figure imgf000061_0001
wherein
T is an aryl ring or heteroaryl ring, optionally independently substituted by [R]n, wherein n is an integer 0-5, and R is hydrogen, aryl, heteroaryl, a heterocyclic ring, optionally halogenated C1-6-alkyl, optionally halogenated C1-6-alkoxy, C1-6-alkylsulfonyl, carboxy, cyano, nitro, halogen, amine which is optionally mono- or di-substituted, amide which is optionally mono- or di-substituted, aryloxy, arylsulfonyl, arylamino, wherein aryl, heteroaryl and aryloxy residues and heterocyclic rings are further optionally substituted in one or more positions independently of each other by C1-6-acyl, C1-6- alkylthio, cyano, nitro, hydrogen, halogen, optionally halogenated d-6-alkyl, optionally halogenated C1-6-alkoxy, amide which is optionally mono- or di-substituted, (benzoylamino)methyl, carboxy, 2-thienylmethylamino or ({[4-(2-ethoxy-2-oxoethyl)- 1 ,3 -thiazol-2-yl] amino } carbonyl); R1 is hydrogen or Cι-6-alkyl;
X is CH2 or CO;
Y is CH2, CO or a single bond;
B is hydrogen, C1-6-alkyl or dimethylaminomethyl; R2 is selected from C1-6-alkyl, azido, arylthio, heteroarylthio, halogen, hydroxymethyl, 2-hydroxyethylaminomethyl, methylsulfonyloxymethyl, 3-oxo-4- moφholinolinylmethylene, C1-6-alkoxycarbonyl, 5-methyl-l,3,4-oxadiazol-2-yl;
NR3R4, wherein R3 and R4 are each independently selected from hydrogen, C1-6- alkyl, optionally halogenated C1-6-alkylsulfonyl, C1-6-alkoxy, 2-methoxyethyl, 2- hydroxyethyl, 1-methylimidazolylsulfonyl, C1-6-acyl, cyclohexylmethyl, cyclopropanecarbonyl, aryl, optionally halogenated arylsulfonyl, furylcarbonyl, tetrahydro-2-furanylmethyl, N-carbethoxypiperidyl or C1-6-alkyl substituted with one or more aryl, heterocyclic or heteroaryl, or
NR3R4 represent together heterocyclic systems which are imidazole, piperidine, pyrrolidine, piperazine, moφholine, oxazepine, oxazole, thiomoφholine, 1,1- dioxidothiomoφholine, 2-(3,4-dihydro-2(lH)isoquinolinyl), or (lS,4S)-2-oxa-5- azabicyclo[2.2.1]hept-5-yl, which heterocyclic systems are optionally substituted by C1-6- alkyl, C1-6-acyl, hydroxy, oxo, t-butoxycarbonyl;
OCONR3R4, wherein R3 and R4 are each independently selected from hydrogen, C1-6-alkyl or form together with the N-atom to which they are attached moφholinyl;
R5O, wherein R5 is hydrogen, optionally halogenated C1-6-alkyl, aryl, heteroaryl, C1-6-acyl, C1-6-alkylsulfonyl, arylcarbonyl, heteroarylcarbonyl, 2-carbomethoxyphenyl; or a salt, hydrate or solvate thereof; with the proviso that when: X is CH2, Y is CH2, then R2 is not methyl and ethyl;
X is CH2, Y is a single bond, then R is not ethyl and n-propyl;
X is CH2, Y is a single bond, R2 is methyl, B is methyl, then T is not 3-chloro-2- methylphenyl;
X is CO, Y is a single bond, then R2 is not methyl; X is CO, Y is a single bond, R2 is ethoxy, B is methyl, then T is not 3-chloro-2- methylphenyl, l, -biphenyl-4-yl, 4-n-propylphenyl, 2,4-dichloro-6-methylphenyl, and 2,4,6-trichlorophenyl.
10. The method according to claim 9, wherein
T is selected from 5-chloro-l,3-dimethyl-lH-pyrazol-4-yl; 4-chloro-2,3,l- benzoxadiazolyl; 5-(dimethylamino)- 1-naphthyl; l-methylimidazol-4-yl; 1-naphthyl; 2- naphthyl; 8-quinolinyl; thienyl substituted with one or more of (benzoylamino)methyl, bromo, chloro, 3- isoxazolyl, 2-(methylsulfanyl)-4-pyrimidinyl, 1 -methyl-5-(trifluoromethyl)pyrazol-3-yl, phenylsulfonyl, pyridyl; phenyl substituted with one or more of acetylamino, 3-acetylaminophenyl, 3- acetylphenyl, benzeneamino, l,3-benzodioxol-5-yl, 2-benzofuryl, benzylamino, 3,5- bis(trifluoromethyl)phenyl, bromo, butoxy, carboxy, chloro, 4-carboxyphenyl, 3-chloro- 2-cyanophenoxy, 4-chlorophenyl, 5-chloro-2-thienyl, cyano, 3,4-dichlorophenyl, ({[4-(2- ethoxy-2-oxoethyl)-l,3-thiazol-2-yl]amino}carbonyl), fluoro, 5-fluoro-2-methoxyphenyl, 2-furyl, hydrogen, iodo, isopropyl, methanesulfonyl, methoxy, methyl, 4-methyl- 1- piperazinyl, 4-methyl-l -piperidinyl, 4-methylsulfanylphenyl, 5-methyl-2-thienyl, 4- moφholinyl, nitro, 3-nitrophenyl, phenoxy, phenyl, n-propyl, 4-pyridyl, 3- pyridylmethylamino, 1-pynolidinyl, 2-thienyl, 3-thienyl, 2-thienylmethylamino, trifluoromethoxy, 4-trifluoromethoxyphenyl, trifluoromethyl; or
R1 is hydrogen or methyl;
X is CH2 or CO; Y is CH2, CO or a single bond;
B is hydrogen, methyl or dimethylaminomethyl;
R2 is selected from n-propyl, azido, bromo, chloro, 2-pyridinylsulfanyl, 3-oxo-4-moφholinolinyl- methylene, ethoxy carbonyl, 5-methyl-l,3,4-oxadiazol-2-yl, hydroxymethyl, 2- hydroxyethylaminomethyl, methylsulfonyloxymethyl;
NR3R4, wherein R3 and R4 are each independently selected from acetyl, benzhydryl, l,3-benzodioxol-5-ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexyl, cyclohexylmethyl, cyclopropanecarbonyl, ethyl, 2-furylcarbonyl, 2- furylmethyl, hydrogen, 2-hydroxyethyl, 2-(lH-indol-3-yl)ethyl, isopropyl, methoxy, 2- methoxyethyl, methyl, 4-(l-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl, (1S)- phenylethyl, n-propyl, tetrahydro-2-furanylmethyl, trifluoromethylsulfonyl, N- carbethoxypiperidyl; or
NR3R4 represent together 4-acetylpiperazinyl, 4-t-butoxycarbonylpiperazinyl, 2- (3,4-dihydro-2(lH)isoquinolinyl), (2R,6S)-2,6-dimethylmoφholinyl, (2R)-2,4-dimethyl- 1 -piperazinyl, 2-hydroxy-3-oxomoφholinyl, imidazolyl, 2-methyl-3-oxomoφholinyl, 4- methyl-2-oxopiperazinyl, 4-methylpiperazinyl, moφholinyl, (lS,4S)-2-oxa-5-aza- bicyclo[2.2.1]hept-5-yl, 2-oxoimidazolinyl, 3-oxomoφholinyl, 3-oxo-l,4-oxazepinyl, 2- oxooxazolinyl, piperazinyl; piperidinyl; pyrrolidinyl; pyrrolidonyl, thiomoφholinyl; 1,1- dioxido-thiomoφholinyl;
OCONR3R4, wherein R3 and R4 are each independently selected from ethyl, hydrogen or form together with the N-atom to which they are attached moφholinyl;
R5O, wherein R5 is acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, n-propionyl, 3-pyridinyl, 2,2,2-trifluoroethyl; with the proviso that when:
X is CH2, Y is a single bond, then R2 is not n-propyl;
X is CO, Y is a single bond, R2 is ethoxy, B is methyl, then T is not 3-chloro-2- methylphenyl, l,l'-biphenyl-4-yl, 4-n-propylphenyl, 2,4-dichloro-6-methylphenyl, and 2,4,6-trichlorophenyl.
11. The method according to claim 9-10, wherein the compound is selected from the compounds as defined in claim 3, and (2-{[(3-chloro-2- methylphenyl)sulfonyl]amino}-l,3-thiazol-5-yl)acetic acid.
12. The method according to claim 9-11, wherein the subject is a human.
13. A method for treating a 11-β-hydroxysteroid dehydrogenase type 1 enzyme- mediated disorder, comprising administering to a subject in need thereof an effective amount of a compound of formula (I)
Figure imgf000064_0001
wherein T is an aryl ring or heteroaryl ring, optionally independently substituted by [R]n, wherein n is an integer 0-5, and R is hydrogen, aryl, heteroaryl, a heterocyclic ring, optionally halogenated C1-6-alkyl, optionally halogenated C1-6-alkoxy, C1-6-alkylsulfonyl, carboxy, cyano, nitro, halogen, amine which is optionally mono- or di-substituted, amide which is optionally mono- or di-substituted, aryloxy, arylsulfonyl, arylamino, wherein aryl, heteroaryl and aryloxy residues and heterocyclic rings are further optionally substituted in one or more positions independently of each other by C1-6-acyl, C1-6- alkylthio, cyano, nitro, hydrogen, halogen, optionally halogenated C1-6-alkyl, optionally halogenated C1-6-alkoxy, amide which is optionally mono- or di-substituted, (benzoylamino)methyl, carboxy, 2-thienylmethylamino or ({[4-(2-ethoxy-2-oxoethyl)- 1 ,3 -thiazol-2-yl] amino } carbonyl);
R1 is hydrogen or C1-6-alkyl;
X is CH2 or CO;
Y is CH , CO or a single bond; B is hydrogen, C1-6-alkyl or dimethylaminomethyl;
R2 is selected from C1-6-alkyl, azido, arylthio, heteroarylthio, halogen, hydroxymethyl, 2-hydroxyethylaminomethyl, methylsulfonyloxymethyl, 3-oxo-4- moφholinolinylmethylene, C1-6-alkoxycarbonyl, 5-methyl- 1 ,3,4-oxadiazol-2-yl;
NR3R4, wherein R3 and R4 are each independently selected from hydrogen, Cι-6- alkyl, optionally halogenated C1-6-alkylsulfonyl, C1-6-alkoxy, 2-methoxyethyl, 2- hydroxyethyl, 1-methylimidazolylsulfonyl, Ct-6-acyl, cyclohexylmethyl, cyclopropanecarbonyl, aryl, optionally halogenated arylsulfonyl, furylcarbonyl, tetrahydro-2-furanylmethyl, N-carbethoxypiperidyl or C1-6-alkyl substituted with one or more aryl, heterocyclic or heteroaryl, or NR3R represent together heterocyclic systems which are imidazole, piperidine, pyrrolidine, piperazine, moφholine, oxazepine, oxazole, thiomoφholine, 1,1- dioxidothiomoφholine, 2-(3,4-dihydro-2(lH)isoquinolinyl), or (lS,4S)-2-oxa-5- azabicyclo[2.2.1]hept-5-yl, which heterocyclic systems are optionally substituted by C1-6- alkyl, C1-6-acyl, hydroxy, oxo, t-butoxycarbonyl; OCONR3R4, wherein R3 and R4 are each independently selected from hydrogen,
C1-6-alkyl or form together with the N-atom to which they are attached moφholinyl;
R5O, wherein R5 is hydrogen, optionally halogenated C1-6-alkyl, aryl, heteroaryl, C1-6-acyl, C1-6-alkylsulfonyl, arylcarbonyl, heteroarylcarbonyl, 2-carbomethoxyphenyl; or a salt, hydrate or solvate thereof; with the proviso that when:
X is CH2, Y is CH2, then R2 is not methyl and ethyl;
X is CH2, Y is a single bond, then R2 is not ethyl and n-propyl; X is CH2, Y is a single bond, R2 is methyl, B is methyl, then T is not 3-chloro-2- methylphenyl;
X is CO, Y is a single bond, then R2 is not methyl;
X is CO, Y is a single bond, R2 is ethoxy, B is methyl, then T is not 3-chloro-2- methylphenyl, l, -biphenyl-4-yl, 4-n-propylphenyl, 2,4-dichloro-6-methylphenyl, and 2,4,6-trichlorophenyl.
14. The method according to claim 13, wherein the disorder is selected from diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, depression, virus diseases, inflammatory disorders, and immuno-modulation, wherein the treatment of hyperglycemia does not cause hypoglycemia.
15. The method according to claim 13-14, wherein the immuno-modulation is selected from tuberculosis, lepra, and psoriasis.
16. The method according to claim 13-15, wherein
T is selected from 5-chloro-l,3-dimethyl-lH-pyrazol-4-yl; 4-chloro-2,3,l- benzoxadiazolyl; 5-(dimethylamino)- 1-naphthyl; l-methylimidazol-4-yl; 1-naphthyl; 2- naphthyl; 8-quinolinyl; thienyl substituted with one or more of (benzoylamino)methyl, bromo, chloro, 3- isoxazolyl, 2-(methylsulfanyl)-4-pyrimidinyl, 1 -methyl-5-(trifluoromethyl)pyrazol-3-yl, phenylsulfonyl, pyridyl; phenyl substituted with one or more of acetylamino, 3-acetylaminophenyl, 3- acetylphenyl, benzeneamino, l,3-benzodioxol-5-yl, 2-benzofuryl, benzylamino, 3,5- bis(trifluoromethyl)phenyl, bromo, butoxy, carboxy, chloro, 4-carboxyphenyl, 3-chloro- 2-cyanophenoxy, 4-chlorophenyl, 5-chloro-2-thienyl, cyano, 3,4-dichlorophenyl, ({[4-(2- ethoxy-2-oxoethyl)-l,3-thiazol-2-yl]amino}carbonyl), fluoro, 5-fluoro-2-methoxyphenyl, 2-furyl, hydrogen, iodo, isopropyl, methanesulfonyl, methoxy, methyl, 4-methyl- 1- piperazinyl, 4-methyl-l -piperidinyl, 4-methylsulfanylphenyl, 5-methyl-2-thienyl, 4- moφholinyl, nitro, 3-nitrophenyl, phenoxy, phenyl, n-propyl, 4-pyridyl, 3- pyridylmethylamino, 1 -pyrrolidinyl, 2-thienyl, 3-thienyl, 2-thienylmethylamino, trifluoromethoxy, 4-trifluoromethoxyphenyl, trifluoromethyl; or
R1 is hydrogen or methyl; X is CH2 or CO;
Y is CH2, CO or a single bond;
B is hydrogen, methyl or dimethylaminomethyl;
R2 is selected from n-propyl, azido, bromo, chloro, 2-pyridinylsulfanyl, 3-oxo-4-moφholinolinyl- methylene, ethoxycarbonyl, 5-methyl-l,3,4-oxadiazol-2-yl, hydroxymethyl, 2- hydroxyethylaminomethyl, methylsulfonyloxymethyl;
NR3R4, wherein R3 and R4 are each independently selected from acetyl, benzhydryl, l,3-benzodioxol-5-ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexyl, cyclohexylmethyl, cyclopropanecarbonyl, ethyl, 2-furylcarbonyl, 2- furylmethyl, hydrogen, 2-hydroxyethyl, 2-(lH-indol-3-yl)ethyl, isopropyl, methoxy, 2- methoxyethyl, methyl, 4-(l-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl, (1S)- phenylethyl, n-propyl, tetrahydro-2-furanylmethyl, trifluoromethylsulfonyl, N- carbethoxypiperidyl; or
NR3R4 represent together 4-acetylpiperazinyl, 4-t-butoxycarbonylpiperazinyl, 2- (3,4-dihydro-2(lH)isoquinolinyl), (2R,6S)-2,6-dimethylmoφholinyl, (2R)-2,4-dimethyl- 1 -piperazinyl, 2-hydroxy-3-oxomoφholinyl, imidazolyl, 2-methyl-3-oxomoφholinyl, 4- methyl-2-oxopiperazinyl, 4-methylpiperazinyl, moφholinyl, (lS,4S)-2-oxa-5-aza- bicyclo[2.2.1]hept-5-yl, 2-oxoimidazolinyl, 3-oxomoφholinyl, 3-oxo-l,4-oxazepinyl, 2- oxooxazolinyl, piperazinyl; piperidinyl; pyrrolidinyl; pyrrolidonyl, thiomoφholinyl; 1,1- dioxido-thiomoφholinyl;
OCONR3R4, wherein R3 and R4 are each independently selected from ethyl, hydrogen or form together with the N-atom to which they are attached moφholinyl;
R5O, wherein R5 is acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, n-propionyl, 3-pyridinyl, 2,2,2-trifluoroethyl; with the proviso that when:
X is CH2, Y is a single bond, then R2 is not n-propyl; X is CO, Y is a single bond, R2 is ethoxy, B is methyl, then T is not 3-chloro-2- methylphenyl, l,l '-biphenyl-4-yl, 4-n-propylphenyl, 2,4-dichloro-6-methylphenyl, and 2,4,6-trichlorophenyl.
17. The method according to claim 13-16, wherein the compound is selected from the compounds as defined in claim 3, and (2-{[(3-chloro-2- methylρhenyl)sulfonyl] amino } - 1 ,3 -thiazol-5 -yl)acetic acid.
18. The method according to claim 13-17, wherein the subject is a human.
19. The use of a compound of formula (I)
Figure imgf000068_0001
wherein T is an aryl ring or heteroaryl ring, optionally independently substituted by [R]n, wherein n is an integer 0-5, and R is hydrogen, aryl, heteroaryl, a heterocyclic ring, optionally halogenated C1-6-alkyl, optionally halogenated C1-6-alkoxy, C1-6-alkylsulfonyl, carboxy, cyano, nitro, halogen, amine which is optionally mono- or di-substituted, amide which is optionally mono- or di-substituted, aryloxy, arylsulfonyl, arylamino, wherein aryl, heteroaryl and aryloxy residues and heterocyclic rings are further optionally substituted in one or more positions independently of each other by C1-6-acyl, C1-6- alkylthio, cyano, nitro, hydrogen, halogen, optionally halogenated C1-6-alkyl, optionally halogenated C1-6-alkoxy, amide which is optionally mono- or di-substituted, (benzoylamino)methyl, carboxy, 2-thienylmethylamino or ({[4-(2-ethoxy-2-oxoethyl)- l,3-thiazol-2-yl]amino}carbonyl);
R1 is hydrogen or C1-6-alkyl;
X is CH2 or CO;
Y is CH2, CO or a single bond;
B is hydrogen, d-β-alkyl or dimethylaminomethyl; R2 is selected from Q-6-alkyl, azido, arylthio, heteroarylthio, halogen, hydroxymethyl, 2-hydroxyethylaminomethyl, methylsulfonyloxymethyl, 3-oxo-4- moφholinolinylmethylene, C1-6-alkoxycarbonyl, 5-methyl-l ,3,4-oxadiazol-2-yl;
NR3R4, wherein R3 and R4 are each independently selected from hydrogen, C1-6- alkyl, optionally halogenated Cι-6-alkylsulfonyl, C1-6-alkoxy, 2-methoxyethyl, 2- hydroxyethyl, 1-methylimidazolylsulfonyl, C1-6-acyl, cyclohexylmethyl, cyclopropanecarbonyl, aryl, optionally halogenated arylsulfonyl, furylcarbonyl, tetrahydro-2-furanylmethyl, N-carbethoxypiperidyl or C1-6-alkyl substituted with one or more aryl, heterocyclic or heteroaryl, or NR3R4 represent together heterocyclic systems which are imidazole, piperidine, pyrrolidine, piperazine, moφholine, oxazepine, oxazole, thiomoφholine, 1,1- dioxidothiomoφholine, 2-(3,4-dihydro-2(lH)isoquinolinyl), (lS,4S)-2-oxa-5- azabicyclo[2.2.1]hept-5-yl, which heterocyclic systems are optionally substituted by C1-6- alkyl, C1- -acyl, hydroxy, oxo, t-butoxycarbonyl; OCONR3R4, wherein R3 and R4 are each independently selected from hydrogen,
C1-6-alkyl or form together with the N-atom to which they are attached moφholinyl;
R5O, wherein R5 is hydrogen, optionally halogenated C1-6-alkyl, aryl, heteroaryl, C1-6-acyl, C1-6-alkylsulfonyl, arylcarbonyl, heteroarylcarbonyl, 2-carbomethoxyphenyl; or a salt, hydrate or solvate thereof; with the proviso that when:
X is CH2, Y is CH2, then R2 is not methyl and ethyl;
X is CH2, Y is a single bond, then R2 is not ethyl and n-propyl;
X is CH2, Y is a single bond, R2 is methyl, B is methyl, then T is not 3-chloro-2- methylphenyl; X is CO, Y is a single bond, then R2 is not methyl;
X is CO, Y is a single bond, R2 is ethoxy, B is methyl, then T is not 3-chloro-2- methylphenyl, l, -biphenyl-4-yl, 4-n-propylphenyl, 2,4-dichloro-6-methylphenyl, and 2,4,6-trichlorophenyl, in the manufacture of a medicament for the prevention, management or treatment of diabetes, syndrome X, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, hypertension, osteoporosis, dementia, depression, virus diseases or inflammatory disorders without causing hypoglycemia and to achieve immuno- modulation.
20. The use according to claim 19, wherein the immuno-modulation is selected from tuberculosis, lepra, and psoriasis.
21. The use according to claim 19-20, wherein T is selected from 5-chloro-l,3-dimethyl-lH-ρyrazol-4-yl; 4-chloro-2,3,l- benzoxadiazolyl; 5-(dimethylamino)- 1-naphthyl; l-methylimidazol-4-yl; 1-naphthyl; 2- naphthyl; 8-quinolinyl; thienyl substituted with one or more of (benzoylamino)methyl, bromo, chloro, 3- isoxazolyl, 2-(methylsulfanyl)-4-pyrimidinyl, 1 -methyl-5-(trifluoromethyl)pyrazol-3-yl, phenylsulfonyl, pyridyl; phenyl substituted with one or more of acetylamino, 3-acetylaminophenyl, 3- acetylphenyl, benzeneamino, l,3-benzodioxol-5-yl, 2-benzofuryl, benzylamino, 3,5- bis(trifluoromethyl)phenyl, bromo, butoxy, carboxy, chloro, 4-carboxyphenyl, 3-chloro- 2-cyanophenoxy, 4-chlorophenyl, 5-chloro-2-thienyl, cyano, 3,4-dichlorophenyl, ({[4-(2- ethoxy-2-oxoethyl)-l,3-thiazol-2-yl]amino}carbonyl), fluoro, 5-fluoro-2-methoxyphenyl, 2-furyl, hydrogen, iodo, isopropyl, methanesulfonyl, methoxy, methyl, 4-methyl- 1- piperazinyl, 4-methyl-l -piperidinyl, 4-methylsulfanylphenyl, 5-methyl-2-thienyl, 4- moφholinyl, nitro, 3-nitrophenyl, phenoxy, phenyl, n-propyl, 4-pyridyl, 3- pyridylmethylamino, 1 -pyrrolidinyl, 2-thienyl, 3-thienyl, 2-thienylmethylamino, trifluoromethoxy, 4-trifluoromethoxyphenyl, trifluoromethyl; or R1 is hydrogen or methyl; X is CH2 or CO; Y is CH2, CO or a single bond; B is hydrogen, methyl or dimethylaminomethyl; R2 is selected from n-propyl, azido, bromo, chloro, 2-pyridinylsulfanyl, 3-oxo-4-moφholinolinyl- methylene, ethoxycarbonyl, 5-methyl-l,3,4-oxadiazol-2-yl, hydroxymethyl, 2- hydroxyethylaminomethyl, methylsulfonyloxymethyl;
NR3R4, wherein R3 and R4 are each independently selected from acetyl, benzhydryl, l,3-benzodioxol-5-ylmethyl, benzyl, 3-chloro-2-methylphenylsulfonyl, cyclohexyl, cyclohexylmethyl, cyclopropanecarbonyl, ethyl, 2-furylcarbonyl, 2- furylmethyl, hydrogen, 2-hydroxyethyl, 2-(lH-indol-3-yl)ethyl, isopropyl, methoxy, 2- methoxyethyl, methyl, 4-(l-methylimidazolyl)sulfonyl, methylsulfonyl, phenyl, (1S)- phenylethyl, n-propyl, tetrahydro-2-furanylmethyl, trifluoromethylsulfonyl, N- carbethoxypiperidyl; or
NR3R4 represent together 4-acetylpiperazinyl, 4-t-butoxycarbonylpiperazinyl, 2- (3,4-dihydro-2(lH)isoquinolinyl), (2R,6S)-2,6-dime lmoφholinyl, (2R)-2,4-dimethyl- 1 -piperazinyl, 2-hydroxy-3-oxomoφholinyl, imidazolyl, 2-methyl-3-oxomoφholinyl, 4- methyl-2-oxopiperazinyl, 4-methylpiperazinyl, moφholinyl, (lS,4S)-2-oxa-5-aza- bicyclo[2.2.1]hept-5-yl, 2-oxoimidazolinyl, 3-oxomoφholinyl, 3-oxo-l,4-oxazepinyl, 2- oxooxazolinyl, piperazinyl; piperidinyl; pynolidinyl; pyrrolidonyl, thiomoφholinyl; 1,1- dioxido-thiomoφholinyl; OCONR3R4, wherein R3 and R4 are each independently selected from ethyl, hydrogen or form together with the N-atom to which they are attached moφholinyl;
R5O, wherein R5 is acetyl, benzoyl, benzyl, ethyl, 2-fluoroethyl, 2-furylcarbonyl, hydrogen, isobutyryl, isopropyl, methyl, 2-carbomethoxyphenyl, methylsulfonyl, phenyl, n-propionyl, 3-pyridinyl, 2,2,2-trifluoroethyl; with the proviso that when:
X is CH2, Y is a single bond, then R2 is not n-propyl;
X is CO, Y is a single bond, R2 is ethoxy, B is methyl, then T is not 3-chloro-2- methylphenyl, l,l '-biphenyl-4-yl, 4-n-propylphenyl, 2,4-dichloro-6-methylphenyl, and 2,4,6-trichlorophenyl.
22. The use according to claim 19-21, wherein the compound is selected from the compounds as defined in claim 3, and (2-{[(3-chloro-2-methylphenyl)sulfonyl]amino}- l,3-thiazol-5-yl)acetic acid.
23. A pharmaceutical composition comprising at least one compound of formula
(I) as defined in any of the claims 1-3, and a pharmaceutically acceptable carrier.
PCT/SE2002/002140 2001-11-22 2002-11-22 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 WO2003043999A1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
MXPA04004779A MXPA04004779A (en) 2001-11-22 2002-11-22 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1.
BR0214343-7A BR0214343A (en) 2001-11-22 2002-11-22 11 - Beta - Hydroxy Steroid Dehydrogenase Inhibitors Type 1
YUP-443/04A RS44304A (en) 2001-11-22 2002-11-22 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EA200400707A EA200400707A1 (en) 2001-11-22 2002-11-22 INHIBITORS 11-BETA-HYDROXYSTEROID DEGYDROGENASE TYPE 1
DE60236541T DE60236541D1 (en) 2001-11-22 2002-11-22 INHIBITORS OF 11-BETA-HYDROXYSTEROIDDEHYDROGENASE TYPE 1
AU2002353718A AU2002353718B2 (en) 2001-11-22 2002-11-22 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
CA002466490A CA2466490C (en) 2001-11-22 2002-11-22 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
JP2003545636A JP4559078B2 (en) 2001-11-22 2002-11-22 Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
IL16115402A IL161154A0 (en) 2001-11-22 2002-11-22 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
EP02789090A EP1461325B1 (en) 2001-11-22 2002-11-22 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AT02789090T ATE469136T1 (en) 2001-11-22 2002-11-22 INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1
NO20042596A NO20042596L (en) 2001-11-22 2004-06-21 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0103911 2001-11-22
SE0103911-4 2001-11-22
US34861702P 2002-01-14 2002-01-14
US60/348,617 2002-01-14

Publications (1)

Publication Number Publication Date
WO2003043999A1 true WO2003043999A1 (en) 2003-05-30

Family

ID=26655600

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2002/002140 WO2003043999A1 (en) 2001-11-22 2002-11-22 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1

Country Status (14)

Country Link
EP (1) EP1461325B1 (en)
JP (1) JP4559078B2 (en)
KR (1) KR20050044577A (en)
CN (1) CN1564816A (en)
AT (1) ATE469136T1 (en)
AU (1) AU2002353718B2 (en)
BR (1) BR0214343A (en)
CA (1) CA2466490C (en)
DE (1) DE60236541D1 (en)
IL (1) IL161154A0 (en)
MX (1) MXPA04004779A (en)
NO (1) NO20042596L (en)
PL (1) PL370111A1 (en)
WO (1) WO2003043999A1 (en)

Cited By (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103980A1 (en) * 2003-05-21 2004-12-02 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
WO2004112782A1 (en) * 2003-06-25 2004-12-29 Biovitrum Ab New use v
US6849636B2 (en) 2002-12-20 2005-02-01 Merck & Co., Inc. Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
WO2005060963A1 (en) * 2003-12-19 2005-07-07 Pfizer Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
WO2005116002A2 (en) * 2004-05-24 2005-12-08 Amgen Inc. Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2006010546A2 (en) * 2004-07-28 2006-02-02 F. Hoffman-La Roche Ag Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors
WO2006048331A1 (en) * 2004-11-08 2006-05-11 Evotec Ag 11β-HSD1 INHIBITORS
WO2006050908A1 (en) * 2004-11-08 2006-05-18 Evotec Ag Inhibitors of 11βετα-hydroxy steroid dehydrogenase type 1 (11beta-hsd1)
US7173030B2 (en) 2003-05-21 2007-02-06 Biovitrum Ab Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
WO2007025892A1 (en) 2005-08-31 2007-03-08 F. Hoffmann-La Roche Ag 11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1
US7230020B2 (en) 2003-10-23 2007-06-12 Sterix Limited 11β-hydroxysteroid dehydrogenase inhibitors
WO2007128761A2 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Uses of dpp-iv inhibitors
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
US7345058B2 (en) 2005-04-05 2008-03-18 Hoffmann-La Roche Inc. Pyrazoles
DE102007005045A1 (en) 2007-01-26 2008-08-07 Sanofi-Aventis New phenothiazine derivative for use in preparing medicine for blood sugar lowering and for treatment of diabetes, nicotine dependence, alcohol dependence, central nervous system disorders, schizophrenia, and Alzheimer's disease
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
EP2036548A1 (en) 2003-09-22 2009-03-18 onepharm Research & Development GmbH Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
US7645773B2 (en) 2006-01-18 2010-01-12 Hoffmann-La Roche Inc. Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US7759339B2 (en) 2005-03-31 2010-07-20 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
US8017638B2 (en) 2006-03-30 2011-09-13 Shionogi & Co., Ltd. Isoxazole derivative and isothiazole derivative having inhibitory activity on 11β-hydroxysteroid dehydrogenase type 1
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2011161030A1 (en) 2010-06-21 2011-12-29 Sanofi Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators
WO2012004269A1 (en) 2010-07-05 2012-01-12 Sanofi (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals
WO2012004270A1 (en) 2010-07-05 2012-01-12 Sanofi Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament
WO2012010413A1 (en) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120058A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8357711B2 (en) 2007-03-23 2013-01-22 Pfizer Limited Heterocyclic sulfonamides as inhibitors of ion channels
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8541592B2 (en) 2005-11-22 2013-09-24 Amgen Inc. Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
US8686011B2 (en) 2004-05-24 2014-04-01 Amgen Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
US8952176B2 (en) 2005-06-07 2015-02-10 Shionogi & Co., Ltd. Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity
US9067922B2 (en) 2013-04-19 2015-06-30 Pfizer Limited Chemical compounds
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0001899D0 (en) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2384489A1 (en) 1977-03-23 1978-10-20 Rosenthal Technik Ag INTERNAL JOINT PROSTHESIS
FR2384498A1 (en) * 1975-11-26 1978-10-20 Parcor Antibacterial, antifungal and hypoglycaemic sulphonamido thiazole(s) - prepd. from a phenyl sulphonamide and an isothiocyanato butyne
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
EP0790057A1 (en) * 1994-11-29 1997-08-20 Hisamitsu Pharmaceutical Co., Inc. Antibacterial or bactericide comprising 2-aminothiazole derivative and salts thereof
US5783597A (en) * 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
WO1999002502A2 (en) * 1997-07-11 1999-01-21 Smithkline Beecham Plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
WO2001054691A1 (en) * 2000-01-26 2001-08-02 Nicox, S.A. Nitrate salts of antimicrobial agents
WO2001090091A1 (en) 2000-05-22 2001-11-29 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2510925A (en) * 1948-03-20 1950-06-06 Allied Lab Inc 2-sulfanilamido-5-carbamylthiazole and its production

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2384498A1 (en) * 1975-11-26 1978-10-20 Parcor Antibacterial, antifungal and hypoglycaemic sulphonamido thiazole(s) - prepd. from a phenyl sulphonamide and an isothiocyanato butyne
FR2384489A1 (en) 1977-03-23 1978-10-20 Rosenthal Technik Ag INTERNAL JOINT PROSTHESIS
US5594021A (en) * 1993-05-20 1997-01-14 Texas Biotechnology Corporation Thienyl-, furyl- and pyrrolyl sulfonamides and derivatives thereof that modulate the activity of endothelin
EP0790057A1 (en) * 1994-11-29 1997-08-20 Hisamitsu Pharmaceutical Co., Inc. Antibacterial or bactericide comprising 2-aminothiazole derivative and salts thereof
US5783597A (en) * 1997-03-04 1998-07-21 Ortho Pharmaceutical Corporation 2,5-disubstituted thiophenes: inhibitors of 5-lipoxygenase and inducible cyclooxygenase (COX-2) enzymes, composition and use
WO1999002502A2 (en) * 1997-07-11 1999-01-21 Smithkline Beecham Plc Sulphonamide derivatives being 5-ht6 receptor antagonists and process for their preparation
WO2001054691A1 (en) * 2000-01-26 2001-08-02 Nicox, S.A. Nitrate salts of antimicrobial agents
WO2001090091A1 (en) 2000-05-22 2001-11-29 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMCATS [online] 1 July 2001 (2001-07-01), "5-Thiazolecarboxylic acid, 4-methyl-2-(((4-methylphenyl)sulfonyl)amino)-, ethyl ester", XP002959048, accession no. STN Database accession no. 2001:1499370 *
DATABASE CHEMCATS [online] 11 February 2002 (2002-02-11), "5-Thiazolecarboxamide, 2-(((2,5-dimethylphenyl)sulfonyl)amino)-4-methyl-N-phenyl-", XP002959053, accession no. STN Database accession no. 2002:310940 *
DATABASE CHEMCATS [online] 11 February 2002 (2002-02-11), "5-Thiazolecarboxamide, 4-methyl-2-(((4-methylphenyl)sulfonyl)amino)-N-phenyl-", XP002959054, accession no. STN Database accession no. 2002:310143 *
DATABASE CHEMCATS [online] 11 February 2002 (2002-02-11), "5-Thiazolecarboxamide, 4-methyl-N-phenyl-2-((phenylsulfonyl)amino)-", XP002959052, accession no. STN Database accession no. 2002:174900 *
DATABASE CHEMCATS [online] 11 February 2002 (2002-02-11), "5-Thiazolecarboxylic acid, 2-(((2,5-dimethylphenyl)sulfonyl)amino)-4-methyl-, ethyl ester", XP002959055, accession no. STN Database accession no. 2002:312516 *
DATABASE CHEMCATS [online] 11 February 2002 (2002-02-11), "5-Thiazolecarboxylic acid, 2-(((2-chlorophenyl)sulfonyl)amino)-4-methyl-, ethyl ester", XP002959051, accession no. STN Database accession no. 2002:175108 *
DATABASE CHEMCATS [online] 14 May 2001 (2001-05-14), "5-Thiazolecarboxylic acid, 2-(((4-chlorophenyl)sulfonyl)amino)-4-methyl-, ethyl ester", XP002959043, accession no. STN Database accession no. 2001:19109 *
DATABASE CHEMCATS [online] 14 May 2001 (2001-05-14), "5-Thiazolecarboxylic acid, 4-methyl-2-(((4-methylphenyl)sulfonyl)amino)-, ethyl ester", XP002959042, accession no. STN Database accession no. 2001:20962 *
DATABASE CHEMCATS [online] 14 May 2001 (2001-05-14), "5-Thiazolecarboxylic acid, 4-methyl-2-((2-naphthalenylsulfonyl)amino)-, ethyl ester", XP002959046, accession no. STN Database accession no. 2001:19110 *
DATABASE CHEMCATS [online] 14 May 2001 (2001-05-14), "5-Thiazolecarboxylic acid, 4-methyl-2-((phenylsulfonyl)amino)-, ethyl ester", XP002959045, accession no. STN Database accession no. 2001:2446055 *
DATABASE CHEMCATS [online] 14 May 2001 (2001-05-14), "5-Thiazolecarboxylic acid, 4-methyl-2-((phenylsulfonyl)amino)-, ethyl ester", XP002959047, accession no. STN Database accession no. 2001:2446055 *
DATABASE CHEMCATS [online] 26 April 2001 (2001-04-26), "5-Thiazolecarboxylic acid, 4-methyl-2-(((3-nitrophenyl)sulfonyl)amino-, ethyl ester", XP002959044, accession no. STN Database accession no. 2001:786400 *
DATABASE HCAPLUS [online] DESAI R.D. ET AL.: "Sulfonamides. II. Preparation of N1-heterocyclic substituted sulfonamides from alpha-naphtylamine and evaluation of their antibacterial properties", XP002959050, accession no. STN Database accession no. 1969:412872 *
DATABASE HCAPLUS [online] DESAI R.D. ET AL.: "Sulfonamides. IV. Some N6-heterocyclic sulfonamides from 2-naphthylamine as possible antibacterial agents", XP002959049, accession no. STN Database accession no. 1969:449825 *
J. INDIAN CHEM. SOC., vol. 46, no. 2, 1969, pages 115 - 118 *
J. INDIAN CHEM. SOC., vol. 46, no. 5, 1969, pages 411 - 414 *

Cited By (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6849636B2 (en) 2002-12-20 2005-02-01 Merck & Co., Inc. Triazole derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1
US7504402B2 (en) 2002-12-20 2009-03-17 Merck & Co., Inc. Triazole derivatives as inhibitors of 11-β-hydroxysteroid dehydrogenase-1
US7173030B2 (en) 2003-05-21 2007-02-06 Biovitrum Ab Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
WO2004103980A1 (en) * 2003-05-21 2004-12-02 Biovitrum Ab Inhibitors of 11-beta-hydroxy steroid dehydrogenase type i
WO2004112782A1 (en) * 2003-06-25 2004-12-29 Biovitrum Ab New use v
EP2036548A1 (en) 2003-09-22 2009-03-18 onepharm Research & Development GmbH Prevention and treatment of inflammation-induced and/or immune-mediated bone loss
US7230020B2 (en) 2003-10-23 2007-06-12 Sterix Limited 11β-hydroxysteroid dehydrogenase inhibitors
WO2005060963A1 (en) * 2003-12-19 2005-07-07 Pfizer Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
EA014419B1 (en) * 2004-05-24 2010-12-30 Эмджен Инк. 5,5-disubstituted-2-amino-4-thiazolidinone and process for preparation thereof, pharmaceutical composition and method for treatment
CN1964956B (en) * 2004-05-24 2013-03-27 安美基公司 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2005116002A3 (en) * 2004-05-24 2006-07-06 Amgen Inc Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2005116002A2 (en) * 2004-05-24 2005-12-08 Amgen Inc. Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US8686011B2 (en) 2004-05-24 2014-04-01 Amgen Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
CN1964956A (en) * 2004-05-24 2007-05-16 安美基公司 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US7807700B2 (en) 2004-05-24 2010-10-05 Amgen Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
US7253196B2 (en) 2004-05-24 2007-08-07 Amgen, Inc. Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
JP4690402B2 (en) * 2004-07-28 2011-06-01 エフ．ホフマン−ラ ロシュ アーゲー Aryl-pyridine derivatives as 11-β-HSD1 inhibitors
JP2008508212A (en) * 2004-07-28 2008-03-21 エフ．ホフマン−ラ ロシュ アーゲー Aryl-pyridine derivatives as 11-β-HSD1 inhibitors
WO2006010546A3 (en) * 2004-07-28 2006-04-13 Hoffmann La Roche Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors
AU2005266531B2 (en) * 2004-07-28 2008-11-20 F. Hoffmann-La Roche Ag Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
WO2006010546A2 (en) * 2004-07-28 2006-02-02 F. Hoffman-La Roche Ag Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors
US7528159B2 (en) 2004-07-28 2009-05-05 Hoffmann-La Roche Inc. 5-aryl pyridines as 11-beta inhibitors for the treatment of diabetes
KR100926842B1 (en) 2004-07-28 2009-11-13 에프. 호프만-라 로슈 아게 Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors
EP1666467A1 (en) * 2004-11-08 2006-06-07 Evotec AG 11Beta-HSD1 Inhibitors
WO2006048331A1 (en) * 2004-11-08 2006-05-11 Evotec Ag 11β-HSD1 INHIBITORS
WO2006050908A1 (en) * 2004-11-08 2006-05-18 Evotec Ag Inhibitors of 11βετα-hydroxy steroid dehydrogenase type 1 (11beta-hsd1)
EP1659113A1 (en) * 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
US7759339B2 (en) 2005-03-31 2010-07-20 Takeda San Diego, Inc. Hydroxysteroid dehydrogenase inhibitors
US7345058B2 (en) 2005-04-05 2008-03-18 Hoffmann-La Roche Inc. Pyrazoles
US8952176B2 (en) 2005-06-07 2015-02-10 Shionogi & Co., Ltd. Heterocyclic compound having type I 11 β hydroxysteroid dehydrogenase inhibitory activity
WO2007025892A1 (en) 2005-08-31 2007-03-08 F. Hoffmann-La Roche Ag 11-beta-hydroxysteroid dehydrogenase-1-inhibitor-diabetes-type 2-1
US7622492B2 (en) 2005-08-31 2009-11-24 Hoffmann-La Roche Inc. Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase
US8541592B2 (en) 2005-11-22 2013-09-24 Amgen Inc. Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1
US7645773B2 (en) 2006-01-18 2010-01-12 Hoffmann-La Roche Inc. Thiazoles as inhibitors of 11β-hydroxysteroid dehydrogenase
US8017638B2 (en) 2006-03-30 2011-09-13 Shionogi & Co., Ltd. Isoxazole derivative and isothiazole derivative having inhibitory activity on 11β-hydroxysteroid dehydrogenase type 1
EP2351568A2 (en) 2006-05-04 2011-08-03 Boehringer Ingelheim International GmbH Uses of dpp-iv inhibitors
WO2007128761A2 (en) 2006-05-04 2007-11-15 Boehringer Ingelheim International Gmbh Uses of dpp-iv inhibitors
WO2008017381A1 (en) 2006-08-08 2008-02-14 Sanofi-Aventis Arylaminoaryl-alkyl-substituted imidazolidine-2,4-diones, processes for preparing them, medicaments comprising these compounds, and their use
DE102007005045A1 (en) 2007-01-26 2008-08-07 Sanofi-Aventis New phenothiazine derivative for use in preparing medicine for blood sugar lowering and for treatment of diabetes, nicotine dependence, alcohol dependence, central nervous system disorders, schizophrenia, and Alzheimer's disease
US8357711B2 (en) 2007-03-23 2013-01-22 Pfizer Limited Heterocyclic sulfonamides as inhibitors of ion channels
US8741934B2 (en) 2007-03-23 2014-06-03 Pfizer Limited Inhibitors of ion channels
WO2009021740A2 (en) 2007-08-15 2009-02-19 Sanofis-Aventis Substituted tetrahydronaphthalenes, process for the preparation thereof and the use thereof as medicaments
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
WO2011023754A1 (en) 2009-08-26 2011-03-03 Sanofi-Aventis Novel crystalline heteroaromatic fluoroglycoside hydrates, pharmaceuticals comprising these compounds and their use
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
WO2011157827A1 (en) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
WO2011161030A1 (en) 2010-06-21 2011-12-29 Sanofi Heterocyclic substituted methoxyphenyl derivatives having an oxo group, method for producing same, and use thereof as gpr40 receptor modulators
WO2012010413A1 (en) 2010-07-05 2012-01-26 Sanofi Aryloxy-alkylene substituted hydroxyphenyl hexynoic acids, methods for the production thereof and use of the same as medicament
WO2012004270A1 (en) 2010-07-05 2012-01-12 Sanofi Spirocyclically substituted 1,3-propane dioxide derivatives, methods for the production thereof and use of the same as medicament
WO2012004269A1 (en) 2010-07-05 2012-01-12 Sanofi (2-aryloxy-acetylamino)-phenyl-propionic acid derivatives, method for producing same and use thereof as pharmaceuticals
WO2012120050A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120056A1 (en) 2011-03-08 2012-09-13 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120054A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120053A1 (en) 2011-03-08 2012-09-13 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120058A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
WO2012120051A1 (en) 2011-03-08 2012-09-13 Sanofi Benzyl-oxathiazine derivates substituted with adamantane or noradamantane, medicaments containing said compounds and use thereof
WO2012120052A1 (en) 2011-03-08 2012-09-13 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
WO2012120057A1 (en) 2011-03-08 2012-09-13 Sanofi Novel substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
WO2012120055A1 (en) 2011-03-08 2012-09-13 Sanofi Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9067922B2 (en) 2013-04-19 2015-06-30 Pfizer Limited Chemical compounds
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
WO2017182464A1 (en) 2016-04-19 2017-10-26 Cidqo 2012, S.L. New aza- tetracyclo derivatives

Also Published As

Publication number Publication date
JP4559078B2 (en) 2010-10-06
CN1564816A (en) 2005-01-12
KR20050044577A (en) 2005-05-12
BR0214343A (en) 2004-09-14
CA2466490A1 (en) 2003-05-30
JP2005509675A (en) 2005-04-14
PL370111A1 (en) 2005-05-16
NO20042596L (en) 2004-06-21
AU2002353718A1 (en) 2003-06-10
EP1461325A1 (en) 2004-09-29
EP1461325B1 (en) 2010-05-26
MXPA04004779A (en) 2004-07-30
DE60236541D1 (en) 2010-07-08
IL161154A0 (en) 2004-08-31
AU2002353718B2 (en) 2007-05-10
CA2466490C (en) 2009-12-29
ATE469136T1 (en) 2010-06-15

Similar Documents

Publication Publication Date Title
EP1461325B1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2002353717B2 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US7125900B2 (en) Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
US7671051B2 (en) Inhibitors of 11-β-hydroxy steroid dehydrogenase type 1
EP1461333A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2001262831A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US7074788B2 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US20030130279A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2007205749B2 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2001264456B2 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
AU2001264456A1 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-443/04

Country of ref document: YU

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2004/01305

Country of ref document: ZA

Ref document number: 200401305

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2003545636

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 161154

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 20028196228

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2002353718

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 532522

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2466490

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1097/CHENP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/004779

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020047007801

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 200400707

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 2002789090

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002789090

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1-2004-500354

Country of ref document: PH

WWG Wipo information: grant in national office

Ref document number: 2002353718

Country of ref document: AU